<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<database>
    <trialList>
        <attritionBiasJudgement>It is reported that no one discontinued due to adverse effects, however it does not state if there were discontinuations due to any other reason.</attritionBiasJudgement>
        <attritionBiasRisk>Unclear Risk</attritionBiasRisk>
        <authorYearLetter>Bailine1987</authorYearLetter>
        <countries>USA</countries>
        <crgID>0</crgID>
        <crossoverTrial>false</crossoverTrial>
        <detectionBiasJudgement>BPRS was rater-blinded. However, it is not clear whether other outcomes were blinded.</detectionBiasJudgement>
        <detectionBiasRisk>Unclear Risk</detectionBiasRisk>
        <dobj>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: b. CHLORPROMAZINE</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>20</group1Total>
            <group2Events>0</group2Events>
            <group2Name>chlorpromazine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>14</group2Total>
            <outcomeName>Leaving the study early</outcomeName>
            <subgroupName>any reason/general reasons</subgroupName>
        </dobj>
        <factorialTrial>false</factorialTrial>
        <mainAuthor>Bailine</mainAuthor>
        <meerKatCountry>USA</meerKatCountry>
        <nrControl>0</nrControl>
        <nrIntervention>0</nrIntervention>
        <nrOfParticipants>0</nrOfParticipants>
        <otherBiasJudgement>Small short study.</otherBiasJudgement>
        <otherBiasRisk>High risk</otherBiasRisk>
        <otherDesign>false</otherDesign>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: b. CHLORPROMAZINE</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>20</group1Total>
            <group2Events>0</group2Events>
            <group2Name>chlorpromazine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>14</group2Total>
            <outcomeName>Leaving the study early</outcomeName>
            <subgroupName>any reason/general reasons</subgroupName>
        </outcomeList>
        <paralellTrial>false</paralellTrial>
        <performanceBiasJudgement>Not stated.</performanceBiasJudgement>
        <performanceBiasRisk>Unclear Risk</performanceBiasRisk>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Bailine SH, Lesser MS, Krubit G, Ravasz TJ, Davis RA, Kane JM</references>
        <references>Comparison of IM haloperidol and IM chlorpromazine in the treatment of acutely psychotic patients</references>
        <references>Psychiatric Hospital</references>
        <references>1987</references>
        <references>18</references>
        <references>3</references>
        <references>127-9</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>Only the significant findings/factors are reported for a number of outcomes.</reportingBiasJudgement>
        <reportingBiasRisk>High risk</reportingBiasRisk>
        <revManID>STD-Bailine-1987</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement>Not stated.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Low risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>"random number sequence".</selectionBiasRandomSequenceJudgement>
        <year>1987</year>
    </trialList>
    <trialList>
        <attritionBiasJudgement>No evidence of incomplete outcome data.</attritionBiasJudgement>
        <attritionBiasRisk>Low risk</attritionBiasRisk>
        <authorYearLetter>Baldacara2011</authorYearLetter>
        <countries></countries>
        <crgID>0</crgID>
        <crossoverTrial>false</crossoverTrial>
        <detectionBiasJudgement>"Patients were assessed by two psychiatrists. The psychiatrists were all masked with regard to the patient’s treatment assignment" (p.31); no information whether the blindness was effective.</detectionBiasJudgement>
        <detectionBiasRisk>High risk</detectionBiasRisk>
        <dobj>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: d. HALOPERIDOL + PROMETHAZINE</comparisonName>
            <group1Events>5</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>30</group1Total>
            <group2Events>5</group2Events>
            <group2Name>haloperidol//promethazine</group2Name>
            <group2NameProse> combinations: d. haloperidol + promethazine</group2NameProse>
            <group2Total>30</group2Total>
            <outcomeName>Adverse effects: 2f. Specific - movement disorders</outcomeName>
            <subgroupName>EPS by 12 hours</subgroupName>
        </dobj>
        <factorialTrial>false</factorialTrial>
        <mainAuthor>Baldacara</mainAuthor>
        <meerKatCountry></meerKatCountry>
        <nrControl>0</nrControl>
        <nrIntervention>0</nrIntervention>
        <nrOfParticipants>0</nrOfParticipants>
        <otherBiasJudgement>None obvious.</otherBiasJudgement>
        <otherBiasRisk>Low risk</otherBiasRisk>
        <otherDesign>false</otherDesign>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE</comparisonName>
            <group1Events>4</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>30</group1Total>
            <group2Events>1</group2Events>
            <group2Name>olanzapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>30</group2Total>
            <outcomeName>Repeated need for tranquillisation - needing additional injection</outcomeName>
            <subgroupName>by 2 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE</comparisonName>
            <group1Events>23</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>30</group1Total>
            <group2Events>7</group2Events>
            <group2Name>olanzapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>30</group2Total>
            <outcomeName>Repeated need for tranquillisation - needing additional injection</outcomeName>
            <subgroupName>by 12 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE</comparisonName>
            <group1Events>6</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>30</group1Total>
            <group2Events>1</group2Events>
            <group2Name>olanzapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>30</group2Total>
            <outcomeName>Global outcome: 1a. General - need for additional measures</outcomeName>
            <subgroupName>additional restraint, seclusion or special observation</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE</comparisonName>
            <group1Events>11</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>30</group1Total>
            <group2Events>5</group2Events>
            <group2Name>olanzapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>30</group2Total>
            <outcomeName>Adverse effects: 1a. General</outcomeName>
            <subgroupName>one or more drug related adverse events</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>30</group1Total>
            <group2Events>0</group2Events>
            <group2Name>olanzapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>30</group2Total>
            <outcomeName>Adverse effects: 1b. General - serious</outcomeName>
            <subgroupName>death</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE</comparisonName>
            <group1Events>3</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>30</group1Total>
            <group2Events>1</group2Events>
            <group2Name>olanzapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>30</group2Total>
            <outcomeName>Adverse effects: 2b. Specific - arousal level - i. various</outcomeName>
            <subgroupName>excessive sedation during 24 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol </group1Name>
            <group1NameProse>HALOPERIDOL </group1NameProse>
            <group1Total>30</group1Total>
            <group2Events>1</group2Events>
            <group2Name>olanzapine</group2Name>
            <group2NameProse> other antipsychotic: e. olanzapine</group2NameProse>
            <group2Total>30</group2Total>
            <outcomeName>Adverse effects: 2f. Specific - cardiovascular i. binary</outcomeName>
            <subgroupName>hypotension during 24 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE</comparisonName>
            <group1Events>5</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>30</group1Total>
            <group2Events>0</group2Events>
            <group2Name>olanzapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>30</group2Total>
            <outcomeName>Adverse effects: 2i. Specific - movement disorder - i. various</outcomeName>
            <subgroupName>EPS during 24 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZIPRASIDONE</comparisonName>
            <group1Events>4</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>30</group1Total>
            <group2Events>11</group2Events>
            <group2Name>ziprasidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>30</group2Total>
            <outcomeName>Repeated need for tranquillisation - need for additional drugs for tranquillisation</outcomeName>
            <subgroupName>up to 2 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZIPRASIDONE</comparisonName>
            <group1Events>23</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>30</group1Total>
            <group2Events>14</group2Events>
            <group2Name>ziprasidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>30</group2Total>
            <outcomeName>Repeated need for tranquillisation - need for additional drugs for tranquillisation</outcomeName>
            <subgroupName>up to 24 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZIPRASIDONE</comparisonName>
            <group1Events>6</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>30</group1Total>
            <group2Events>10</group2Events>
            <group2Name>ziprasidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>30</group2Total>
            <outcomeName>Global outcome: 1. General - need for additional measures</outcomeName>
            <subgroupName>additional restraint, seclusion or special observation during 12 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZIPRASIDONE</comparisonName>
            <group1Events>11</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>30</group1Total>
            <group2Events>8</group2Events>
            <group2Name>ziprasidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>30</group2Total>
            <outcomeName>Adverse effects: 1a. General - i. up to 24 hours</outcomeName>
            <subgroupName>one or more drug related adverse effects - by 12 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZIPRASIDONE</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>30</group1Total>
            <group2Events>0</group2Events>
            <group2Name>ziprasidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>30</group2Total>
            <outcomeName>Adverse effects: 1c. General - serious</outcomeName>
            <subgroupName>death</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZIPRASIDONE</comparisonName>
            <group1Events>3</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>30</group1Total>
            <group2Events>3</group2Events>
            <group2Name>ziprasidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>30</group2Total>
            <outcomeName>Adverse effects: 2b. Specific - arousal level - i. various</outcomeName>
            <subgroupName>excessive sedation at 12 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZIPRASIDONE</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>30</group1Total>
            <group2Events>6</group2Events>
            <group2Name>ziprasidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>30</group2Total>
            <outcomeName>Adverse effects: 2f. Specific - cardiovascular</outcomeName>
            <subgroupName>hypotension at 12 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZIPRASIDONE</comparisonName>
            <group1Events>5</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>30</group1Total>
            <group2Events>0</group2Events>
            <group2Name>ziprasidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>30</group2Total>
            <outcomeName>Adverse effects: 2i. Specific - movement disorders - i. binary measures</outcomeName>
            <subgroupName>EPS - by 12 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: c. HALOPERIDOL + MIDAZOLAM</comparisonName>
            <group1Events>4</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>30</group1Total>
            <group2Events>15</group2Events>
            <group2Name>haloperidol//midazolam</group2Name>
            <group2NameProse> combinations: c. haloperidol + midazolam</group2NameProse>
            <group2Total>30</group2Total>
            <outcomeName>Repeated need for tranquillisation</outcomeName>
            <subgroupName>need for additional drugs for tranquillisation up to 2 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: c. HALOPERIDOL + MIDAZOLAM</comparisonName>
            <group1Events>23</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>30</group1Total>
            <group2Events>26</group2Events>
            <group2Name>haloperidol//midazolam</group2Name>
            <group2NameProse> combinations: c. haloperidol + midazolam</group2NameProse>
            <group2Total>30</group2Total>
            <outcomeName>Repeated need for tranquillisation</outcomeName>
            <subgroupName>need for additional drugs for tranquillisation by 12 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: c. HALOPERIDOL + MIDAZOLAM</comparisonName>
            <group1Events>6</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>30</group1Total>
            <group2Events>21</group2Events>
            <group2Name>haloperidol//midazolam</group2Name>
            <group2NameProse> combinations: c. haloperidol + midazolam</group2NameProse>
            <group2Total>30</group2Total>
            <outcomeName>Global outcomes: 1. General - need for additional measures</outcomeName>
            <subgroupName>additional restraint, seclusion or special observation during 12 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: c. HALOPERIDOL + MIDAZOLAM</comparisonName>
            <group1Events>11</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>30</group1Total>
            <group2Events>15</group2Events>
            <group2Name>haloperidol//midazolam</group2Name>
            <group2NameProse> combinations: c. haloperidol + midazolam</group2NameProse>
            <group2Total>30</group2Total>
            <outcomeName>Adverse effects: 1b. General - one or more adverse events</outcomeName>
            <subgroupName>during 12 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: c. HALOPERIDOL + MIDAZOLAM</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>30</group1Total>
            <group2Events>0</group2Events>
            <group2Name>haloperidol//midazolam</group2Name>
            <group2NameProse> combinations: c. haloperidol + midazolam</group2NameProse>
            <group2Total>30</group2Total>
            <outcomeName>Adverse effects: 1a. General - serious</outcomeName>
            <subgroupName>death</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: c. HALOPERIDOL + MIDAZOLAM</comparisonName>
            <group1Events>3</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>30</group1Total>
            <group2Events>12</group2Events>
            <group2Name>haloperidol//midazolam</group2Name>
            <group2NameProse> combinations: c. haloperidol + midazolam</group2NameProse>
            <group2Total>30</group2Total>
            <outcomeName>Adverse effects: 2a. Specific - arousal - i. various</outcomeName>
            <subgroupName>excessive sedation by 12 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: c. HALOPERIDOL + MIDAZOLAM</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>30</group1Total>
            <group2Events>5</group2Events>
            <group2Name>haloperidol//midazolam</group2Name>
            <group2NameProse> combinations: c. haloperidol + midazolam</group2NameProse>
            <group2Total>30</group2Total>
            <outcomeName>Adverse effects: 2e. Specific - cardiovascular</outcomeName>
            <subgroupName>hypotension by 12 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: c. HALOPERIDOL + MIDAZOLAM</comparisonName>
            <group1Events>5</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>30</group1Total>
            <group2Events>3</group2Events>
            <group2Name>haloperidol//midazolam</group2Name>
            <group2NameProse> combinations: c. haloperidol + midazolam</group2NameProse>
            <group2Total>30</group2Total>
            <outcomeName>Adverse effects: 2f. Specific - movement disorders</outcomeName>
            <subgroupName>EPS by 12 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: d. HALOPERIDOL + PROMETHAZINE</comparisonName>
            <group1Events>4</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>30</group1Total>
            <group2Events>14</group2Events>
            <group2Name>haloperidol//promethazine</group2Name>
            <group2NameProse> combinations: d. haloperidol + promethazine</group2NameProse>
            <group2Total>30</group2Total>
            <outcomeName>Repeated need for tranquillisation - need for additional drugs for tranquillisation</outcomeName>
            <subgroupName>by 2 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: d. HALOPERIDOL + PROMETHAZINE</comparisonName>
            <group1Events>23</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>30</group1Total>
            <group2Events>21</group2Events>
            <group2Name>haloperidol//promethazine</group2Name>
            <group2NameProse> combinations: d. haloperidol + promethazine</group2NameProse>
            <group2Total>30</group2Total>
            <outcomeName>Repeated need for tranquillisation - need for additional drugs for tranquillisation</outcomeName>
            <subgroupName>by 12 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: d. HALOPERIDOL + PROMETHAZINE</comparisonName>
            <group1Events>6</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>30</group1Total>
            <group2Events>5</group2Events>
            <group2Name>haloperidol//promethazine</group2Name>
            <group2NameProse> combinations: d. haloperidol + promethazine</group2NameProse>
            <group2Total>30</group2Total>
            <outcomeName>Global outcomes: 1. General - need for additional measures</outcomeName>
            <subgroupName>additional restraint, seclusion or special observation during 12 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: d. HALOPERIDOL + PROMETHAZINE</comparisonName>
            <group1Events>11</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>30</group1Total>
            <group2Events>10</group2Events>
            <group2Name>haloperidol//promethazine</group2Name>
            <group2NameProse> combinations: d. haloperidol + promethazine</group2NameProse>
            <group2Total>30</group2Total>
            <outcomeName>Adverse effects: 1a. General</outcomeName>
            <subgroupName>one or more adverse effects up to 24 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: d. HALOPERIDOL + PROMETHAZINE</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>30</group1Total>
            <group2Events>0</group2Events>
            <group2Name>haloperidol//promethazine</group2Name>
            <group2NameProse> combinations: d. haloperidol + promethazine</group2NameProse>
            <group2Total>30</group2Total>
            <outcomeName>Adverse effects: 1b. General - serious</outcomeName>
            <subgroupName>death</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: d. HALOPERIDOL + PROMETHAZINE</comparisonName>
            <group1Events>3</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>30</group1Total>
            <group2Events>1</group2Events>
            <group2Name>haloperidol//promethazine</group2Name>
            <group2NameProse> combinations: d. haloperidol + promethazine</group2NameProse>
            <group2Total>30</group2Total>
            <outcomeName>Adverse effects: 2a. Specific - arousal - i. various</outcomeName>
            <subgroupName>excessive sedation by 12 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: d. HALOPERIDOL + PROMETHAZINE</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>30</group1Total>
            <group2Events>3</group2Events>
            <group2Name>haloperidol//promethazine</group2Name>
            <group2NameProse> combinations: d. haloperidol + promethazine</group2NameProse>
            <group2Total>30</group2Total>
            <outcomeName>Adverse effects: 2e. Specific - cardiovascular</outcomeName>
            <subgroupName>hypotension by 12 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: d. HALOPERIDOL + PROMETHAZINE</comparisonName>
            <group1Events>5</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>30</group1Total>
            <group2Events>5</group2Events>
            <group2Name>haloperidol//promethazine</group2Name>
            <group2NameProse> combinations: d. haloperidol + promethazine</group2NameProse>
            <group2Total>30</group2Total>
            <outcomeName>Adverse effects: 2f. Specific - movement disorders</outcomeName>
            <subgroupName>EPS by 12 hours</subgroupName>
        </outcomeList>
        <paralellTrial>false</paralellTrial>
        <performanceBiasJudgement>"study medications were packaged in identical color-coded boxes" (p.31); stated as double blind, however "patients were instructed not to reveal their current treatment to the investigators" (p.31); no information whether the blindness was effective.</performanceBiasJudgement>
        <performanceBiasRisk>High risk</performanceBiasRisk>
        <references>OTHER</references>
        <references>NO</references>
        <references>Baldacara L, Sanches M, Cordeiro DC, Jackoswski AP</references>
        <references>Rapid tranquilization for agitated patients in emergency psychiatric rooms: A randomized trial of olanzapine, ziprasidone, haloperidol plus promethazine, haloperidol plus midazolam and haloperidol alone</references>
        <references>Revista Brasileira de Psiquiatria</references>
        <references>2011</references>
        <references>33</references>
        <references>1</references>
        <references>30-9</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>Endpoint scores at 1 hour are discordant between text (p.32-33) and Table 2 (p.35).</reportingBiasJudgement>
        <reportingBiasRisk>High risk</reportingBiasRisk>
        <revManID>STD-Baldacara-2011</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement>Not stated.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Unclear Risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>"randomization employed in this clinical trial was allocation by permuted blocks" (p.31); no further informations on the randomisation process.</selectionBiasRandomSequenceJudgement>
        <year>2011</year>
    </trialList>
    <trialList>
        <attritionBiasJudgement>"two patients were excluded from the efficacy analysis. It was determined after enrolment that both received proscribed antipsychotic medication before entering the study."</attritionBiasJudgement>
        <attritionBiasRisk>High risk</attritionBiasRisk>
        <authorYearLetter>Battaglia1997</authorYearLetter>
        <countries>USA</countries>
        <crgID>0</crgID>
        <crossoverTrial>false</crossoverTrial>
        <detectionBiasJudgement>"The ED [Emergency Department] psychiatrist who treated and rated the patient remained blinded to the identity of the patient's medication throughout treatment" (p.336).[italic added by reviewers]. Not tested.</detectionBiasJudgement>
        <detectionBiasRisk>Low risk</detectionBiasRisk>
        <dobj>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: b. HALOPERIDOL + LORAZEPAM</comparisonName>
            <group1Events>9</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>35</group1Total>
            <group2Events>3</group2Events>
            <group2Name>haloperidol//lorazepam</group2Name>
            <group2NameProse> combinations: b. haloperidol + lorazepam</group2NameProse>
            <group2Total>32</group2Total>
            <outcomeName>Adverse effects: 2c. Specific - movement disorders</outcomeName>
            <subgroupName>use of additional benztropine during 24 hours</subgroupName>
        </dobj>
        <factorialTrial>false</factorialTrial>
        <mainAuthor>Battaglia</mainAuthor>
        <meerKatCountry>USA</meerKatCountry>
        <nrControl>0</nrControl>
        <nrIntervention>0</nrIntervention>
        <nrOfParticipants>0</nrOfParticipants>
        <otherBiasJudgement>Sponsored by drug company.</otherBiasJudgement>
        <otherBiasRisk>High risk</otherBiasRisk>
        <otherDesign>false</otherDesign>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs BENZODIAZEPINE: b. LORAZEPAM</comparisonName>
            <group1Events>24</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>35</group1Total>
            <group2Events>11</group2Events>
            <group2Name>lorazepam</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>31</group2Total>
            <outcomeName>Tranquillisation or asleep - not asleep</outcomeName>
            <subgroupName>by 3 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs BENZODIAZEPINE: b. LORAZEPAM</comparisonName>
            <group1Events>31</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>35</group1Total>
            <group2Events>24</group2Events>
            <group2Name>lorazepam</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>31</group2Total>
            <outcomeName>Repeated need for rapid tranquillisation</outcomeName>
            <subgroupName>more than 1 injection</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs BENZODIAZEPINE: b. LORAZEPAM</comparisonName>
            <group1Events>10</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>35</group1Total>
            <group2Events>8</group2Events>
            <group2Name>lorazepam</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>31</group2Total>
            <outcomeName>Repeated need for rapid tranquillisation</outcomeName>
            <subgroupName>more than 3 injections</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs BENZODIAZEPINE: b. LORAZEPAM</comparisonName>
            <group1Events>14</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol </group1Name>
            <group1NameProse>HALOPERIDOL </group1NameProse>
            <group1Total>35</group1Total>
            <group2Events>11</group2Events>
            <group2Name>lorazepam</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>31</group2Total>
            <outcomeName>Adverse effects: 1a. General</outcomeName>
            <subgroupName>one or more drug-related adverse effect up to 24 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs BENZODIAZEPINE: b. LORAZEPAM</comparisonName>
            <group1Events>3</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>35</group1Total>
            <group2Events>5</group2Events>
            <group2Name>lorazepam</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>31</group2Total>
            <outcomeName>Adverse effects: 2a. Specific - anticholinergic</outcomeName>
            <subgroupName>dry mouth up to 24 hours (only reported if occurred ≥9%)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs BENZODIAZEPINE: b. LORAZEPAM</comparisonName>
            <group1Events>3</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>35</group1Total>
            <group2Events>3</group2Events>
            <group2Name>lorazepam</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>31</group2Total>
            <outcomeName>Adverse effects: 2c. Specific - cardiovascular</outcomeName>
            <subgroupName>dizziness (only reported if occurred in ≧9%) - during 24 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs BENZODIAZEPINE: b. LORAZEPAM</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>35</group1Total>
            <group2Events>0</group2Events>
            <group2Name>lorazepam</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>31</group2Total>
            <outcomeName>Adverse effects: 2c. Specific - cardiovascular</outcomeName>
            <subgroupName>hypertension - use of additional clonidine - during 24 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs BENZODIAZEPINE: b. LORAZEPAM</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>35</group1Total>
            <group2Events>2</group2Events>
            <group2Name>lorazepam</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>31</group2Total>
            <outcomeName>Adverse effects: 2d. Specific - movement disorder</outcomeName>
            <subgroupName>ataxia (only reported if occurred in ≧9%) - during 24 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs BENZODIAZEPINE: b. LORAZEPAM</comparisonName>
            <group1Events>4</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>35</group1Total>
            <group2Events>1</group2Events>
            <group2Name>lorazepam</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>31</group2Total>
            <outcomeName>Adverse effects: 2d. Specific - movement disorder</outcomeName>
            <subgroupName>dystonia (only reported if occurred in ≧9%) - during 24 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs BENZODIAZEPINE: b. LORAZEPAM</comparisonName>
            <group1Events>3</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>35</group1Total>
            <group2Events>0</group2Events>
            <group2Name>lorazepam</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>31</group2Total>
            <outcomeName>Adverse effects: 2d. Specific - movement disorder</outcomeName>
            <subgroupName>hypertonia/rigidity (only reported if occurred in ≧9%) - during 24 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs BENZODIAZEPINE: b. LORAZEPAM</comparisonName>
            <group1Events>4</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>35</group1Total>
            <group2Events>2</group2Events>
            <group2Name>lorazepam</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>31</group2Total>
            <outcomeName>Adverse effects: 2d. Specific - movement disorder</outcomeName>
            <subgroupName>speech disorder (only reported if occurred in ≧9%) - during 24 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs BENZODIAZEPINE: b. LORAZEPAM</comparisonName>
            <group1Events>2</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>35</group1Total>
            <group2Events>1</group2Events>
            <group2Name>lorazepam</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>31</group2Total>
            <outcomeName>Adverse effects: 2d. Specific - movement disorder</outcomeName>
            <subgroupName>tremor (only reported if occurred in ≧9%) - during 24 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs BENZODIAZEPINE: b. LORAZEPAM</comparisonName>
            <group1Events>9</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>35</group1Total>
            <group2Events>4</group2Events>
            <group2Name>lorazepam</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>31</group2Total>
            <outcomeName>Adverse effects: 2d. Specific - movement disorder</outcomeName>
            <subgroupName>use of additional benztropine - during 24 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: b. HALOPERIDOL + LORAZEPAM</comparisonName>
            <group1Events>24</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>35</group1Total>
            <group2Events>12</group2Events>
            <group2Name>haloperidol//lorazepam</group2Name>
            <group2NameProse> combinations: b. haloperidol + lorazepam</group2NameProse>
            <group2Total>32</group2Total>
            <outcomeName>Tranquillisation or asleep - asleep</outcomeName>
            <subgroupName>not asleep by 3 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: b. HALOPERIDOL + LORAZEPAM</comparisonName>
            <group1Events>31</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>35</group1Total>
            <group2Events>27</group2Events>
            <group2Name>haloperidol//lorazepam</group2Name>
            <group2NameProse> combinations: b. haloperidol + lorazepam</group2NameProse>
            <group2Total>32</group2Total>
            <outcomeName>Repeated need for rapid tranquillisation</outcomeName>
            <subgroupName>needing additional injection during 24 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: b. HALOPERIDOL + LORAZEPAM</comparisonName>
            <group1Events>10</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>35</group1Total>
            <group2Events>3</group2Events>
            <group2Name>haloperidol//lorazepam</group2Name>
            <group2NameProse> combinations: b. haloperidol + lorazepam</group2NameProse>
            <group2Total>32</group2Total>
            <outcomeName>Repeated need for rapid tranquillisation</outcomeName>
            <subgroupName>more than 3 injections during 24 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: b. HALOPERIDOL + LORAZEPAM</comparisonName>
            <group1Events>14</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>35</group1Total>
            <group2Events>11</group2Events>
            <group2Name>haloperidol//lorazepam</group2Name>
            <group2NameProse> combinations: b. haloperidol + lorazepam</group2NameProse>
            <group2Total>32</group2Total>
            <outcomeName>Adverse effects: 1. General</outcomeName>
            <subgroupName>one or more drug-related adverse effect during 24 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: b. HALOPERIDOL + LORAZEPAM</comparisonName>
            <group1Events>3</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>35</group1Total>
            <group2Events>3</group2Events>
            <group2Name>haloperidol//lorazepam</group2Name>
            <group2NameProse> combinations: b. haloperidol + lorazepam</group2NameProse>
            <group2Total>32</group2Total>
            <outcomeName>Adverse effects: 2a. Specific - anticholinergic</outcomeName>
            <subgroupName>dry mouth (only reported if occurred in ≧9%) during 24 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: b. HALOPERIDOL + LORAZEPAM</comparisonName>
            <group1Events>3</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>35</group1Total>
            <group2Events>2</group2Events>
            <group2Name>haloperidol//lorazepam</group2Name>
            <group2NameProse> combinations: b. haloperidol + lorazepam</group2NameProse>
            <group2Total>32</group2Total>
            <outcomeName>Adverse effects: 2b. Specific - cardiovascular</outcomeName>
            <subgroupName>dizziness (only reported if occurred in ≧9%) during 24 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: b. HALOPERIDOL + LORAZEPAM</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>35</group1Total>
            <group2Events>1</group2Events>
            <group2Name>haloperidol//lorazepam</group2Name>
            <group2NameProse> combinations: b. haloperidol + lorazepam</group2NameProse>
            <group2Total>32</group2Total>
            <outcomeName>Adverse effects: 2b. Specific - cardiovascular</outcomeName>
            <subgroupName>hypertension - use of additional clonidine during 24 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: b. HALOPERIDOL + LORAZEPAM</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>35</group1Total>
            <group2Events>3</group2Events>
            <group2Name>haloperidol//lorazepam</group2Name>
            <group2NameProse> combinations: b. haloperidol + lorazepam</group2NameProse>
            <group2Total>32</group2Total>
            <outcomeName>Adverse effects: 2c. Specific - movement disorders</outcomeName>
            <subgroupName>ataxia (only reported if occurred in &gt;9%) during 24 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: b. HALOPERIDOL + LORAZEPAM</comparisonName>
            <group1Events>4</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>35</group1Total>
            <group2Events>0</group2Events>
            <group2Name>haloperidol//lorazepam</group2Name>
            <group2NameProse> combinations: b. haloperidol + lorazepam</group2NameProse>
            <group2Total>32</group2Total>
            <outcomeName>Adverse effects: 2c. Specific - movement disorders</outcomeName>
            <subgroupName>dystonia (only reported if occurred in &gt;9%) during 24 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: b. HALOPERIDOL + LORAZEPAM</comparisonName>
            <group1Events>3</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>35</group1Total>
            <group2Events>1</group2Events>
            <group2Name>haloperidol//lorazepam</group2Name>
            <group2NameProse> combinations: b. haloperidol + lorazepam</group2NameProse>
            <group2Total>32</group2Total>
            <outcomeName>Adverse effects: 2c. Specific - movement disorders</outcomeName>
            <subgroupName>hypertonia/rigidity (only reported if occurred in &gt;9%) during 24 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: b. HALOPERIDOL + LORAZEPAM</comparisonName>
            <group1Events>2</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>35</group1Total>
            <group2Events>1</group2Events>
            <group2Name>haloperidol//lorazepam</group2Name>
            <group2NameProse> combinations: b. haloperidol + lorazepam</group2NameProse>
            <group2Total>32</group2Total>
            <outcomeName>Adverse effects: 2c. Specific - movement disorders</outcomeName>
            <subgroupName>tremor (only reported if occurred in &gt;9%) during 24 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: b. HALOPERIDOL + LORAZEPAM</comparisonName>
            <group1Events>4</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>35</group1Total>
            <group2Events>3</group2Events>
            <group2Name>haloperidol//lorazepam</group2Name>
            <group2NameProse> combinations: b. haloperidol + lorazepam</group2NameProse>
            <group2Total>32</group2Total>
            <outcomeName>Adverse effects: 2c. Specific - movement disorders</outcomeName>
            <subgroupName>speech disorder (only reported if occurred in &gt;9%) during 24 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: b. HALOPERIDOL + LORAZEPAM</comparisonName>
            <group1Events>9</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>35</group1Total>
            <group2Events>3</group2Events>
            <group2Name>haloperidol//lorazepam</group2Name>
            <group2NameProse> combinations: b. haloperidol + lorazepam</group2NameProse>
            <group2Total>32</group2Total>
            <outcomeName>Adverse effects: 2c. Specific - movement disorders</outcomeName>
            <subgroupName>use of additional benztropine during 24 hours</subgroupName>
        </outcomeList>
        <paralellTrial>false</paralellTrial>
        <performanceBiasJudgement>"The ED [Emergency Department] psychiatrist who treated and rated the patient remained blinded to the identity of the patient's medication throughout treatment" (p.336). [italic added by reviewers], "Double blind" - participant blinding not specifically mentioned.</performanceBiasJudgement>
        <performanceBiasRisk>Low risk</performanceBiasRisk>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Battaglia J, Moss S, Rush J, Kang J, Mendoza R, Leedom L, et al</references>
        <references>Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study</references>
        <references>American Journal of Emergency Medicine</references>
        <references>1997</references>
        <references>15</references>
        <references>4</references>
        <references>335-40</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>More details on level of significance for outcomes with P &lt; 0.05. Adverse effects for central nervous system reported only if present in ≥ 9%.</reportingBiasJudgement>
        <reportingBiasRisk>High risk</reportingBiasRisk>
        <revManID>STD-Battaglia-1997</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement>Not stated.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Low risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>"Computer-generated table of random numbers".</selectionBiasRandomSequenceJudgement>
        <year>1997</year>
    </trialList>
    <trialList>
        <attritionBiasJudgement>The authors only account for 5 of the 26 people who did not complete the 24 hours study.</attritionBiasJudgement>
        <attritionBiasRisk>High risk</attritionBiasRisk>
        <authorYearLetter>Battaglia2002</authorYearLetter>
        <countries>Australia, Austria, Belgium, Canada, Czech Republic, France, Greece, Hungary, Israel, South Africa, Spain, UK, USA</countries>
        <crgID>0</crgID>
        <crossoverTrial>false</crossoverTrial>
        <detectionBiasJudgement>"Both drugs and placebo were administered in identical, color-blinded, translucent standard syringes, and raters and study personnel were blind to treatment assignment" (Wright 2001, p.1149). [italic added by reviewers].</detectionBiasJudgement>
        <detectionBiasRisk>Low risk</detectionBiasRisk>
        <dobj>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE</comparisonName>
            <group1Events>26</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>126</group1Total>
            <group2Events>6</group2Events>
            <group2Name>olanzapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>131</group2Total>
            <outcomeName>Adverse effects: 2i. Specific - movement disorder - i. various</outcomeName>
            <subgroupName>extrapyramidal effects - use of antiparkinson drugs during 24 hours</subgroupName>
        </dobj>
        <factorialTrial>false</factorialTrial>
        <mainAuthor>Battaglia</mainAuthor>
        <meerKatCountry>Multi-Center//Australia//Austria//Belgium//Canada//Czech Republic//France//Greece//Hungary//Israel//South Africa//Spain//UK//USA</meerKatCountry>
        <nrControl>0</nrControl>
        <nrIntervention>0</nrIntervention>
        <nrOfParticipants>0</nrOfParticipants>
        <otherBiasJudgement>Sponsored by the manufacturers of olanzapine.</otherBiasJudgement>
        <otherBiasRisk>High risk</otherBiasRisk>
        <otherDesign>false</otherDesign>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs PLACEBO/NIL</comparisonName>
            <group1Events>106</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>126</group1Total>
            <group2Events>53</group2Events>
            <group2Name>placebo</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>54</group2Total>
            <outcomeName>Tranquillisation or asleep - asleep</outcomeName>
            <subgroupName>not asleep up to 2 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs PLACEBO/NIL</comparisonName>
            <group1Events>36</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>126</group1Total>
            <group2Events>27</group2Events>
            <group2Name>placebo</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>54</group2Total>
            <outcomeName>Repeated need for tranquillisation</outcomeName>
            <subgroupName>needing additional injection during 24 hours (agitation only)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs PLACEBO/NIL</comparisonName>
            <group1Events>25</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>126</group1Total>
            <group2Events>21</group2Events>
            <group2Name>placebo</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>54</group2Total>
            <outcomeName>Global outcome: 2. Need for benzodiazepine up to 24 hours</outcomeName>
            <subgroupName>need for benzodiazepine up to 24 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs PLACEBO/NIL</comparisonName>
            <group1Events>10</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>126</group1Total>
            <group2Events>2</group2Events>
            <group2Name>placebo</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>54</group2Total>
            <outcomeName>Adverse effects: 2a. Specific - arousal level</outcomeName>
            <subgroupName>somnolence during 24 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs PLACEBO/NIL</comparisonName>
            <group1Events>26</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>126</group1Total>
            <group2Events>2</group2Events>
            <group2Name>placebo</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>54</group2Total>
            <outcomeName>Adverse effects: 2d. Specific - movement disorders</outcomeName>
            <subgroupName>extrapyramidal effects - use of antiparkinson drugs during 24 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE</comparisonName>
            <group1Events>106</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>126</group1Total>
            <group2Events>95</group2Events>
            <group2Name>olanzapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>131</group2Total>
            <outcomeName>Tranquillisation or asleep - asleep</outcomeName>
            <subgroupName>not asleep up to 2 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE</comparisonName>
            <group1Events>36</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>126</group1Total>
            <group2Events>31</group2Events>
            <group2Name>olanzapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>131</group2Total>
            <outcomeName>Repeated need for tranquillisation - needing additional injection</outcomeName>
            <subgroupName>by 24 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE</comparisonName>
            <group1Events>25</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>126</group1Total>
            <group2Events>21</group2Events>
            <group2Name>olanzapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>131</group2Total>
            <outcomeName>Global outcome: 1a. General - need for additional measures</outcomeName>
            <subgroupName>need for benzodiazepine during 24 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE</comparisonName>
            <group1Events>10</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>126</group1Total>
            <group2Events>10</group2Events>
            <group2Name>olanzapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>131</group2Total>
            <outcomeName>Adverse effects: 2b. Specific - arousal level - i. various</outcomeName>
            <subgroupName>somnolence at 24 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE</comparisonName>
            <group1Events>9</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>126</group1Total>
            <group2Events>0</group2Events>
            <group2Name>olanzapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>131</group2Total>
            <outcomeName>Adverse effects: 2i. Specific - movement disorder - i. various</outcomeName>
            <subgroupName>dystonia during 24 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE</comparisonName>
            <group1Events>7</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>126</group1Total>
            <group2Events>1</group2Events>
            <group2Name>olanzapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>131</group2Total>
            <outcomeName>Adverse effects: 2i. Specific - movement disorder - i. various</outcomeName>
            <subgroupName>EPS during 24 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE</comparisonName>
            <group1Events>26</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>126</group1Total>
            <group2Events>6</group2Events>
            <group2Name>olanzapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>131</group2Total>
            <outcomeName>Adverse effects: 2i. Specific - movement disorder - i. various</outcomeName>
            <subgroupName>extrapyramidal effects - use of antiparkinson drugs during 24 hours</subgroupName>
        </outcomeList>
        <paralellTrial>false</paralellTrial>
        <performanceBiasJudgement>"Both drugs and placebo were administered in identical, color-blinded, translucent standard syringes, and raters and study personnel were blind to treatment assignment" (Wright 2001, p.1149). [italic added by reviewers].</performanceBiasJudgement>
        <performanceBiasRisk>Low risk</performanceBiasRisk>
        <references>JOURNAL_ARTICLE</references>
        <references>YES</references>
        <references>Battaglia J, David SR, Alaka K, Meehan K, Wright P</references>
        <references>Calming versus sedative effects of IM olanzapine in agitated patients</references>
        <references>Schizophrenia Research</references>
        <references>2002</references>
        <references>53</references>
        <references>3 Suppl 1</references>
        <references>183</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Battaglia J, Houston JP, Ahl J, Meyers AL, Kaiser CJ</references>
        <references>A post hoc analysis of transitioning to oral treatment with olanzapine or haloperidol after 24-hour intramuscular treatment in acutely agitated adult patients with schizophrenia</references>
        <references>Clinical Therapeutics</references>
        <references>2005</references>
        <references>27</references>
        <references>10</references>
        <references>1612-8</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Battaglia J, Lindborg SR, Alaka K, Meehan K, Wright P</references>
        <references>Calming versus sedative effects of intramuscular olanzapine in agitated patients</references>
        <references>American Journal of Emergency Medicine</references>
        <references>2003</references>
        <references>21</references>
        <references>3</references>
        <references>192-8</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>David SR, Battaglia J, Alaka K, Meehan K, Wright P</references>
        <references>Calming versus sedative effects of IM olanzapine in agitated patients</references>
        <references>Proceedings of the 11th Congress of the Association of European Psychiatrists; 2002 May 4-8; Stockholm, Sweden</references>
        <references>2002</references>
        <references>17</references>
        <references>Suppl 1</references>
        <references>104s</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>David SR, Beasley CM Jr, Alaka K</references>
        <references>Analysis of the QTC interval in acutely agitated patients with schizophrenia, bipolar mania, or dementia treated with intramuscular (IM) olanzapine vs. IM placebo or IM haloperidol</references>
        <references>European Neuropsychopharmacology</references>
        <references>2001</references>
        <references>11</references>
        <references>3</references>
        <references>276</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>David SR, Beasley CM Jr, Alaka K</references>
        <references>QTC intervals during treatment with IM olanzapine in acutely agitated patients</references>
        <references>Schizophrenia Research</references>
        <references>2002</references>
        <references>53</references>
        <references>3 Suppl 1</references>
        <references>164</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>David SR, Meehan K, Birkett MA, Wright P, Ferchland I, Alaka K, et al</references>
        <references>Intramuscular olanzapine versus intramuscular haloperidol and intramuscular placebo: an international double-blind study in acutely agitated patients with schizophrenia</references>
        <references>Schizophrenia Research</references>
        <references>2001</references>
        <references>49</references>
        <references>1-2</references>
        <references>224</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>CONFERENCE_PROC</references>
        <references>NO</references>
        <references>Houston JP, Kaiser CJ, Ahl J</references>
        <references>Oral olanzapine transition dose following intramuscular olanzapine treatment</references>
        <references>International Congress on Schizophrenia Research; 2005 Apr 2-5, Savanagh, Georgia USA</references>
        <references>2005</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>CONFERENCE_PROC</references>
        <references>NO</references>
        <references>King KG, Wright P, Meehan K, Birkett M, David SR, Taylor CC</references>
        <references>Transition from intramuscular to oral olanzapine</references>
        <references>Proceedings of the 12th World Congress of Psychiatry; 2002 Aug 24-29; Yokohama, Japan</references>
        <references>2002</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Lindborg SR, Beasley CM, Alaka K, Taylor CC</references>
        <references>Effects of intramuscular olanzapine vs haloperidol and placebo on QTc intervals in acutely agitated patients</references>
        <references>Psychiatry Research</references>
        <references>2003</references>
        <references>119</references>
        <references>1-2</references>
        <references>113-23</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Meehan K, Alaka KJ, Birkett M, Breier A, David S, Ferchland I, et al</references>
        <references>Short-acting intramuscular olanzapine in acutely agitated schizophrenic patients: A randomized double blind trial vs. placebo and haloperidol</references>
        <references>Psychosomatics</references>
        <references>2001</references>
        <references>42</references>
        <references>2</references>
        <references>197-8</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>CONFERENCE_PROC</references>
        <references>NO</references>
        <references>Meehan K, Wright P, David SR, Alaka K, Taylor CC, Breier A, et al</references>
        <references>Agitation as a treatable symptom common to schizophrenia, acute mania and dementia</references>
        <references>Proceedings of the 57th Annual Meeting of the Society of Biological Psychiatry; 2002 May 16-18; Philadelphia, Pennsylvania, USA</references>
        <references>2002</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Meehan K, Wright P, David SR, Alaka K, Taylor CC, Breier A, et al</references>
        <references>Agitation as a treatable symptom common to schizophrenia, acute mania, and dementia</references>
        <references>Schizophrenia Research</references>
        <references>2002</references>
        <references>53</references>
        <references>3 Suppl 1</references>
        <references>63</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Wright P, Birkett M, David SR, Meehan K, Ferchland I, Alaka KJ, et al</references>
        <references>Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia</references>
        <references>American Journal of Psychiatry</references>
        <references>2001</references>
        <references>158</references>
        <references>7</references>
        <references>1149-51</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Wright P, Birkett M, Ferchland I, David S, Alaka K, Pullen P, et al</references>
        <references>A double-blind study of intramuscular olanzapine, haloperidol and placebo in acutely agitated schizophrenic patients</references>
        <references>European Neuropsychopharmacology</references>
        <references>2000</references>
        <references>10</references>
        <references>Suppl 3</references>
        <references>S304</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Wright P, Birkett M, Meehan K, Ferchland I, David S, Alaka K, et al</references>
        <references>A double-blind study of intramuscular olanzapine, haloperidol and placebo in acutely agitated schizophrenic patients</references>
        <references>International Journal of Neuropsychopharmacology</references>
        <references>2000</references>
        <references>3</references>
        <references>Suppl 1</references>
        <references>S139</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Wright P, Lindborg SR, Birkett M, Meehan K, Jones B, Alaka K, et al</references>
        <references>Intramuscular olanzapine and intramuscular haloperidol in acute schizophrenia: antipsychotic efficacy and extrapyramidal safety during the first 24 hours of treatment</references>
        <references>Canadian Journal of Psychiatry [Revue Canadienne de Psychiatrie]</references>
        <references>2003</references>
        <references>48</references>
        <references>11</references>
        <references>716-21</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Wright P, Meehan K, Birkett M, Lindborg SR, Taylor CC, Morris PBA</references>
        <references>A comparison of the efficacy and safety of olanzapine versus haloperidol during transition from intramuscular to oral therapy</references>
        <references>Clinical Therapeutics</references>
        <references>2003</references>
        <references>25</references>
        <references>5</references>
        <references>1420-8</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>No indication of selective reporting.</reportingBiasJudgement>
        <reportingBiasRisk>Low risk</reportingBiasRisk>
        <revManID>STD-Battaglia-2002</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement>Not stated.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Unclear Risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>Described as randomised - method of randomisation is not reported.</selectionBiasRandomSequenceJudgement>
        <year>2002</year>
    </trialList>
    <trialList>
        <attritionBiasJudgement></attritionBiasJudgement>
        <attritionBiasRisk>Unclear Risk</attritionBiasRisk>
        <authorYearLetter>bla1993</authorYearLetter>
        <countries></countries>
        <crgID>0</crgID>
        <crossoverTrial>false</crossoverTrial>
        <detectionBiasJudgement></detectionBiasJudgement>
        <detectionBiasRisk>Unclear Risk</detectionBiasRisk>
        <factorialTrial>false</factorialTrial>
        <mainAuthor>bla</mainAuthor>
        <meerKatCountry></meerKatCountry>
        <nrControl>0</nrControl>
        <nrIntervention>0</nrIntervention>
        <nrOfParticipants>0</nrOfParticipants>
        <otherBiasJudgement></otherBiasJudgement>
        <otherBiasRisk>Unclear Risk</otherBiasRisk>
        <otherDesign>false</otherDesign>
        <paralellTrial>false</paralellTrial>
        <performanceBiasJudgement></performanceBiasJudgement>
        <performanceBiasRisk>Unclear Risk</performanceBiasRisk>
        <references>BOOK_SECTION</references>
        <references>NO</references>
        <references>1 to 11</references>
        <references>2</references>
        <references>4</references>
        <references>5</references>
        <references>6</references>
        <references></references>
        <references>7</references>
        <references>3</references>
        <references>8</references>
        <references>9</references>
        <references>10</references>
        <references>11</references>
        <references></references>
        <references>CORRESPONDENCE</references>
        <references>NO</references>
        <references>1 to 5</references>
        <references>2</references>
        <references>4</references>
        <references>5</references>
        <references></references>
        <references></references>
        <references></references>
        <references>3</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>BOOK</references>
        <references>NO</references>
        <references>1 to 7</references>
        <references></references>
        <references>2</references>
        <references>3</references>
        <references>4</references>
        <references></references>
        <references></references>
        <references></references>
        <references>5</references>
        <references></references>
        <references>6</references>
        <references>7</references>
        <references></references>
        <references>COCHRANE_PROTOCOL</references>
        <references>NO</references>
        <references>1-6</references>
        <references>2</references>
        <references>Cochrane Database of Systematic Reviews</references>
        <references>5</references>
        <references></references>
        <references>6</references>
        <references></references>
        <references>3</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>COCHRANE_REVIEW</references>
        <references>NO</references>
        <references>1-6</references>
        <references>2</references>
        <references>Cochrane Database of Systematic Reviews</references>
        <references>5</references>
        <references></references>
        <references>6</references>
        <references></references>
        <references>3</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>COMPUTER_PROGRAM</references>
        <references>NO</references>
        <references>1-8</references>
        <references>2</references>
        <references></references>
        <references>4</references>
        <references></references>
        <references></references>
        <references></references>
        <references>3</references>
        <references>5</references>
        <references></references>
        <references>6</references>
        <references>7</references>
        <references>8</references>
        <reportingBiasJudgement></reportingBiasJudgement>
        <reportingBiasRisk>Unclear Risk</reportingBiasRisk>
        <revManID>STD-bla-1993</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement></selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Unclear Risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement></selectionBiasRandomSequenceJudgement>
        <year>1993</year>
    </trialList>
    <trialList>
        <attritionBiasJudgement>Reasons why all participants that left the study early were not reported.</attritionBiasJudgement>
        <attritionBiasRisk>High risk</attritionBiasRisk>
        <authorYearLetter>Breier2001</authorYearLetter>
        <countries>Croatia, Italy, Romania, South Africa</countries>
        <crgID>0</crgID>
        <crossoverTrial>false</crossoverTrial>
        <detectionBiasJudgement>"Investigators, patients, clinical carers and raters were blinded."</detectionBiasJudgement>
        <detectionBiasRisk>Low risk</detectionBiasRisk>
        <dobj>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE</comparisonName>
            <group1Events>7</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>40</group1Total>
            <group2Events>1</group2Events>
            <group2Name>olanzapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>46</group2Total>
            <outcomeName>Adverse effects: 2i. Specific - movement disorder - i. various</outcomeName>
            <subgroupName>EPS during 24 hours</subgroupName>
        </dobj>
        <factorialTrial>false</factorialTrial>
        <mainAuthor>Breier</mainAuthor>
        <meerKatCountry>Multi-Center//Croatia//Italy//Romania//South Africa</meerKatCountry>
        <nrControl>0</nrControl>
        <nrIntervention>0</nrIntervention>
        <nrOfParticipants>0</nrOfParticipants>
        <otherBiasJudgement>Trial sponsored by manufacturers of olanzapine IM.</otherBiasJudgement>
        <otherBiasRisk>High risk</otherBiasRisk>
        <otherDesign>false</otherDesign>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs PLACEBO/NIL</comparisonName>
            <group1Events>10</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>40</group1Total>
            <group2Events>30</group2Events>
            <group2Name>placebo</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>45</group2Total>
            <outcomeName>Repeated need for tranquillisation</outcomeName>
            <subgroupName>needing additional injection during 24 hours (agitation only)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs PLACEBO/NIL</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>40</group1Total>
            <group2Events>16</group2Events>
            <group2Name>placebo</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>45</group2Total>
            <outcomeName>Global outcome: 2. Need for benzodiazepine up to 24 hours</outcomeName>
            <subgroupName>need for benzodiazepine up to 24 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs PLACEBO/NIL</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>40</group1Total>
            <group2Events>0</group2Events>
            <group2Name>placebo</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>45</group2Total>
            <outcomeName>Adverse effects: 2b. Specific - cardiovascular - miscellaneous outcomes</outcomeName>
            <subgroupName>hypotension during 24 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs PLACEBO/NIL</comparisonName>
            <group1Events>2</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>40</group1Total>
            <group2Events>0</group2Events>
            <group2Name>placebo</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>45</group2Total>
            <outcomeName>Adverse effects: 2d. Specific - movement disorders</outcomeName>
            <subgroupName>dystonia during 24 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs PLACEBO/NIL</comparisonName>
            <group1Events>7</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>40</group1Total>
            <group2Events>0</group2Events>
            <group2Name>placebo</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>45</group2Total>
            <outcomeName>Adverse effects: 2d. Specific - movement disorders</outcomeName>
            <subgroupName>EPS during 24 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE</comparisonName>
            <group1Events>10</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>40</group1Total>
            <group2Events>11</group2Events>
            <group2Name>olanzapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>46</group2Total>
            <outcomeName>Repeated need for tranquillisation - needing additional injection</outcomeName>
            <subgroupName>by 24 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>40</group1Total>
            <group2Events>4</group2Events>
            <group2Name>olanzapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>46</group2Total>
            <outcomeName>Global outcome: 1a. General - need for additional measures</outcomeName>
            <subgroupName>need for benzodiazepine during 24 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol </group1Name>
            <group1NameProse>HALOPERIDOL </group1NameProse>
            <group1Total>40</group1Total>
            <group2Events>2</group2Events>
            <group2Name>olanzapine</group2Name>
            <group2NameProse> other antipsychotic: e. olanzapine</group2NameProse>
            <group2Total>46</group2Total>
            <outcomeName>Adverse effects: 2f. Specific - cardiovascular i. binary</outcomeName>
            <subgroupName>hypotension during 24 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE</comparisonName>
            <group1Events>2</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>40</group1Total>
            <group2Events>0</group2Events>
            <group2Name>olanzapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>46</group2Total>
            <outcomeName>Adverse effects: 2i. Specific - movement disorder - i. various</outcomeName>
            <subgroupName>dystonia during 24 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE</comparisonName>
            <group1Events>7</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>40</group1Total>
            <group2Events>1</group2Events>
            <group2Name>olanzapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>46</group2Total>
            <outcomeName>Adverse effects: 2i. Specific - movement disorder - i. various</outcomeName>
            <subgroupName>EPS during 24 hours</subgroupName>
        </outcomeList>
        <paralellTrial>false</paralellTrial>
        <performanceBiasJudgement>"unblinded third-party personnel, who played no role in evaluating patients, were trained to handle and administer injections in identical, unmarked syringes." "Investigators, patients, clinical carers and raters were blinded."</performanceBiasJudgement>
        <performanceBiasRisk>Low risk</performanceBiasRisk>
        <references>JOURNAL_ARTICLE</references>
        <references>YES</references>
        <references>Breier A, Meehan K, Birkett M, David S, Ferchland I, Sutton V, et al</references>
        <references>A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia</references>
        <references>Archives of General Psychiatry</references>
        <references>2002</references>
        <references>59</references>
        <references>5</references>
        <references>441-8</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Breier A, Wright P, Birkett M, David S, Brook S, Meehan K</references>
        <references>A double-blind dose response study comparing intramuscular (IM) olanzapine, haloperidol, and placebo in acutely agitated schizophrenic patients</references>
        <references>Biological Psychiatry</references>
        <references>2001</references>
        <references>49</references>
        <references>8</references>
        <references>121S</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>CONFERENCE_PROC</references>
        <references>NO</references>
        <references>Breier A, Wright P, Birkett M, Meehan K, David S, Brook S</references>
        <references>A double-blind dose response study comparing intramuscular olanzapine, haloperidol and placebo in acutely agitated schizophrenic patients</references>
        <references>Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology; 2000 Dec 10-14; San Juan, Puerto Rico</references>
        <references>2000</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>CONFERENCE_PROC</references>
        <references>NO</references>
        <references>Breier AF, Wright P, Birkett M, Meehan K, David SR, Brook S</references>
        <references>Intramuscular olanzapine: dose-related improvement in acutely agitated patients with schizophrenia</references>
        <references>Proceedings of the 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans, Louisiana, USA</references>
        <references>2001</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>Marathon Multimedia</references>
        <references></references>
        <references></references>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Smith RC</references>
        <references>10 mg intramuscular olanzapine reduces acute agitation in schizophrenia more effectively than lower doses [Commentary]</references>
        <references>Evidence-Based Mental Health</references>
        <references>2003</references>
        <references>6</references>
        <references>1</references>
        <references>27</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Wright P, Birkett MA, Meehan K, David SR, Brook S, Breier</references>
        <references>A double-blind dose response study comparing intramuscular olanzapine, haloperidol and placebo in acutely agitated schizophrenic patients</references>
        <references>Schizophrenia Research</references>
        <references>2001</references>
        <references>49</references>
        <references>1-2</references>
        <references>250-1</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>It is not clear whether all side effects are reported.</reportingBiasJudgement>
        <reportingBiasRisk>Unclear Risk</reportingBiasRisk>
        <revManID>STD-Breier-2002</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Low risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement>"Allocation concealed placebo-controlled trial." Method of randomisation not reported.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Unclear Risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>Described as randomised - method of randomisation is not reported.</selectionBiasRandomSequenceJudgement>
        <year>2001</year>
    </trialList>
    <trialList>
        <attritionBiasJudgement>Reasons why all participants that left the study early were not reported.</attritionBiasJudgement>
        <attritionBiasRisk>High risk</attritionBiasRisk>
        <authorYearLetter>Bristol-Myers2004a</authorYearLetter>
        <countries>Croatia, Czech Republic, Estonia, France, Italy, Latvia, Puerto Rico, Poland, South Africa, Spain, USA</countries>
        <crgID>0</crgID>
        <crossoverTrial>false</crossoverTrial>
        <detectionBiasJudgement>Described as "double blind", however no further details are given.</detectionBiasJudgement>
        <detectionBiasRisk>Unclear Risk</detectionBiasRisk>
        <dobj>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: a. ARIPIPRAZOLE</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>185</group1Total>
            <group2Events>2</group2Events>
            <group2Name>aripiprazole</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>175</group2Total>
            <outcomeName>Leaving the study early: 1. For specific reasons</outcomeName>
            <subgroupName>other</subgroupName>
        </dobj>
        <factorialTrial>false</factorialTrial>
        <mainAuthor>Bristol-Myers</mainAuthor>
        <meerKatCountry>Multi-Center//Croatia//Czech Republic//Estonia//France//Italy//Latvia//Puerto Rico//Poland//South Africa//Spain//USA</meerKatCountry>
        <nrControl>0</nrControl>
        <nrIntervention>0</nrIntervention>
        <nrOfParticipants>0</nrOfParticipants>
        <otherBiasJudgement>Sponsored by the manufacturers of aripiprazole.</otherBiasJudgement>
        <otherBiasRisk>High risk</otherBiasRisk>
        <otherDesign>false</otherDesign>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs PLACEBO/NIL</comparisonName>
            <group1Events>63</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>185</group1Total>
            <group2Events>50</group2Events>
            <group2Name>placebo</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>88</group2Total>
            <outcomeName>Repeated need for tranquillisation</outcomeName>
            <subgroupName>needing additional injection during 24 hours (agitation only)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs PLACEBO/NIL</comparisonName>
            <group1Events>107</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>185</group1Total>
            <group2Events>32</group2Events>
            <group2Name>placebo</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>88</group2Total>
            <outcomeName>Specific behaviour: 1a. Agitation - various measures</outcomeName>
            <subgroupName>PANSS-EC response at 2 hours (at least 40% change on PANSS-EC from baseline)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs PLACEBO/NIL</comparisonName>
            <group1Events>22</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>185</group1Total>
            <group2Events>17</group2Events>
            <group2Name>placebo</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>88</group2Total>
            <outcomeName>Global outcome: 2. Need for benzodiazepine up to 24 hours</outcomeName>
            <subgroupName>need for benzodiazepine up to 24 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs PLACEBO/NIL</comparisonName>
            <group1Events>82</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>185</group1Total>
            <group2Events>24</group2Events>
            <group2Name>placebo</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>88</group2Total>
            <outcomeName>Adverse effects: 1a. General</outcomeName>
            <subgroupName>one or more drug related adverse events during 24 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs PLACEBO/NIL</comparisonName>
            <group1Events>82</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>185</group1Total>
            <group2Events>12</group2Events>
            <group2Name>placebo</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>88</group2Total>
            <outcomeName>Adverse effects: 1a. General</outcomeName>
            <subgroupName>increased severity of adverse effects after 2nd injection</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs PLACEBO/NIL</comparisonName>
            <group1Events>90</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>185</group1Total>
            <group2Events>24</group2Events>
            <group2Name>placebo</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>88</group2Total>
            <outcomeName>Adverse effects: 1a. General</outcomeName>
            <subgroupName>overall adverse events during 72 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs PLACEBO/NIL</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>185</group1Total>
            <group2Events>0</group2Events>
            <group2Name>placebo</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>88</group2Total>
            <outcomeName>Adverse effects: 1b. General - serious</outcomeName>
            <subgroupName>death</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs PLACEBO/NIL</comparisonName>
            <group1Events>22</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>185</group1Total>
            <group2Events>8</group2Events>
            <group2Name>placebo</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>88</group2Total>
            <outcomeName>Adverse effects: 2a. Specific - arousal level</outcomeName>
            <subgroupName>insomnia during 24 hours (only reported if occurred in ≧5%)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs PLACEBO/NIL</comparisonName>
            <group1Events>28</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>185</group1Total>
            <group2Events>5</group2Events>
            <group2Name>placebo</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>88</group2Total>
            <outcomeName>Adverse effects: 2a. Specific - arousal level</outcomeName>
            <subgroupName>"over" sedated</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs PLACEBO/NIL</comparisonName>
            <group1Events>6</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>185</group1Total>
            <group2Events>1</group2Events>
            <group2Name>placebo</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>88</group2Total>
            <outcomeName>Adverse effects: 2a. Specific - arousal level</outcomeName>
            <subgroupName>somnolence during 24 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs PLACEBO/NIL</comparisonName>
            <group1Events>7</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>185</group1Total>
            <group2Events>2</group2Events>
            <group2Name>placebo</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>88</group2Total>
            <outcomeName>Adverse effects: 2b. Specific - cardiovascular - miscellaneous outcomes</outcomeName>
            <subgroupName>dizziness during 24 hours (only reported if occurred in ≧5%)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs PLACEBO/NIL</comparisonName>
            <group1Events>23</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>185</group1Total>
            <group2Events>2</group2Events>
            <group2Name>placebo</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>88</group2Total>
            <outcomeName>Adverse effects: 2d. Specific - movement disorders</outcomeName>
            <subgroupName>EPS during 24 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs PLACEBO/NIL</comparisonName>
            <group1Events>8</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>185</group1Total>
            <group2Events>5</group2Events>
            <group2Name>placebo</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>88</group2Total>
            <outcomeName>Adverse effects: 2f. Specific - miscellaneous</outcomeName>
            <subgroupName>agitation during 24 hours (only reported if occurred in ≧5%)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs PLACEBO/NIL</comparisonName>
            <group1Events>15</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>185</group1Total>
            <group2Events>6</group2Events>
            <group2Name>placebo</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>88</group2Total>
            <outcomeName>Adverse effects: 2f. Specific - miscellaneous</outcomeName>
            <subgroupName>headache during 24 hours (only reported if occurred in ≧5%)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs PLACEBO/NIL</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>185</group1Total>
            <group2Events>2</group2Events>
            <group2Name>placebo</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>88</group2Total>
            <outcomeName>Adverse effects: 2f. Specific - miscellaneous</outcomeName>
            <subgroupName>pain (1st injection)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs PLACEBO/NIL</comparisonName>
            <group1Events>82</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>185</group1Total>
            <group2Events>12</group2Events>
            <group2Name>placebo</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>88</group2Total>
            <outcomeName>Adverse effects: 2f. Specific - miscellaneous</outcomeName>
            <subgroupName>pain (2nd injection)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs PLACEBO/NIL</comparisonName>
            <group1Events>2</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>185</group1Total>
            <group2Events>1</group2Events>
            <group2Name>placebo</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>88</group2Total>
            <outcomeName>Adverse effects: 2f. Specific - miscellaneous</outcomeName>
            <subgroupName>nausea during 24 hours (only reported if occurred in ≧5%)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs PLACEBO/NIL</comparisonName>
            <group1Events>7</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>185</group1Total>
            <group2Events>1</group2Events>
            <group2Name>placebo</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>88</group2Total>
            <outcomeName>Leaving the study early</outcomeName>
            <subgroupName>any reason</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs PLACEBO/NIL</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>185</group1Total>
            <group2Events>1</group2Events>
            <group2Name>placebo</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>88</group2Total>
            <outcomeName>Leaving the study early</outcomeName>
            <subgroupName>lack of efficacy</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs PLACEBO/NIL</comparisonName>
            <group1Events>3</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>185</group1Total>
            <group2Events>0</group2Events>
            <group2Name>placebo</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>88</group2Total>
            <outcomeName>Leaving the study early</outcomeName>
            <subgroupName>withdrew</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs PLACEBO/NIL</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>185</group1Total>
            <group2Events>0</group2Events>
            <group2Name>placebo</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>88</group2Total>
            <outcomeName>Leaving the study early</outcomeName>
            <subgroupName>consent</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs PLACEBO/NIL</comparisonName>
            <group1Events>2</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>185</group1Total>
            <group2Events>0</group2Events>
            <group2Name>placebo</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>88</group2Total>
            <outcomeName>Leaving the study early</outcomeName>
            <subgroupName>adverse effects</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs PLACEBO/NIL</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>185</group1Total>
            <group2Events>0</group2Events>
            <group2Name>placebo</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>88</group2Total>
            <outcomeName>Leaving the study early</outcomeName>
            <subgroupName>other</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: a. ARIPIPRAZOLE</comparisonName>
            <group1Events>82</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>185</group1Total>
            <group2Events>64</group2Events>
            <group2Name>aripiprazole</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>175</group2Total>
            <outcomeName>Adverse effects: 1a. General</outcomeName>
            <subgroupName>one or more drug related adverse effects during 24 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: a. ARIPIPRAZOLE</comparisonName>
            <group1Events>82</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>185</group1Total>
            <group2Events>58</group2Events>
            <group2Name>aripiprazole</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>175</group2Total>
            <outcomeName>Adverse effects: 1a. General</outcomeName>
            <subgroupName>increased severity of adverse effects after 2nd injection</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: a. ARIPIPRAZOLE</comparisonName>
            <group1Events>90</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>185</group1Total>
            <group2Events>64</group2Events>
            <group2Name>aripiprazole</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>175</group2Total>
            <outcomeName>Adverse effects: 1a. General</outcomeName>
            <subgroupName>overall adverse events during 72 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: a. ARIPIPRAZOLE</comparisonName>
            <group1Events>4</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>185</group1Total>
            <group2Events>4</group2Events>
            <group2Name>aripiprazole</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>175</group2Total>
            <outcomeName>Adverse effects: 1b. General - serious</outcomeName>
            <subgroupName>any</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: a. ARIPIPRAZOLE</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>185</group1Total>
            <group2Events>0</group2Events>
            <group2Name>aripiprazole</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>175</group2Total>
            <outcomeName>Adverse effects: 1b. General - serious</outcomeName>
            <subgroupName>death</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: a. ARIPIPRAZOLE</comparisonName>
            <group1Events>22</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>185</group1Total>
            <group2Events>10</group2Events>
            <group2Name>aripiprazole</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>175</group2Total>
            <outcomeName>Adverse effects: 2a. Specific - arousal level</outcomeName>
            <subgroupName>insomnia - between 0-1 days (IM phase) (only reported if occurred in ≥5%)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: a. ARIPIPRAZOLE</comparisonName>
            <group1Events>20</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>185</group1Total>
            <group2Events>23</group2Events>
            <group2Name>aripiprazole</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>175</group2Total>
            <outcomeName>Adverse effects: 2a. Specific - arousal level</outcomeName>
            <subgroupName>insomnia - between 3 - 7 days (oral phase) (only reported if occurred in ≥ 2%)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: a. ARIPIPRAZOLE</comparisonName>
            <group1Events>28</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>185</group1Total>
            <group2Events>16</group2Events>
            <group2Name>aripiprazole</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>175</group2Total>
            <outcomeName>Adverse effects: 2a. Specific - arousal level</outcomeName>
            <subgroupName>"over" sedated</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: a. ARIPIPRAZOLE</comparisonName>
            <group1Events>6</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>185</group1Total>
            <group2Events>8</group2Events>
            <group2Name>aripiprazole</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>175</group2Total>
            <outcomeName>Adverse effects: 2a. Specific - arousal level</outcomeName>
            <subgroupName>somnolence - between 0-1 days</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: a. ARIPIPRAZOLE</comparisonName>
            <group1Events>3</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>185</group1Total>
            <group2Events>1</group2Events>
            <group2Name>aripiprazole</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>175</group2Total>
            <outcomeName>Adverse effects: 2a. Specific - arousal level</outcomeName>
            <subgroupName>somnolence - between 3 - 7 days (oral phase) (only reported if occurred in ≥ 2%)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: a. ARIPIPRAZOLE</comparisonName>
            <group1Events>7</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>185</group1Total>
            <group2Events>11</group2Events>
            <group2Name>aripiprazole</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>175</group2Total>
            <outcomeName>Adverse effects: 2b. Specific - cardiac</outcomeName>
            <subgroupName>dizziness - between 0 -1 day (IM phase) (only reported if occurred in ≥5%)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: a. ARIPIPRAZOLE</comparisonName>
            <group1Events>11</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>185</group1Total>
            <group2Events>1</group2Events>
            <group2Name>aripiprazole</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>175</group2Total>
            <outcomeName>Adverse effects: 2c. Specific - gastrointestinal</outcomeName>
            <subgroupName>dyspepsia - between 3 - 7 days (oral phase) (only reported if occurred in ≥ 2%)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: a. ARIPIPRAZOLE</comparisonName>
            <group1Events>5</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>185</group1Total>
            <group2Events>5</group2Events>
            <group2Name>aripiprazole</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>175</group2Total>
            <outcomeName>Adverse effects: 2c. Specific - gastrointestinal</outcomeName>
            <subgroupName>diarrhoea - between 3 - 7 days (oral phase) (only reported if occurred in ≥ 2%)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: a. ARIPIPRAZOLE</comparisonName>
            <group1Events>2</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>185</group1Total>
            <group2Events>10</group2Events>
            <group2Name>aripiprazole</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>175</group2Total>
            <outcomeName>Adverse effects: 2c. Specific - gastrointestinal</outcomeName>
            <subgroupName>nausea - between 0-1 days (IM phase) (only reported if occurred in ≥5%)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: a. ARIPIPRAZOLE</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>185</group1Total>
            <group2Events>7</group2Events>
            <group2Name>aripiprazole</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>175</group2Total>
            <outcomeName>Adverse effects: 2c. Specific - gastrointestinal</outcomeName>
            <subgroupName>nausea - between 3 - 7 days (oral phase) (only reported if occurred in ≥ 2%)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: a. ARIPIPRAZOLE</comparisonName>
            <group1Events>2</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>185</group1Total>
            <group2Events>5</group2Events>
            <group2Name>aripiprazole</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>175</group2Total>
            <outcomeName>Adverse effects: 2c. Specific - gastrointestinal</outcomeName>
            <subgroupName>vomiting - between 3 - 7 days (oral phase) (only reported if occurred in ≥ 2%)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: a. ARIPIPRAZOLE</comparisonName>
            <group1Events>6</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>185</group1Total>
            <group2Events>1</group2Events>
            <group2Name>aripiprazole</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>175</group2Total>
            <outcomeName>Adverse effects: 2d. Specific - movement disorder</outcomeName>
            <subgroupName>akathisia - between 0 -1 day (IM phase) (only reported if occurred in ≥5%)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: a. ARIPIPRAZOLE</comparisonName>
            <group1Events>7</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>185</group1Total>
            <group2Events>3</group2Events>
            <group2Name>aripiprazole</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>175</group2Total>
            <outcomeName>Adverse effects: 2d. Specific - movement disorder</outcomeName>
            <subgroupName>akathisia - between 3 - 7 days (oral phase) (only reported if occurred in ≥ 2%)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: a. ARIPIPRAZOLE</comparisonName>
            <group1Events>10</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>185</group1Total>
            <group2Events>1</group2Events>
            <group2Name>aripiprazole</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>175</group2Total>
            <outcomeName>Adverse effects: 2d. Specific - movement disorder</outcomeName>
            <subgroupName>dystonia - between 0 -1 day (IM phase) (only reported if occurred in ≥5%)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: a. ARIPIPRAZOLE</comparisonName>
            <group1Events>10</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>185</group1Total>
            <group2Events>1</group2Events>
            <group2Name>aripiprazole</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>175</group2Total>
            <outcomeName>Adverse effects: 2d. Specific - movement disorder</outcomeName>
            <subgroupName>EPS - between 0 -1 day (IM phase) (only reported if occurred in ≥5%)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: a. ARIPIPRAZOLE</comparisonName>
            <group1Events>15</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>185</group1Total>
            <group2Events>2</group2Events>
            <group2Name>aripiprazole</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>175</group2Total>
            <outcomeName>Adverse effects: 2d. Specific - movement disorder</outcomeName>
            <subgroupName>EPS - between 3 - 7 days (oral phase) (only reported if occurred in ≥ 2%)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: a. ARIPIPRAZOLE</comparisonName>
            <group1Events>47</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>185</group1Total>
            <group2Events>9</group2Events>
            <group2Name>aripiprazole</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>175</group2Total>
            <outcomeName>Adverse effects: 2d. Specific - movement disorder</outcomeName>
            <subgroupName>Use of antiparkinson drugs - between 3 - 7 days (oral phase)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: a. ARIPIPRAZOLE</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>185</group1Total>
            <group2Events>0</group2Events>
            <group2Name>aripiprazole</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>175</group2Total>
            <outcomeName>Adverse effects: 2d. Specific - movement disorder</outcomeName>
            <subgroupName>dystonia</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: a. ARIPIPRAZOLE</comparisonName>
            <group1Events>8</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>185</group1Total>
            <group2Events>5</group2Events>
            <group2Name>aripiprazole</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>175</group2Total>
            <outcomeName>Adverse effects: 2e. Specific - miscellaneous</outcomeName>
            <subgroupName>agitation - between 0 -1 day (IM phase) (only reported if occurred in ≥5%)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: a. ARIPIPRAZOLE</comparisonName>
            <group1Events>31</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>185</group1Total>
            <group2Events>27</group2Events>
            <group2Name>aripiprazole</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>175</group2Total>
            <outcomeName>Adverse effects: 2e. Specific - miscellaneous</outcomeName>
            <subgroupName>agitation - between 3 - 7 days (oral phase) (only reported if occurred in ≥ 2%)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: a. ARIPIPRAZOLE</comparisonName>
            <group1Events>11</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>185</group1Total>
            <group2Events>8</group2Events>
            <group2Name>aripiprazole</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>175</group2Total>
            <outcomeName>Adverse effects: 2e. Specific - miscellaneous</outcomeName>
            <subgroupName>anxiety - between 3 - 7 days (oral phase) (only reported if occurred in ≥ 2%)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: a. ARIPIPRAZOLE</comparisonName>
            <group1Events>15</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>185</group1Total>
            <group2Events>13</group2Events>
            <group2Name>aripiprazole</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>175</group2Total>
            <outcomeName>Adverse effects: 2e. Specific - miscellaneous</outcomeName>
            <subgroupName>headache - between 0 -1 day (IM phase) (only reported if occurred in ≥5%)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: a. ARIPIPRAZOLE</comparisonName>
            <group1Events>19</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>185</group1Total>
            <group2Events>17</group2Events>
            <group2Name>aripiprazole</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>175</group2Total>
            <outcomeName>Adverse effects: 2e. Specific - miscellaneous</outcomeName>
            <subgroupName>headache - between 3 - 7 days (oral phase) (only reported if occurred in ≥ 2%)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: a. ARIPIPRAZOLE</comparisonName>
            <group1Events>2</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>185</group1Total>
            <group2Events>6</group2Events>
            <group2Name>aripiprazole</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>175</group2Total>
            <outcomeName>Adverse effects: 2e. Specific - miscellaneous</outcomeName>
            <subgroupName>pain (1st injection)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: a. ARIPIPRAZOLE</comparisonName>
            <group1Events>82</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>185</group1Total>
            <group2Events>58</group2Events>
            <group2Name>aripiprazole</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>175</group2Total>
            <outcomeName>Adverse effects: 2e. Specific - miscellaneous</outcomeName>
            <subgroupName>pain (2nd injection)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: a. ARIPIPRAZOLE</comparisonName>
            <group1Events>7</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>185</group1Total>
            <group2Events>5</group2Events>
            <group2Name>aripiprazole</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>175</group2Total>
            <outcomeName>Leaving the study early: 1. For specific reasons</outcomeName>
            <subgroupName>any</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: a. ARIPIPRAZOLE</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>185</group1Total>
            <group2Events>0</group2Events>
            <group2Name>aripiprazole</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>175</group2Total>
            <outcomeName>Leaving the study early: 1. For specific reasons</outcomeName>
            <subgroupName>lack of efficacy</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: a. ARIPIPRAZOLE</comparisonName>
            <group1Events>2</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>185</group1Total>
            <group2Events>1</group2Events>
            <group2Name>aripiprazole</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>175</group2Total>
            <outcomeName>Leaving the study early: 1. For specific reasons</outcomeName>
            <subgroupName>adverse effects</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: a. ARIPIPRAZOLE</comparisonName>
            <group1Events>3</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>185</group1Total>
            <group2Events>2</group2Events>
            <group2Name>aripiprazole</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>175</group2Total>
            <outcomeName>Leaving the study early: 1. For specific reasons</outcomeName>
            <subgroupName>withdrew</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: a. ARIPIPRAZOLE</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>185</group1Total>
            <group2Events>0</group2Events>
            <group2Name>aripiprazole</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>175</group2Total>
            <outcomeName>Leaving the study early: 1. For specific reasons</outcomeName>
            <subgroupName>consent</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: a. ARIPIPRAZOLE</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>185</group1Total>
            <group2Events>2</group2Events>
            <group2Name>aripiprazole</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>175</group2Total>
            <outcomeName>Leaving the study early: 1. For specific reasons</outcomeName>
            <subgroupName>other</subgroupName>
        </outcomeList>
        <paralellTrial>false</paralellTrial>
        <performanceBiasJudgement>During the IM phase, haloperidol, aripiprazole and placebo were delivered in 1.3 mL injections. However, in the oral phase a tablet was used for aripiprazole and a capsule was used for haloperidol and so it is possible that this presented a risk to blinding.</performanceBiasJudgement>
        <performanceBiasRisk>Unclear Risk</performanceBiasRisk>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Andrezina R, Josiassen RC, Marcus RN, Oren DA, Manos G, Stock E, et al</references>
        <references>Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol</references>
        <references>Psychopharmacology</references>
        <references>2006</references>
        <references>188</references>
        <references>3</references>
        <references>281-92</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Andrezina R, Marcus RN, Oren DA, Manos G, Stock E, Carson WH, et al</references>
        <references>Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: sub-analysis of a double-blind study</references>
        <references>Current Medical Research and Opinion</references>
        <references>2006</references>
        <references>22</references>
        <references>11</references>
        <references>2209-19</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>OTHER</references>
        <references>YES</references>
        <references>Bristol-Myers S</references>
        <references>A randomized, double-blind comparison of the efficacy and safety of aripiprazole intramuscular formula, haloperidol, or placebo in the treatment of acutely agitated patients with a diagnosis of schizophrenia or schizoaffective disorder</references>
        <references>http://www.clinicalstudyresults.org/</references>
        <references>2004</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>CONFERENCE_PROC</references>
        <references>NO</references>
        <references>Citrome LL, Vester-Blokland E, Archibald D, McQuade R, Kostic D, Pikalov A, et al</references>
        <references>Benefits of a second dose of intramuscular (IM) aripiprazole to control agitation in patients with schizophrenia or bipolar I disorder</references>
        <references>Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25, Toronto, Canada</references>
        <references>2006</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>CONFERENCE_PROC</references>
        <references>NO</references>
        <references>Currier GW, Crandall D, Archibald D, Nyilas M, Kostic D, Pikalov A, et al</references>
        <references>Intramuscular (IM) aripiprazole controls agitation in patients with schizophrenia or bipolar disorder without excessive sedation</references>
        <references>Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25; Toronto, Canada</references>
        <references>2006</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Daniel DG, Currier GW, Zimbroff DL, Allen MH, Oren D, Manos G, et al</references>
        <references>Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations</references>
        <references>Journal of Psychiatric Practice</references>
        <references>2007</references>
        <references>13</references>
        <references>3</references>
        <references>170-7</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>CONFERENCE_PROC</references>
        <references>NO</references>
        <references>Daniel DG, Stock EG, Wilber CH, Marcus RN, Carson WH Jr, Manos G, et al</references>
        <references>Intramuscular aripiprazole in acutely agitated psychotic patients</references>
        <references>Proceedings of the 157th Annual Meeting of the American Psychiatric Association; 2004 May 1-6; New York, USA</references>
        <references>2004</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Dillenschneider A, Oren D, Marcus R, Kostic D, McQuade R, Iwamoto T, et al</references>
        <references>Comparison of intramuscular aripiprazole and haloperidol with placebo in acutely agitated schizophrenia patients</references>
        <references>European Neuropsychopharmacology</references>
        <references>2005</references>
        <references>15</references>
        <references>Suppl 3</references>
        <references>S509</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>OTHER</references>
        <references>NO</references>
        <references>Dillenschneider A, Oren D, Marcus R, Kostic D, McQuade R, Iwamoto T, et al</references>
        <references>Intramuscular aripiprazole in acute schizophrenia: a pivotal phase III study</references>
        <references>Proceedings of the 18th European College of Neuropsychopharmacology Congress; 2005 Oct 22-26; Amsterdam, Netherlands</references>
        <references>2005</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>CONFERENCE_PROC</references>
        <references>NO</references>
        <references>McQuade R, Auby P, Oren D, Marcus R, Kostic D, Iwamoto T, et al</references>
        <references>Intramuscular aripiprazole in acute schizophrenia: a double-blind, placebo-controlled comparison with IM haloperidol</references>
        <references>Proceedings of the 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4-10; Davos, Switzerland</references>
        <references>2006</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Oren D, Marcus R, Kostic D, McQuade R, Iwamoto T, Archibald D</references>
        <references>Efficacy and safety of intramuscular aripiprazole, haloperidol or PLACEBO in acutely agitated patients with schizophrenia or schizoaffective disorder</references>
        <references>Schizophrenia Bulletin</references>
        <references>2005</references>
        <references>31</references>
        <references></references>
        <references>499</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>OTHER</references>
        <references>NO</references>
        <references>Oren D, Marcus R, Kostic D, McQuade R, Iwamoto T, Archibald D</references>
        <references>Efficacy and safety of intramuscular aripiprazole, haloperidol or placebo in acutely agitated patients with schizophrenia or schizoaffective disorder</references>
        <references>Proceedings of the 158th Annual Meeting of the American Psychiatric Association; 2005 May 21-26; Atlanta, Georgia, USA</references>
        <references>2005</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Oren DA, Marcus RN, Manos G, Carson WH, McQuade D</references>
        <references>Non-inferiority of intramuscular aripiprazole versus intramuscular haloperidol for the treatment of agitation associated with schizophrenia/schizoaffective disorder</references>
        <references>Schizophrenia Bulletin</references>
        <references>2007</references>
        <references>33</references>
        <references>2</references>
        <references>451</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>OTHER</references>
        <references>NO</references>
        <references>Yocca F, Marcus R, Oren D, Manos G, Carson W, Iwamoto T, et al</references>
        <references>Intramuscular aripiprazole in acute schizophrenia: a pivotal phase III study</references>
        <references>Proceedings of the 158th Annual Meeting of the American Psychiatric Association; 2005 May 21-26, Atlanta, Georgia, USA</references>
        <references>2005</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>The author mentions that there is increased glucose levels in both aripiprazole and haloperidol group but does not provide data. The authors only report the side effects that occurred in ≥ 2% of people.</reportingBiasJudgement>
        <reportingBiasRisk>High risk</reportingBiasRisk>
        <revManID>STD-Bristol-Myers-2004a</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Low risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement>"Randomization was conducted via a centralized call-in system and was organized by study center using permuted block randomization".</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Unclear Risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>Described as randomised - method of randomisation is not reported.</selectionBiasRandomSequenceJudgement>
        <year>2004</year>
    </trialList>
    <trialList>
        <attritionBiasJudgement>The reasons for leaving the study early were reported for those participants who did not complete the study. However, the number of participants completing different assessments at the same time point vary and reasons are not given.</attritionBiasJudgement>
        <attritionBiasRisk>Unclear Risk</attritionBiasRisk>
        <authorYearLetter>Bristol-Myers2005b</authorYearLetter>
        <countries>Canada, Czech Republic, Estonia, France, Latvia, Lithuania, Spain, USA</countries>
        <crgID>0</crgID>
        <crossoverTrial>false</crossoverTrial>
        <detectionBiasJudgement>Study investigators conducting the assessments were blinded to treatment.</detectionBiasJudgement>
        <detectionBiasRisk>Low risk</detectionBiasRisk>
        <dobj>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: a. ARIPIPRAZOLE</comparisonName>
            <group1Events>2</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>60</group1Total>
            <group2Events>0</group2Events>
            <group2Name>aripiprazole</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>60</group2Total>
            <outcomeName>Leaving the study early: 1. For specific reasons</outcomeName>
            <subgroupName>other</subgroupName>
        </dobj>
        <factorialTrial>false</factorialTrial>
        <mainAuthor>Bristol-Myers</mainAuthor>
        <meerKatCountry>Multi-Center//Canada//Czech Republic//Estonia//France//Latvia//Lithuania//Spain//USA</meerKatCountry>
        <nrControl>0</nrControl>
        <nrIntervention>0</nrIntervention>
        <nrOfParticipants>0</nrOfParticipants>
        <otherBiasJudgement>Sponsored by the manufacturers of aripiprazole.</otherBiasJudgement>
        <otherBiasRisk>High risk</otherBiasRisk>
        <otherDesign>false</otherDesign>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs PLACEBO/NIL</comparisonName>
            <group1Events>15</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>60</group1Total>
            <group2Events>38</group2Events>
            <group2Name>placebo</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>62</group2Total>
            <outcomeName>Repeated need for tranquillisation</outcomeName>
            <subgroupName>needing additional injection during 24 hours (agitation only)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs PLACEBO/NIL</comparisonName>
            <group1Events>36</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>60</group1Total>
            <group2Events>22</group2Events>
            <group2Name>placebo</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>62</group2Total>
            <outcomeName>Specific behaviour: 1a. Agitation - various measures</outcomeName>
            <subgroupName>PANSS-EC response at 2 hours (at least 40% change on PANSS-EC from baseline)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs PLACEBO/NIL</comparisonName>
            <group1Events>6</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>60</group1Total>
            <group2Events>13</group2Events>
            <group2Name>placebo</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>62</group2Total>
            <outcomeName>Global outcome: 2. Need for benzodiazepine up to 24 hours</outcomeName>
            <subgroupName>need for benzodiazepine up to 24 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs PLACEBO/NIL</comparisonName>
            <group1Events>29</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>60</group1Total>
            <group2Events>18</group2Events>
            <group2Name>placebo</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>62</group2Total>
            <outcomeName>Adverse effects: 1a. General</outcomeName>
            <subgroupName>one or more drug related adverse events during 24 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs PLACEBO/NIL</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>60</group1Total>
            <group2Events>1</group2Events>
            <group2Name>placebo</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>62</group2Total>
            <outcomeName>Adverse effects: 1b. General - serious</outcomeName>
            <subgroupName>rated as serious</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs PLACEBO/NIL</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>60</group1Total>
            <group2Events>0</group2Events>
            <group2Name>placebo</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>57</group2Total>
            <outcomeName>Adverse effects: 1b. General - serious</outcomeName>
            <subgroupName>tonic clonic seizure</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs PLACEBO/NIL</comparisonName>
            <group1Events>7</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>60</group1Total>
            <group2Events>3</group2Events>
            <group2Name>placebo</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>62</group2Total>
            <outcomeName>Adverse effects: 2a. Specific - arousal level</outcomeName>
            <subgroupName>somnolence during 24 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs PLACEBO/NIL</comparisonName>
            <group1Events>4</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>57</group1Total>
            <group2Events>4</group2Events>
            <group2Name>placebo</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>62</group2Total>
            <outcomeName>Adverse effects: 2b. Specific - cardiovascular - miscellaneous outcomes</outcomeName>
            <subgroupName>dizziness during 24 hours (only reported if occurred in ≧5%)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs PLACEBO/NIL</comparisonName>
            <group1Events>3</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>60</group1Total>
            <group2Events>1</group2Events>
            <group2Name>placebo</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>62</group2Total>
            <outcomeName>Adverse effects: 2b. Specific - cardiovascular - miscellaneous outcomes</outcomeName>
            <subgroupName>QTc abnormality</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs PLACEBO/NIL</comparisonName>
            <group1Events>3</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>60</group1Total>
            <group2Events>1</group2Events>
            <group2Name>placebo</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>62</group2Total>
            <outcomeName>Adverse effects: 2b. Specific - cardiovascular - miscellaneous outcomes</outcomeName>
            <subgroupName>sinus tachycardia during 24 hours (only reported if occurred in ≥5%)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs PLACEBO/NIL</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>60</group1Total>
            <group2Events>1</group2Events>
            <group2Name>placebo</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>62</group2Total>
            <outcomeName>Adverse effects: 2b. Specific - cardiovascular - miscellaneous outcomes</outcomeName>
            <subgroupName>tachycardia during 24 hours (only reported if occurred in ≥5%)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs PLACEBO/NIL</comparisonName>
            <group1Events>6</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>60</group1Total>
            <group2Events>0</group2Events>
            <group2Name>placebo</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>62</group2Total>
            <outcomeName>Adverse effects: 2d. Specific - movement disorders</outcomeName>
            <subgroupName>akathisia during 24 hours (only reported if occurred in ≥5%)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs PLACEBO/NIL</comparisonName>
            <group1Events>4</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>60</group1Total>
            <group2Events>0</group2Events>
            <group2Name>placebo</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>62</group2Total>
            <outcomeName>Adverse effects: 2d. Specific - movement disorders</outcomeName>
            <subgroupName>dystonia during 24 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs PLACEBO/NIL</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>60</group1Total>
            <group2Events>1</group2Events>
            <group2Name>placebo</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>62</group2Total>
            <outcomeName>Adverse effects: 2f. Specific - miscellaneous</outcomeName>
            <subgroupName>agitation during 24 hours (only reported if occurred in ≧5%)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs PLACEBO/NIL</comparisonName>
            <group1Events>2</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>60</group1Total>
            <group2Events>1</group2Events>
            <group2Name>placebo</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>62</group2Total>
            <outcomeName>Adverse effects: 2f. Specific - miscellaneous</outcomeName>
            <subgroupName>headache during 24 hours (only reported if occurred in ≧5%)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs PLACEBO/NIL</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>60</group1Total>
            <group2Events>2</group2Events>
            <group2Name>placebo</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>62</group2Total>
            <outcomeName>Adverse effects: 2f. Specific - miscellaneous</outcomeName>
            <subgroupName>pain at injection site</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs PLACEBO/NIL</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>60</group1Total>
            <group2Events>2</group2Events>
            <group2Name>placebo</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>62</group2Total>
            <outcomeName>Adverse effects: 2f. Specific - miscellaneous</outcomeName>
            <subgroupName>nausea during 24 hours (only reported if occurred in ≧5%)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs PLACEBO/NIL</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>60</group1Total>
            <group2Events>1</group2Events>
            <group2Name>placebo</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>62</group2Total>
            <outcomeName>Adverse effects: 2f. Specific - miscellaneous</outcomeName>
            <subgroupName>vomiting during 24 hours (only reported if occurred in ≧5%)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs PLACEBO/NIL</comparisonName>
            <group1Events>8</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>60</group1Total>
            <group2Events>3</group2Events>
            <group2Name>placebo</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>62</group2Total>
            <outcomeName>Leaving the study early</outcomeName>
            <subgroupName>any reason</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs PLACEBO/NIL</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>60</group1Total>
            <group2Events>1</group2Events>
            <group2Name>placebo</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>62</group2Total>
            <outcomeName>Leaving the study early</outcomeName>
            <subgroupName>lack of efficacy</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs PLACEBO/NIL</comparisonName>
            <group1Events>6</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>60</group1Total>
            <group2Events>1</group2Events>
            <group2Name>placebo</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>62</group2Total>
            <outcomeName>Leaving the study early</outcomeName>
            <subgroupName>consent</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs PLACEBO/NIL</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>60</group1Total>
            <group2Events>0</group2Events>
            <group2Name>placebo</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>62</group2Total>
            <outcomeName>Leaving the study early</outcomeName>
            <subgroupName>adverse effects</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs PLACEBO/NIL</comparisonName>
            <group1Events>2</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>60</group1Total>
            <group2Events>1</group2Events>
            <group2Name>placebo</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>62</group2Total>
            <outcomeName>Leaving the study early</outcomeName>
            <subgroupName>other</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: a. ARIPIPRAZOLE</comparisonName>
            <group1Events>29</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>60</group1Total>
            <group2Events>25</group2Events>
            <group2Name>aripiprazole</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>57</group2Total>
            <outcomeName>Adverse effects: 1a. General</outcomeName>
            <subgroupName>one or more drug related adverse effects during 24 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: a. ARIPIPRAZOLE</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>60</group1Total>
            <group2Events>3</group2Events>
            <group2Name>aripiprazole</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>57</group2Total>
            <outcomeName>Adverse effects: 1b. General - serious</outcomeName>
            <subgroupName>any</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: a. ARIPIPRAZOLE</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>60</group1Total>
            <group2Events>1</group2Events>
            <group2Name>aripiprazole</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>57</group2Total>
            <outcomeName>Adverse effects: 1b. General - serious</outcomeName>
            <subgroupName>tonic clonic seizure</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: a. ARIPIPRAZOLE</comparisonName>
            <group1Events>7</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>60</group1Total>
            <group2Events>3</group2Events>
            <group2Name>aripiprazole</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>57</group2Total>
            <outcomeName>Adverse effects: 2a. Specific - arousal level</outcomeName>
            <subgroupName>somnolence - between 0-1 days (IM phase) (only reported if occurred in ≥5%)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: a. ARIPIPRAZOLE</comparisonName>
            <group1Events>4</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>60</group1Total>
            <group2Events>4</group2Events>
            <group2Name>aripiprazole</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>57</group2Total>
            <outcomeName>Adverse effects: 2b. Specific - cardiac</outcomeName>
            <subgroupName>dizziness - between 0 -1 day (IM phase) (only reported if occurred in ≥5%)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: a. ARIPIPRAZOLE</comparisonName>
            <group1Events>3</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>60</group1Total>
            <group2Events>0</group2Events>
            <group2Name>aripiprazole</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>57</group2Total>
            <outcomeName>Adverse effects: 2b. Specific - cardiac</outcomeName>
            <subgroupName>sinus tachycardia - between 0 -1 day (IM phase) (only reported if occurred in ≥5%)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: a. ARIPIPRAZOLE</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>60</group1Total>
            <group2Events>4</group2Events>
            <group2Name>aripiprazole</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>57</group2Total>
            <outcomeName>Adverse effects: 2b. Specific - cardiac</outcomeName>
            <subgroupName>tachycardia - between 0 -1 day (IM phase) (only reported if occurred in ≥5%)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: a. ARIPIPRAZOLE</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>60</group1Total>
            <group2Events>6</group2Events>
            <group2Name>aripiprazole</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>57</group2Total>
            <outcomeName>Adverse effects: 2c. Specific - gastrointestinal</outcomeName>
            <subgroupName>nausea - between 0-1 days (IM phase) (only reported if occurred in ≥5%)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: a. ARIPIPRAZOLE</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>60</group1Total>
            <group2Events>2</group2Events>
            <group2Name>aripiprazole</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>57</group2Total>
            <outcomeName>Adverse effects: 2c. Specific - gastrointestinal</outcomeName>
            <subgroupName>vomiting - between 0-1 days (IM phase) (only reported if occurred in ≥5%)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: a. ARIPIPRAZOLE</comparisonName>
            <group1Events>6</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>60</group1Total>
            <group2Events>3</group2Events>
            <group2Name>aripiprazole</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>57</group2Total>
            <outcomeName>Adverse effects: 2d. Specific - movement disorder</outcomeName>
            <subgroupName>akathisia - between 0 -1 day (IM phase) (only reported if occurred in ≥5%)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: a. ARIPIPRAZOLE</comparisonName>
            <group1Events>4</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>60</group1Total>
            <group2Events>1</group2Events>
            <group2Name>aripiprazole</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>57</group2Total>
            <outcomeName>Adverse effects: 2d. Specific - movement disorder</outcomeName>
            <subgroupName>dystonia - between 0 -1 day (IM phase) (only reported if occurred in ≥5%)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: a. ARIPIPRAZOLE</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>60</group1Total>
            <group2Events>2</group2Events>
            <group2Name>aripiprazole</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>57</group2Total>
            <outcomeName>Adverse effects: 2e. Specific - miscellaneous</outcomeName>
            <subgroupName>agitation - between 0 -1 day (IM phase) (only reported if occurred in ≥5%)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: a. ARIPIPRAZOLE</comparisonName>
            <group1Events>2</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>60</group1Total>
            <group2Events>6</group2Events>
            <group2Name>aripiprazole</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>57</group2Total>
            <outcomeName>Adverse effects: 2e. Specific - miscellaneous</outcomeName>
            <subgroupName>headache - between 0 -1 day (IM phase) (only reported if occurred in ≥5%)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: a. ARIPIPRAZOLE</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>60</group1Total>
            <group2Events>1</group2Events>
            <group2Name>aripiprazole</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>57</group2Total>
            <outcomeName>Adverse effects: 2e. Specific - miscellaneous</outcomeName>
            <subgroupName>pain at injection site</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: a. ARIPIPRAZOLE</comparisonName>
            <group1Events>8</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>60</group1Total>
            <group2Events>2</group2Events>
            <group2Name>aripiprazole</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>60</group2Total>
            <outcomeName>Leaving the study early: 1. For specific reasons</outcomeName>
            <subgroupName>any</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: a. ARIPIPRAZOLE</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>60</group1Total>
            <group2Events>1</group2Events>
            <group2Name>aripiprazole</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>60</group2Total>
            <outcomeName>Leaving the study early: 1. For specific reasons</outcomeName>
            <subgroupName>adverse effects</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: a. ARIPIPRAZOLE</comparisonName>
            <group1Events>6</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>60</group1Total>
            <group2Events>1</group2Events>
            <group2Name>aripiprazole</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>60</group2Total>
            <outcomeName>Leaving the study early: 1. For specific reasons</outcomeName>
            <subgroupName>consent</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: a. ARIPIPRAZOLE</comparisonName>
            <group1Events>2</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>60</group1Total>
            <group2Events>0</group2Events>
            <group2Name>aripiprazole</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>60</group2Total>
            <outcomeName>Leaving the study early: 1. For specific reasons</outcomeName>
            <subgroupName>other</subgroupName>
        </outcomeList>
        <paralellTrial>false</paralellTrial>
        <performanceBiasJudgement>No blinding was used during the preparation of injections and in most cases the person preparing the drug administered the injection.</performanceBiasJudgement>
        <performanceBiasRisk>High risk</performanceBiasRisk>
        <references>OTHER</references>
        <references>YES</references>
        <references>Bristol-Myers S</references>
        <references>Randomized, double-blind, dose-ranging study of intramuscular aripiprazole in the treatment of acute agitation in patients with a diagnosis of schizophrenia, schizoaffective, or schizophreniform disorder</references>
        <references>http://www.clinicalstudyresults.org/</references>
        <references>2005</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>CONFERENCE_PROC</references>
        <references>NO</references>
        <references>Currier GW, Crandall D, Archibald D, Nyilas M, Kostic D, Pikalov A, et al</references>
        <references>Intramuscular (IM) aripiprazole controls agitation in patients with schizophrenia or bipolar disorder without excessive sedation</references>
        <references>Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25; Toronto, Canada</references>
        <references>2006</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Gismondi R, Daniel D, Stock E, Wilber R, Marcus R, Carson W, et al</references>
        <references>Intramuscular aripiprazole treatment for acute agitation in patients with psychosis</references>
        <references>European Neuropsychopharmacology</references>
        <references>2004</references>
        <references>14</references>
        <references>Suppl 3</references>
        <references>S261</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>CONFERENCE_PROC</references>
        <references>NO</references>
        <references>Kungel M, Czaniera R, Ebrecht M, Werner C, Oren D, McQuade R, et al</references>
        <references>Intramuscular aripiprazole for the treatment of acute agitation accompanied with schizophrenia: Subanalysis of a double-blind controlled study to find the dosage</references>
        <references>Proceedings of the 25th Symposium of the Arbeitsgemeinschaft Neuropsychopharmakologie und Pharmakopsychiatrie; 2007 Oct 3-6; Munich, Germany</references>
        <references>2007</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>CONFERENCE_PROC</references>
        <references>NO</references>
        <references>Kungel M, Daniel D, Stock E, Wilber R, Marcus R, Carson W, et al</references>
        <references>Efficacy and safety of intramuscular aripiprazole in acutely agitated patients with psychosis</references>
        <references>Proceedings of the Thematic Conference of the World Psychiatric Association on "Treatments in Psychiatry: An Update"; 2004 Nov 10-13; Florence, Italy</references>
        <references>2004</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Oren DA, Manos G, Markovic O, McQuade RD</references>
        <references>Intramuscular aripiprazole for the treatment of acute agitation associated with schizophrenia: Sub-analysis of a double-blind, controlled, dose-ranging study</references>
        <references>European Psychiatry</references>
        <references>2007</references>
        <references>22</references>
        <references></references>
        <references>S124-S</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Tran-Johnson TK, Sack DA, Marcus RN, Auby P, McQuade RD, Oren DA</references>
        <references>Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial</references>
        <references>Journal of Clinical Psychiatry</references>
        <references>2007</references>
        <references>68</references>
        <references>1</references>
        <references>111-9</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>The authors only report the adverse effects that occurred in ≥ 5% of people. The QTc abnormality for 9.75 mg is not reported.</reportingBiasJudgement>
        <reportingBiasRisk>High risk</reportingBiasRisk>
        <revManID>STD-Bristol_x002d_Myers-2005b</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement>Not stated.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Unclear Risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>Described as randomised - method of randomisation is not reported.</selectionBiasRandomSequenceJudgement>
        <year>2005</year>
    </trialList>
    <trialList>
        <attritionBiasJudgement>No evidence of incomplete outcome data. A table is provided which presents a summary of discontinuations.</attritionBiasJudgement>
        <attritionBiasRisk>Low risk</attritionBiasRisk>
        <authorYearLetter>Brook2000</authorYearLetter>
        <countries></countries>
        <crgID>0</crgID>
        <crossoverTrial>false</crossoverTrial>
        <detectionBiasJudgement>Open trial.</detectionBiasJudgement>
        <detectionBiasRisk>High risk</detectionBiasRisk>
        <dobj>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZIPRASIDONE</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>42</group1Total>
            <group2Events>4</group2Events>
            <group2Name>ziprasidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>90</group2Total>
            <outcomeName>Leaving the study early: 2. For specific reasons - i. over 24 hours</outcomeName>
            <subgroupName>adverse events - by 7 days</subgroupName>
        </dobj>
        <factorialTrial>false</factorialTrial>
        <mainAuthor>Brook</mainAuthor>
        <meerKatCountry></meerKatCountry>
        <nrControl>0</nrControl>
        <nrIntervention>0</nrIntervention>
        <nrOfParticipants>0</nrOfParticipants>
        <otherBiasJudgement>Sponsored by drug company.</otherBiasJudgement>
        <otherBiasRisk>High risk</otherBiasRisk>
        <otherDesign>false</otherDesign>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZIPRASIDONE</comparisonName>
            <group1Events>27</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>42</group1Total>
            <group2Events>52</group2Events>
            <group2Name>ziprasidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>90</group2Total>
            <outcomeName>Global outcome: 1. General - need for additional measures</outcomeName>
            <subgroupName>need for anxiolytic during 7 days</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZIPRASIDONE</comparisonName>
            <group1Events>3</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>42</group1Total>
            <group2Events>9</group2Events>
            <group2Name>ziprasidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>90</group2Total>
            <outcomeName>Global outcome: 1. General - need for additional measures</outcomeName>
            <subgroupName>need for hypnotics for night time sedation during 7 days</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZIPRASIDONE</comparisonName>
            <group1Events>21</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>42</group1Total>
            <group2Events>28</group2Events>
            <group2Name>ziprasidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>90</group2Total>
            <outcomeName>Adverse effects: 1b. General - ii. over 24 hours</outcomeName>
            <subgroupName>one or more drug related adverse effects - by 72 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZIPRASIDONE</comparisonName>
            <group1Events>25</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>42</group1Total>
            <group2Events>41</group2Events>
            <group2Name>ziprasidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>90</group2Total>
            <outcomeName>Adverse effects: 1b. General - ii. over 24 hours</outcomeName>
            <subgroupName>one or more drug related adverse effects - by 7 days</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZIPRASIDONE</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>42</group1Total>
            <group2Events>2</group2Events>
            <group2Name>ziprasidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>90</group2Total>
            <outcomeName>Adverse effects: 2f. Specific - cardiovascular</outcomeName>
            <subgroupName>tachycardia - by 72 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZIPRASIDONE</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>42</group1Total>
            <group2Events>3</group2Events>
            <group2Name>ziprasidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>90</group2Total>
            <outcomeName>Adverse effects: 2g. Specific - gastrointestinal</outcomeName>
            <subgroupName>vomiting by 72 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZIPRASIDONE</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>42</group1Total>
            <group2Events>6</group2Events>
            <group2Name>ziprasidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>90</group2Total>
            <outcomeName>Adverse effects: 2g. Specific - gastrointestinal</outcomeName>
            <subgroupName>vomiting by 7 days</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZIPRASIDONE</comparisonName>
            <group1Events>6</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>42</group1Total>
            <group2Events>12</group2Events>
            <group2Name>ziprasidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>90</group2Total>
            <outcomeName>Adverse effects: 2h. Specific - hematological tests</outcomeName>
            <subgroupName>abnormal lab results - by 72 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZIPRASIDONE</comparisonName>
            <group1Events>8</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>42</group1Total>
            <group2Events>17</group2Events>
            <group2Name>ziprasidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>90</group2Total>
            <outcomeName>Adverse effects: 2h. Specific - hematological tests</outcomeName>
            <subgroupName>abnormal lab results - by 7 days</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZIPRASIDONE</comparisonName>
            <group1Events>4</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>42</group1Total>
            <group2Events>9</group2Events>
            <group2Name>ziprasidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>90</group2Total>
            <outcomeName>Adverse effects: 2h. Specific - hematological tests</outcomeName>
            <subgroupName>glucose increased - by 24 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZIPRASIDONE</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>42</group1Total>
            <group2Events>2</group2Events>
            <group2Name>ziprasidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>90</group2Total>
            <outcomeName>Adverse effects: 2i. Specific - movement disorders - i. binary measures</outcomeName>
            <subgroupName>akathisia - by 72 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZIPRASIDONE</comparisonName>
            <group1Events>6</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>42</group1Total>
            <group2Events>3</group2Events>
            <group2Name>ziprasidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>90</group2Total>
            <outcomeName>Adverse effects: 2i. Specific - movement disorders - i. binary measures</outcomeName>
            <subgroupName>akathisia - by 7 days</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZIPRASIDONE</comparisonName>
            <group1Events>3</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>42</group1Total>
            <group2Events>1</group2Events>
            <group2Name>ziprasidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>90</group2Total>
            <outcomeName>Adverse effects: 2i. Specific - movement disorders - i. binary measures</outcomeName>
            <subgroupName>dystonia - by 72 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZIPRASIDONE</comparisonName>
            <group1Events>5</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>42</group1Total>
            <group2Events>4</group2Events>
            <group2Name>ziprasidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>90</group2Total>
            <outcomeName>Adverse effects: 2i. Specific - movement disorders - i. binary measures</outcomeName>
            <subgroupName>dystonia - by 7 days</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZIPRASIDONE</comparisonName>
            <group1Events>9</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>42</group1Total>
            <group2Events>0</group2Events>
            <group2Name>ziprasidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>90</group2Total>
            <outcomeName>Adverse effects: 2i. Specific - movement disorders - i. binary measures</outcomeName>
            <subgroupName>EPS - by 72 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZIPRASIDONE</comparisonName>
            <group1Events>16</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>42</group1Total>
            <group2Events>1</group2Events>
            <group2Name>ziprasidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>90</group2Total>
            <outcomeName>Adverse effects: 2i. Specific - movement disorders - i. binary measures</outcomeName>
            <subgroupName>EPS - by 7 days</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZIPRASIDONE</comparisonName>
            <group1Events>20</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>42</group1Total>
            <group2Events>13</group2Events>
            <group2Name>ziprasidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>90</group2Total>
            <outcomeName>Adverse effects: 2i. Specific - movement disorders - i. binary measures</outcomeName>
            <subgroupName>extrapyramidal effects - use of antiparkinson drugs - by 7 days</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZIPRASIDONE</comparisonName>
            <group1Events>3</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>42</group1Total>
            <group2Events>0</group2Events>
            <group2Name>ziprasidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>90</group2Total>
            <outcomeName>Adverse effects: 2i. Specific - movement disorders - i. binary measures</outcomeName>
            <subgroupName>hypertonia/rigidity - by 72 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZIPRASIDONE</comparisonName>
            <group1Events>5</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>42</group1Total>
            <group2Events>3</group2Events>
            <group2Name>ziprasidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>90</group2Total>
            <outcomeName>Adverse effects: 2i. Specific - movement disorders - i. binary measures</outcomeName>
            <subgroupName>hypertonia - by 7 days</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZIPRASIDONE</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>42</group1Total>
            <group2Events>1</group2Events>
            <group2Name>ziprasidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>90</group2Total>
            <outcomeName>Adverse effects: 2i. Specific - movement disorders - i. binary measures</outcomeName>
            <subgroupName>tremor - by 72 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZIPRASIDONE</comparisonName>
            <group1Events>4</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>42</group1Total>
            <group2Events>2</group2Events>
            <group2Name>ziprasidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>90</group2Total>
            <outcomeName>Adverse effects: 2i. Specific - movement disorders - i. binary measures</outcomeName>
            <subgroupName>tremor - by 7 days</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZIPRASIDONE</comparisonName>
            <group1Events>8</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>42</group1Total>
            <group2Events>8</group2Events>
            <group2Name>ziprasidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>90</group2Total>
            <outcomeName>Leaving the study early: 1. For any reason - i. over 24 hours</outcomeName>
            <subgroupName>by 7 days</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZIPRASIDONE</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>42</group1Total>
            <group2Events>1</group2Events>
            <group2Name>ziprasidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>90</group2Total>
            <outcomeName>Leaving the study early: 2. For specific reasons - i. over 24 hours</outcomeName>
            <subgroupName>adverse events - by 72 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZIPRASIDONE</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>42</group1Total>
            <group2Events>4</group2Events>
            <group2Name>ziprasidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>90</group2Total>
            <outcomeName>Leaving the study early: 2. For specific reasons - i. over 24 hours</outcomeName>
            <subgroupName>adverse events - by 7 days</subgroupName>
        </outcomeList>
        <paralellTrial>false</paralellTrial>
        <performanceBiasJudgement>Open trial.</performanceBiasJudgement>
        <performanceBiasRisk>High risk</performanceBiasRisk>
        <references>CONFERENCE_PROC</references>
        <references>NO</references>
        <references>Brook S, Krams M, Gunn K</references>
        <references>Intramuscular (IM) ziprasidone vs. IM haloperidol in patients with acute, non-organic psychosis</references>
        <references>Proceedings of the 9th Congress of the Association of European Psychiatrists; 1998 Sep 20-24; Copenhagen, Denmark</references>
        <references>1998</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>CONFERENCE_PROC</references>
        <references>NO</references>
        <references>Brook S, Krams M, Gunn KP, and the Ziprasidone IM Study Group</references>
        <references>The efficacy and tolerability of intramuscular (IM) ziprasidone versus IM haloperidol in patients with acute non-organic psychosis</references>
        <references>Proceedings of the 151st Annual Meeting of the American Psychiatric Association; 1998 May 30 - Jun 4; Toronto, Ontario, Canada</references>
        <references>1998</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>OTHER</references>
        <references>NO</references>
        <references>Brook S, Krams M, Gunn KP</references>
        <references>Intramuscular ziprasidone versus intramuscular haloperidol</references>
        <references>Proceedings of the 21st Collegium Internationale Neuro-Psychopharmacologicum Congress; 1998 Jul 12-16; Glasgow, UK</references>
        <references>1998</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>JOURNAL_ARTICLE</references>
        <references>YES</references>
        <references>Brook S, Lucey JV, Gunn KP</references>
        <references>Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis</references>
        <references>Journal of Clinical Psychological Medicine [临床精神医学杂志]</references>
        <references>2000</references>
        <references>61</references>
        <references>12</references>
        <references>933-41</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Daniel DG, Brook S, Reeves KR</references>
        <references>An overview of the efficacy and safety of rapid acting intramuscular ziprasidone</references>
        <references>European Neuropsychopharmacology</references>
        <references>2000</references>
        <references>10</references>
        <references>Suppl 3</references>
        <references>S239</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>CONFERENCE_PROC</references>
        <references>NO</references>
        <references>Zimbroff DL, Daniel DG, Brook S, Reeves KR</references>
        <references>An overview of the efficacy and safety of rapid-acting intramuscular ziprasidone</references>
        <references>Proceedings of the 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13-18; Chicago, Illinois, USA</references>
        <references>2000</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>The number of participants reported as discontinuing due to adverse effects is reported inconsistently (see Brook 1998c table 2 and Brook 2000 table 4). It is not clear whether all adverse events are reported. Brook 2000 table 4 only reports adverse events occurring in ≥10 of people, however there are more adverse events mentioned throughout the text.</reportingBiasJudgement>
        <reportingBiasRisk>High risk</reportingBiasRisk>
        <revManID>STD-Brook-2000</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement>Not stated.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Low risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>"Computerized randomization assigned".</selectionBiasRandomSequenceJudgement>
        <year>2000</year>
    </trialList>
    <trialList>
        <attritionBiasJudgement>No evidence of incomplete outcome data.</attritionBiasJudgement>
        <attritionBiasRisk>Low risk</attritionBiasRisk>
        <authorYearLetter>Calver2015</authorYearLetter>
        <countries></countries>
        <crgID>0</crgID>
        <crossoverTrial>false</crossoverTrial>
        <detectionBiasJudgement>"labels A or B and not the drug names were known to the investigator. This investigator analysed the data independently and presented this to the other investigators" (p.224).</detectionBiasJudgement>
        <detectionBiasRisk>Low risk</detectionBiasRisk>
        <dobj>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: c. DROPERIDOL</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>110</group1Total>
            <group2Events>1</group2Events>
            <group2Name>droperidol</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>118</group2Total>
            <outcomeName>Adverse effects: 2d. Specific - miscellaneous</outcomeName>
            <subgroupName>desaturation</subgroupName>
        </dobj>
        <factorialTrial>false</factorialTrial>
        <mainAuthor>Calver</mainAuthor>
        <meerKatCountry></meerKatCountry>
        <nrControl>0</nrControl>
        <nrIntervention>0</nrIntervention>
        <nrOfParticipants>0</nrOfParticipants>
        <otherBiasJudgement>Short study.</otherBiasJudgement>
        <otherBiasRisk>High risk</otherBiasRisk>
        <otherDesign>false</otherDesign>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: c. DROPERIDOL</comparisonName>
            <group1Events>9</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>110</group1Total>
            <group2Events>9</group2Events>
            <group2Name>droperidol</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>118</group2Total>
            <outcomeName>Tranquillisation or asleep: 1. Not asleep</outcomeName>
            <subgroupName>up to 2 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: c. DROPERIDOL</comparisonName>
            <group1Events>14</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>110</group1Total>
            <group2Events>6</group2Events>
            <group2Name>droperidol</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>118</group2Total>
            <outcomeName>Repeated need for rapid tranquillisation</outcomeName>
            <subgroupName>more than 1 injection</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: c. DROPERIDOL</comparisonName>
            <group1Events>2</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>110</group1Total>
            <group2Events>7</group2Events>
            <group2Name>droperidol</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>118</group2Total>
            <outcomeName>Global outcome: 1. Need for benzodiazepine</outcomeName>
            <subgroupName>up to 2 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: c. DROPERIDOL</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>110</group1Total>
            <group2Events>7</group2Events>
            <group2Name>droperidol</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>118</group2Total>
            <outcomeName>Adverse effects: 1. General</outcomeName>
            <subgroupName>overall adverse events up to 2 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: c. DROPERIDOL</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>110</group1Total>
            <group2Events>6</group2Events>
            <group2Name>droperidol</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>118</group2Total>
            <outcomeName>Adverse effects: 1. General</outcomeName>
            <subgroupName>patients with one or more AEs</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: c. DROPERIDOL</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>110</group1Total>
            <group2Events>1</group2Events>
            <group2Name>droperidol</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>118</group2Total>
            <outcomeName>Adverse effects: 2a. Specific - arousal level</outcomeName>
            <subgroupName>"over" sedated</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: c. DROPERIDOL</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>110</group1Total>
            <group2Events>4</group2Events>
            <group2Name>droperidol</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>118</group2Total>
            <outcomeName>Adverse effects: 2b. Specific - cardiovascular</outcomeName>
            <subgroupName>hypotension up to 2 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: c. DROPERIDOL</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>110</group1Total>
            <group2Events>1</group2Events>
            <group2Name>droperidol</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>118</group2Total>
            <outcomeName>Adverse effects: 2c. Specific - movement disorders</outcomeName>
            <subgroupName>dystonia</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: c. DROPERIDOL</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>110</group1Total>
            <group2Events>1</group2Events>
            <group2Name>droperidol</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>118</group2Total>
            <outcomeName>Adverse effects: 2d. Specific - miscellaneous</outcomeName>
            <subgroupName>desaturation</subgroupName>
        </outcomeList>
        <paralellTrial>false</paralellTrial>
        <performanceBiasJudgement>Double-blind study.</performanceBiasJudgement>
        <performanceBiasRisk>Low risk</performanceBiasRisk>
        <references>OTHER</references>
        <references>NO</references>
        <references>Calver L, Drinkwater V, Gupta R, Page CB, Isbister GK</references>
        <references>Droperidol v. haloperidol for sedation of aggressive behaviour in acute mental health: Randomized controlled trial</references>
        <references>British Journal of Psychiatry</references>
        <references>2015</references>
        <references>206</references>
        <references>3</references>
        <references>223-8</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>"In breach of the study protocol midazolam was given nine times simultaneously with the study drug" (p.226); no further evidence of selective reporting.</reportingBiasJudgement>
        <reportingBiasRisk>Unclear Risk</reportingBiasRisk>
        <revManID>STD-Calver-2015</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Low risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement>"Pre-packed treatment kits [...] contained either droperidol (10mg in 2ml) or haloperidol (10mg in 2ml) [...] transferred into vials identical" (p.224).</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Low risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>"Block randomisation was used. Microsoft Excel was used to randomly create blocks of four (ABAB, AABB, etc.) or six (ABABAB, AAABBB, etc.)" (p.224).</selectionBiasRandomSequenceJudgement>
        <year>2015</year>
    </trialList>
    <trialList>
        <attritionBiasJudgement>A flow diagram is provided with the reasons for leaving the study early reported. However, the number of participants completing different assessments at the same time point vary and reasons are not given.</attritionBiasJudgement>
        <attritionBiasRisk>Unclear Risk</attritionBiasRisk>
        <authorYearLetter>Currier2004</authorYearLetter>
        <countries>USA</countries>
        <crgID>0</crgID>
        <crossoverTrial>false</crossoverTrial>
        <detectionBiasJudgement>"independent raters blinded to the treatment arm conducted efficacy assessments". (p.387).</detectionBiasJudgement>
        <detectionBiasRisk>Low risk</detectionBiasRisk>
        <dobj>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: h. RISPERIDONE</comparisonName>
            <group1Events>14</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>79</group1Total>
            <group2Events>19</group2Events>
            <group2Name>risperidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>83</group2Total>
            <outcomeName>Leaving the study early - i. up to 24 hours</outcomeName>
            <subgroupName>unspecified general reasons</subgroupName>
        </dobj>
        <factorialTrial>false</factorialTrial>
        <mainAuthor>Currier</mainAuthor>
        <meerKatCountry>USA</meerKatCountry>
        <nrControl>0</nrControl>
        <nrIntervention>0</nrIntervention>
        <nrOfParticipants>0</nrOfParticipants>
        <otherBiasJudgement>Sponsored by drug company (Janssen Phamaceutica).</otherBiasJudgement>
        <otherBiasRisk>High risk</otherBiasRisk>
        <otherDesign>false</otherDesign>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: h. RISPERIDONE</comparisonName>
            <group1Events>62</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>79</group1Total>
            <group2Events>78</group2Events>
            <group2Name>risperidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>83</group2Total>
            <outcomeName>Tranquillisation or asleep - i. by 30 minutes</outcomeName>
            <subgroupName>not asleep at 30 minutes</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: h. RISPERIDONE</comparisonName>
            <group1Events>45</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>79</group1Total>
            <group2Events>64</group2Events>
            <group2Name>risperidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>83</group2Total>
            <outcomeName>Tranquillisation or asleep - ii. up to 2 hours</outcomeName>
            <subgroupName>not asleep at 1 hour</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: h. RISPERIDONE</comparisonName>
            <group1Events>31</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>79</group1Total>
            <group2Events>46</group2Events>
            <group2Name>risperidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>83</group2Total>
            <outcomeName>Tranquillisation or asleep - ii. up to 2 hours</outcomeName>
            <subgroupName>not asleep at 2 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: h. RISPERIDONE</comparisonName>
            <group1Events>25</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>79</group1Total>
            <group2Events>28</group2Events>
            <group2Name>risperidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>83</group2Total>
            <outcomeName>Global outcome: 1. Binary measures</outcomeName>
            <subgroupName>needing additional benzodiazepine</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: h. RISPERIDONE</comparisonName>
            <group1Events>17</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>79</group1Total>
            <group2Events>20</group2Events>
            <group2Name>risperidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>83</group2Total>
            <outcomeName>Global outcome: 1. Binary measures</outcomeName>
            <subgroupName>rated as severe at 24 hours (CGI-S)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: h. RISPERIDONE</comparisonName>
            <group1Events>58</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>79</group1Total>
            <group2Events>61</group2Events>
            <group2Name>risperidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>83</group2Total>
            <outcomeName>Adverse effects: 1a. General - one or more adverse effects</outcomeName>
            <subgroupName>up to 24 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: h. RISPERIDONE</comparisonName>
            <group1Events>56</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>79</group1Total>
            <group2Events>31</group2Events>
            <group2Name>risperidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>83</group2Total>
            <outcomeName>Adverse effects: 2a. Specific - arousal</outcomeName>
            <subgroupName>sedated at 30 minutes</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: h. RISPERIDONE</comparisonName>
            <group1Events>67</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>79</group1Total>
            <group2Events>50</group2Events>
            <group2Name>risperidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>83</group2Total>
            <outcomeName>Adverse effects: 2a. Specific - arousal</outcomeName>
            <subgroupName>sedated at 60 minutes</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: h. RISPERIDONE</comparisonName>
            <group1Events>73</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>79</group1Total>
            <group2Events>70</group2Events>
            <group2Name>risperidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>83</group2Total>
            <outcomeName>Adverse effects: 2a. Specific - arousal</outcomeName>
            <subgroupName>sedated at 120 minutes</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: h. RISPERIDONE</comparisonName>
            <group1Events>10</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>79</group1Total>
            <group2Events>11</group2Events>
            <group2Name>risperidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>83</group2Total>
            <outcomeName>Adverse effects: 2a. Specific - arousal</outcomeName>
            <subgroupName>somnolence during 24 hours (only reported if occurred in ≥5%)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: h. RISPERIDONE</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>79</group1Total>
            <group2Events>1</group2Events>
            <group2Name>risperidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>83</group2Total>
            <outcomeName>Adverse effects: 2a. Specific - arousal</outcomeName>
            <subgroupName>insomnia - severe</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: h. RISPERIDONE</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>79</group1Total>
            <group2Events>0</group2Events>
            <group2Name>risperidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>83</group2Total>
            <outcomeName>Adverse effects: 2a. Specific - arousal</outcomeName>
            <subgroupName>somnolence - severe</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: h. RISPERIDONE</comparisonName>
            <group1Events>2</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>79</group1Total>
            <group2Events>0</group2Events>
            <group2Name>risperidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>83</group2Total>
            <outcomeName>Adverse effects: 2b. Specific - cardiovascular - i. binary outcomes</outcomeName>
            <subgroupName>orthostatic hypertension</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: h. RISPERIDONE</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>79</group1Total>
            <group2Events>2</group2Events>
            <group2Name>risperidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>83</group2Total>
            <outcomeName>Adverse effects: 2e. Specific - movement disorder - i. binary outcomes</outcomeName>
            <subgroupName>dystonia during 24 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: h. RISPERIDONE</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>79</group1Total>
            <group2Events>0</group2Events>
            <group2Name>risperidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>83</group2Total>
            <outcomeName>Adverse effects: 2e. Specific - movement disorder - i. binary outcomes</outcomeName>
            <subgroupName>dyskinesia during 24 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: h. RISPERIDONE</comparisonName>
            <group1Events>4</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>79</group1Total>
            <group2Events>1</group2Events>
            <group2Name>risperidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>83</group2Total>
            <outcomeName>Adverse effects: 2e. Specific - movement disorder - i. binary outcomes</outcomeName>
            <subgroupName>hyperkinesia during 24 hours (only reported if occurred in ≥5%)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: h. RISPERIDONE</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>79</group1Total>
            <group2Events>1</group2Events>
            <group2Name>risperidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>83</group2Total>
            <outcomeName>Adverse effects: 2e. Specific - movement disorder - i. binary outcomes</outcomeName>
            <subgroupName>hypertonia/rigidity during 24 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: h. RISPERIDONE</comparisonName>
            <group1Events>2</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>79</group1Total>
            <group2Events>0</group2Events>
            <group2Name>risperidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>83</group2Total>
            <outcomeName>Adverse effects: 2e. Specific - movement disorder - i. binary outcomes</outcomeName>
            <subgroupName>tremor during 24 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: h. RISPERIDONE</comparisonName>
            <group1Events>4</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>79</group1Total>
            <group2Events>4</group2Events>
            <group2Name>risperidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>83</group2Total>
            <outcomeName>Adverse effects: 2h. Specific - miscellaneous</outcomeName>
            <subgroupName>agitation during 24 hours (only reported if occurred in ≥5%)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: h. RISPERIDONE</comparisonName>
            <group1Events>2</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>79</group1Total>
            <group2Events>1</group2Events>
            <group2Name>risperidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>83</group2Total>
            <outcomeName>Adverse effects: 2h. Specific - miscellaneous</outcomeName>
            <subgroupName>agitation - severe</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: h. RISPERIDONE</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>79</group1Total>
            <group2Events>0</group2Events>
            <group2Name>risperidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>83</group2Total>
            <outcomeName>Adverse effects: 2h. Specific - miscellaneous</outcomeName>
            <subgroupName>anxiety - severe</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: h. RISPERIDONE</comparisonName>
            <group1Events>5</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>79</group1Total>
            <group2Events>4</group2Events>
            <group2Name>risperidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>83</group2Total>
            <outcomeName>Adverse effects: 2h. Specific - miscellaneous</outcomeName>
            <subgroupName>headache during 24 hours (only reported if occurred in ≥5%)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: h. RISPERIDONE</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>79</group1Total>
            <group2Events>1</group2Events>
            <group2Name>risperidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>83</group2Total>
            <outcomeName>Leaving the study early - i. up to 24 hours</outcomeName>
            <subgroupName>due to adverse effects</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: h. RISPERIDONE</comparisonName>
            <group1Events>14</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>79</group1Total>
            <group2Events>19</group2Events>
            <group2Name>risperidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>83</group2Total>
            <outcomeName>Leaving the study early - i. up to 24 hours</outcomeName>
            <subgroupName>unspecified general reasons</subgroupName>
        </outcomeList>
        <paralellTrial>false</paralellTrial>
        <performanceBiasJudgement>Single-blind study.</performanceBiasJudgement>
        <performanceBiasRisk>High risk</performanceBiasRisk>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Currier GW, Chou JC, Feifel D, Bossie CA, Turkoz I, Mahmoud R, et al</references>
        <references>Acute treatment of psychotic agitation: a randomized comparison of oral treatment with risperidone and lorazepam versus intramuscular treatment with haloperidol and lorazepam</references>
        <references>Journal of Clinical Psychiatry</references>
        <references>2004</references>
        <references>65</references>
        <references>3</references>
        <references>386-94</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>The authors only report the side effects that occurred in ≥ 5% of people.</reportingBiasJudgement>
        <reportingBiasRisk>High risk</reportingBiasRisk>
        <revManID>STD-Currier-2004</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Low risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement>"A telephone-based central service was used to randomly assign eligible patients to receive a single dose of oral treatment or IM injection." (p.387).</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Unclear Risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>Described as randomised - method of randomisation is not reported.</selectionBiasRandomSequenceJudgement>
        <year>2004</year>
    </trialList>
    <trialList>
        <attritionBiasJudgement>No evidence of incomplete outcome data.</attritionBiasJudgement>
        <attritionBiasRisk>Low risk</attritionBiasRisk>
        <authorYearLetter>Dorevitch1999</authorYearLetter>
        <countries></countries>
        <crgID>0</crgID>
        <crossoverTrial>false</crossoverTrial>
        <detectionBiasJudgement>"All ratings were completed by the same rater (N.K.), who was blind to the study medications." (p.143).</detectionBiasJudgement>
        <detectionBiasRisk>Low risk</detectionBiasRisk>
        <dobj>
            <comparisonName>HALOPERIDOL vs BENZODIAZEPINE: a. FLUNITRAZEPAM</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>13</group1Total>
            <group2Events>0</group2Events>
            <group2Name>flunitrazepam</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>15</group2Total>
            <outcomeName>Adverse effects: 1. Specific - movement disorders - i. binary measures - i. by 30 minutes</outcomeName>
            <subgroupName>EPS by 30 minutes</subgroupName>
        </dobj>
        <factorialTrial>false</factorialTrial>
        <mainAuthor>Dorevitch</mainAuthor>
        <meerKatCountry></meerKatCountry>
        <nrControl>0</nrControl>
        <nrIntervention>0</nrIntervention>
        <nrOfParticipants>0</nrOfParticipants>
        <otherBiasJudgement>Small short study.</otherBiasJudgement>
        <otherBiasRisk>Unclear Risk</otherBiasRisk>
        <otherDesign>false</otherDesign>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs BENZODIAZEPINE: a. FLUNITRAZEPAM</comparisonName>
            <group1Events>12</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>13</group1Total>
            <group2Events>12</group2Events>
            <group2Name>flunitrazepam</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>15</group2Total>
            <outcomeName>Specific behaviour: 1. Aggression - binary measures - i. up to 2 hours</outcomeName>
            <subgroupName>≥50% reduction at 90 minutes (OAS)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs BENZODIAZEPINE: a. FLUNITRAZEPAM</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>13</group1Total>
            <group2Events>0</group2Events>
            <group2Name>flunitrazepam</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>15</group2Total>
            <outcomeName>Adverse effects: 1. Specific - movement disorders - i. binary measures - i. by 30 minutes</outcomeName>
            <subgroupName>EPS by 30 minutes</subgroupName>
        </outcomeList>
        <paralellTrial>false</paralellTrial>
        <performanceBiasJudgement>Described as double-blind, however further details regarding the blinding of participants and personnel are not reported.</performanceBiasJudgement>
        <performanceBiasRisk>Unclear Risk</performanceBiasRisk>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Dorevitch A, Katz N, Zemishlany Z, Aizenberg D, Weizman A</references>
        <references>Intramuscular flunitrazepam versus intramuscular haloperidol in the emergency treatment of aggressive psychotic behavior</references>
        <references>American Journal of Psychiatry</references>
        <references>1999</references>
        <references>156</references>
        <references>1</references>
        <references>142-4</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>It is not clear whether all side effects are reported.</reportingBiasJudgement>
        <reportingBiasRisk>Unclear Risk</reportingBiasRisk>
        <revManID>STD-Dorevitch-1999</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement>Not stated.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Low risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>"assigned by a table of random numbers." (p.142).</selectionBiasRandomSequenceJudgement>
        <year>1999</year>
    </trialList>
    <trialList>
        <attritionBiasJudgement>The number of patients that completed the study is unclear: authors assert 45 in a study, 46 participants in the other one out of a possible 49 participants. However, only 42 participants are included in the analysis for the CGI-I (at the end of the study), SAS, BAS, clinical laboratory evaluations, vital signs and ECG, without explanation for the missing participants.</attritionBiasJudgement>
        <attritionBiasRisk>High risk</attritionBiasRisk>
        <authorYearLetter>Eli-Lilly2004</authorYearLetter>
        <countries>Taiwan</countries>
        <crgID>0</crgID>
        <crossoverTrial>false</crossoverTrial>
        <detectionBiasJudgement>Described as double-blind, however no further details reported regarding rater-blinding.</detectionBiasJudgement>
        <detectionBiasRisk>Unclear Risk</detectionBiasRisk>
        <dobj>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>24</group1Total>
            <group2Events>0</group2Events>
            <group2Name>olanzapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>24</group2Total>
            <outcomeName>Leaving the study early</outcomeName>
            <subgroupName>any reason</subgroupName>
        </dobj>
        <factorialTrial>false</factorialTrial>
        <mainAuthor>Eli-Lilly</mainAuthor>
        <meerKatCountry>Taiwan</meerKatCountry>
        <nrControl>0</nrControl>
        <nrIntervention>0</nrIntervention>
        <nrOfParticipants>0</nrOfParticipants>
        <otherBiasJudgement>Sponsored by the manufacturers of olanzapine.</otherBiasJudgement>
        <otherBiasRisk>High risk</otherBiasRisk>
        <otherDesign>false</otherDesign>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE</comparisonName>
            <group1Events>2</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>24</group1Total>
            <group2Events>6</group2Events>
            <group2Name>olanzapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>25</group2Total>
            <outcomeName>Repeated need for tranquillisation - needing additional injection</outcomeName>
            <subgroupName>by 24 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE</comparisonName>
            <group1Events>13</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>23</group1Total>
            <group2Events>13</group2Events>
            <group2Name>olanzapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>22</group2Total>
            <outcomeName>Specific behaviour: 1a. Agitation - various measures</outcomeName>
            <subgroupName>response - up to 2 hours (≥40% reduction in PANSS-EC)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>24</group1Total>
            <group2Events>1</group2Events>
            <group2Name>olanzapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>25</group2Total>
            <outcomeName>Specific behaviour: 1a. Agitation - various measures</outcomeName>
            <subgroupName>agitation - reported as 'adverse effect'</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>24</group1Total>
            <group2Events>1</group2Events>
            <group2Name>olanzapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>25</group2Total>
            <outcomeName>Mental state: 1. Various outcomes reported as 'adverse events'</outcomeName>
            <subgroupName>anxiety</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>24</group1Total>
            <group2Events>1</group2Events>
            <group2Name>olanzapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>25</group2Total>
            <outcomeName>Mental state: 1. Various outcomes reported as 'adverse events'</outcomeName>
            <subgroupName>delusions</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>24</group1Total>
            <group2Events>1</group2Events>
            <group2Name>olanzapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>25</group2Total>
            <outcomeName>Adverse effects: 1a. General</outcomeName>
            <subgroupName>one or more drug related adverse events</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE</comparisonName>
            <group1Events>7</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>24</group1Total>
            <group2Events>9</group2Events>
            <group2Name>olanzapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>25</group2Total>
            <outcomeName>Adverse effects: 1b. General - serious</outcomeName>
            <subgroupName>one or more treatment emergent adverse events</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE</comparisonName>
            <group1Events>13</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>24</group1Total>
            <group2Events>11</group2Events>
            <group2Name>olanzapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>25</group2Total>
            <outcomeName>Adverse effects: 1b. General - serious</outcomeName>
            <subgroupName>treatment emergent adverse events - all</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>25</group1Total>
            <group2Events>0</group2Events>
            <group2Name>olanzapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>24</group2Total>
            <outcomeName>Adverse effects: 1b. General - serious</outcomeName>
            <subgroupName>overall serious adverse effects</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>24</group1Total>
            <group2Events>0</group2Events>
            <group2Name>olanzapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>25</group2Total>
            <outcomeName>Adverse effects: 1b. General - serious</outcomeName>
            <subgroupName>death</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE</comparisonName>
            <group1Events>6</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>24</group1Total>
            <group2Events>6</group2Events>
            <group2Name>olanzapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>25</group2Total>
            <outcomeName>Adverse effects: 2b. Specific - arousal level - i. various</outcomeName>
            <subgroupName>insomnia</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol </group1Name>
            <group1NameProse>HALOPERIDOL </group1NameProse>
            <group1Total>24</group1Total>
            <group2Events>0</group2Events>
            <group2Name>olanzapine</group2Name>
            <group2NameProse> other antipsychotic: e. olanzapine</group2NameProse>
            <group2Total>25</group2Total>
            <outcomeName>Adverse effects: 2f. Specific - cardiovascular i. binary</outcomeName>
            <subgroupName>clinically significant ECG change</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>24</group1Total>
            <group2Events>0</group2Events>
            <group2Name>olanzapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>25</group2Total>
            <outcomeName>Adverse effects: 2h. Specific - gastrointestinal</outcomeName>
            <subgroupName>abdominal pain</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE</comparisonName>
            <group1Events>2</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>24</group1Total>
            <group2Events>0</group2Events>
            <group2Name>olanzapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>25</group2Total>
            <outcomeName>Adverse effects: 2h. Specific - gastrointestinal</outcomeName>
            <subgroupName>vomiting</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>24</group1Total>
            <group2Events>1</group2Events>
            <group2Name>olanzapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>25</group2Total>
            <outcomeName>Adverse effects: 2i. Specific - movement disorder - i. various</outcomeName>
            <subgroupName>EPS during study</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>24</group1Total>
            <group2Events>1</group2Events>
            <group2Name>olanzapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>25</group2Total>
            <outcomeName>Adverse effects: 2i. Specific - movement disorder - i. various</outcomeName>
            <subgroupName>extrapyramidal effects - use of antiparkinson drugs during study</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>24</group1Total>
            <group2Events>0</group2Events>
            <group2Name>olanzapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>25</group2Total>
            <outcomeName>Adverse effects: 2m. Specific - miscellaneous</outcomeName>
            <subgroupName>pain</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>24</group1Total>
            <group2Events>0</group2Events>
            <group2Name>olanzapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>25</group2Total>
            <outcomeName>Adverse effects: 2m. Specific - miscellaneous</outcomeName>
            <subgroupName>other - nose bleed</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>24</group1Total>
            <group2Events>0</group2Events>
            <group2Name>olanzapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>25</group2Total>
            <outcomeName>Adverse effects: 2m. Specific - miscellaneous</outcomeName>
            <subgroupName>other - clinically relevant laboratory changes</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>24</group1Total>
            <group2Events>0</group2Events>
            <group2Name>olanzapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>24</group2Total>
            <outcomeName>Leaving the study early</outcomeName>
            <subgroupName>any reason</subgroupName>
        </outcomeList>
        <paralellTrial>false</paralellTrial>
        <performanceBiasJudgement>Described as double-blind, however no further details reported regarding the blinding of participants and personnel are not reported.</performanceBiasJudgement>
        <performanceBiasRisk>Unclear Risk</performanceBiasRisk>
        <references>OTHER</references>
        <references>NO</references>
        <references>Chan HY, Ree SC, Su LW, Chen JJ, Chou SY, Chen CK, et al</references>
        <references>A double-blind, randomized comparison study of efficacy and safety of intramuscular olanzapine and intramuscular haloperidol in patients with schizophrenia and acute agitated behavior</references>
        <references>Journal of Clinical Psychopharmacology</references>
        <references>2014</references>
        <references>34</references>
        <references>3</references>
        <references>355-8</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>OTHER</references>
        <references>NO</references>
        <references>Eli Lilly</references>
        <references>Comparison of intramuscular olanzapine and intramuscular haloperidol in patients with schizophrenia</references>
        <references>Eli Lilly and Company Clinical Trial Registry</references>
        <references>2004</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>OTHER</references>
        <references>YES</references>
        <references>NCT00485901</references>
        <references>A double-blind randomized comparison of the efficacy and safety of intramuscular olanzapine and intramuscular haloperidol in acutely agitated patients with schizophrenia</references>
        <references>http://www.clinicaltrials.gov</references>
        <references>2007</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>Only the CGI-S baseline score is reported.</reportingBiasJudgement>
        <reportingBiasRisk>High risk</reportingBiasRisk>
        <revManID>STD-Eli-Lilly-2004</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement>Not stated.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Unclear Risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>Described as randomised - method of randomisation is not reported.</selectionBiasRandomSequenceJudgement>
        <year>2004</year>
    </trialList>
    <trialList>
        <attritionBiasJudgement>No evidence of incomplete outcome data.</attritionBiasJudgement>
        <attritionBiasRisk>Low risk</attritionBiasRisk>
        <authorYearLetter>Fang2012</authorYearLetter>
        <countries>China</countries>
        <crgID>0</crgID>
        <crossoverTrial>false</crossoverTrial>
        <detectionBiasJudgement>Open trial.</detectionBiasJudgement>
        <detectionBiasRisk>High risk</detectionBiasRisk>
        <dobj>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: h. RISPERIDONE + CLONAZEPAM</comparisonName>
            <group1Events>56</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>101</group1Total>
            <group2Events>26</group2Events>
            <group2Name>risperidone//clonazepam</group2Name>
            <group2NameProse> combinations: h. risperidone + clonazepam</group2NameProse>
            <group2Total>104</group2Total>
            <outcomeName>Adverse effects: 2c. Specific - movement disorders - i. various</outcomeName>
            <subgroupName>EPS during 5 days (only reported if occurred in ≥5%)</subgroupName>
        </dobj>
        <factorialTrial>false</factorialTrial>
        <mainAuthor>Fang</mainAuthor>
        <meerKatCountry>China</meerKatCountry>
        <nrControl>0</nrControl>
        <nrIntervention>0</nrIntervention>
        <nrOfParticipants>0</nrOfParticipants>
        <otherBiasJudgement>Sponsored by drug company (Xian-Janssen Pharmaceutical Ltd).</otherBiasJudgement>
        <otherBiasRisk>High risk</otherBiasRisk>
        <otherDesign>false</otherDesign>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: h. RISPERIDONE + CLONAZEPAM</comparisonName>
            <group1Events>55</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>101</group1Total>
            <group2Events>53</group2Events>
            <group2Name>risperidone//clonazepam</group2Name>
            <group2NameProse> combinations: h. risperidone + clonazepam</group2NameProse>
            <group2Total>104</group2Total>
            <outcomeName>Tranquillisation or asleep</outcomeName>
            <subgroupName>not asleep at 2 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: h. RISPERIDONE + CLONAZEPAM</comparisonName>
            <group1Events>56</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>101</group1Total>
            <group2Events>70</group2Events>
            <group2Name>risperidone//clonazepam</group2Name>
            <group2NameProse> combinations: h. risperidone + clonazepam</group2NameProse>
            <group2Total>104</group2Total>
            <outcomeName>Tranquillisation or asleep</outcomeName>
            <subgroupName>not asleep at 4 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: h. RISPERIDONE + CLONAZEPAM</comparisonName>
            <group1Events>65</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>101</group1Total>
            <group2Events>39</group2Events>
            <group2Name>risperidone//clonazepam</group2Name>
            <group2NameProse> combinations: h. risperidone + clonazepam</group2NameProse>
            <group2Total>104</group2Total>
            <outcomeName>Adverse effects: 1. General</outcomeName>
            <subgroupName>overall adverse events during 120 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: h. RISPERIDONE + CLONAZEPAM</comparisonName>
            <group1Events>6</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>101</group1Total>
            <group2Events>4</group2Events>
            <group2Name>risperidone//clonazepam</group2Name>
            <group2NameProse> combinations: h. risperidone + clonazepam</group2NameProse>
            <group2Total>104</group2Total>
            <outcomeName>Adverse effects: 2a. Specific - arousal - i. various</outcomeName>
            <subgroupName>insomnia during 5 days (only reported if occurred in ≥5%)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: h. RISPERIDONE + CLONAZEPAM</comparisonName>
            <group1Events>5</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>101</group1Total>
            <group2Events>4</group2Events>
            <group2Name>risperidone//clonazepam</group2Name>
            <group2NameProse> combinations: h. risperidone + clonazepam</group2NameProse>
            <group2Total>104</group2Total>
            <outcomeName>Adverse effects: 2b. Specific - cardiovascular - i. various</outcomeName>
            <subgroupName>tachycardia during 120 hours (only reported if occurred in ≥5%)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: h. RISPERIDONE + CLONAZEPAM</comparisonName>
            <group1Events>46</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>101</group1Total>
            <group2Events>29</group2Events>
            <group2Name>risperidone//clonazepam</group2Name>
            <group2NameProse> combinations: h. risperidone + clonazepam</group2NameProse>
            <group2Total>104</group2Total>
            <outcomeName>Adverse effects: 2c. Specific - movement disorders - i. various</outcomeName>
            <subgroupName>akathisia during 5 days (only reported if occurred in ≥5%)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: h. RISPERIDONE + CLONAZEPAM</comparisonName>
            <group1Events>56</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>101</group1Total>
            <group2Events>26</group2Events>
            <group2Name>risperidone//clonazepam</group2Name>
            <group2NameProse> combinations: h. risperidone + clonazepam</group2NameProse>
            <group2Total>104</group2Total>
            <outcomeName>Adverse effects: 2c. Specific - movement disorders - i. various</outcomeName>
            <subgroupName>EPS during 5 days (only reported if occurred in ≥5%)</subgroupName>
        </outcomeList>
        <paralellTrial>false</paralellTrial>
        <performanceBiasJudgement>Open trial.</performanceBiasJudgement>
        <performanceBiasRisk>High risk</performanceBiasRisk>
        <references>OTHER</references>
        <references>NO</references>
        <references>Fang M, Chen H, Li LH, Wu R, Li Y, Liu L, et al</references>
        <references>Comparison of risperidone oral solution and intramuscular haloperidol with the latter shifting to oral therapy for the treatment of acute agitation in patients with schizophrenia</references>
        <references>International Clinical Psychopharmacology</references>
        <references>2012</references>
        <references>27</references>
        <references>2</references>
        <references>107-13</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>SAS and BAS scores at 2, 4, 24, 72, and 120 hours are not reported. Only side effects occurred in ≥ 5% of people are reported.</reportingBiasJudgement>
        <reportingBiasRisk>High risk</reportingBiasRisk>
        <revManID>STD-Fang-2012</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement>Not stated.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Low risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>"A telephone-based central service was used to randomly assign eligible patients" (p.108).</selectionBiasRandomSequenceJudgement>
        <year>2012</year>
    </trialList>
    <trialList>
        <attritionBiasJudgement>It is reported that 3 participants were discontinued on the medication. According to Table 3, not all participants completed all outcome measures, it is not clear if this is due to attrition or because people were not available for assessment.</attritionBiasJudgement>
        <attritionBiasRisk>Unclear Risk</attritionBiasRisk>
        <authorYearLetter>Fitzgerald1969</authorYearLetter>
        <countries>USA</countries>
        <crgID>0</crgID>
        <crossoverTrial>false</crossoverTrial>
        <detectionBiasJudgement>Described as double-blind - no further details given regarding rater-blinding.</detectionBiasJudgement>
        <detectionBiasRisk>Unclear Risk</detectionBiasRisk>
        <dobj>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: f. PERPHENAZINE</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>23</group1Total>
            <group2Events>0</group2Events>
            <group2Name>perphenazine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>21</group2Total>
            <outcomeName>Leaving the study early: 1. Specific reasons</outcomeName>
            <subgroupName>discontinued due to drowsiness/tension and no therapeutic effect</subgroupName>
        </dobj>
        <factorialTrial>false</factorialTrial>
        <mainAuthor>Fitzgerald</mainAuthor>
        <meerKatCountry>USA</meerKatCountry>
        <nrControl>0</nrControl>
        <nrIntervention>0</nrIntervention>
        <nrOfParticipants>0</nrOfParticipants>
        <otherBiasJudgement>No clear interested funding.</otherBiasJudgement>
        <otherBiasRisk>Unclear Risk</otherBiasRisk>
        <otherDesign>false</otherDesign>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: f. PERPHENAZINE</comparisonName>
            <group1Events>10</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>23</group1Total>
            <group2Events>7</group2Events>
            <group2Name>perphenazine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>21</group2Total>
            <outcomeName>Adverse effects: 1. General</outcomeName>
            <subgroupName>one or more adverse effect</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: f. PERPHENAZINE</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>23</group1Total>
            <group2Events>0</group2Events>
            <group2Name>perphenazine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>21</group2Total>
            <outcomeName>Adverse effects: 1. General</outcomeName>
            <subgroupName>clinically significant laboratory changes</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: f. PERPHENAZINE</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>23</group1Total>
            <group2Events>1</group2Events>
            <group2Name>perphenazine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>21</group2Total>
            <outcomeName>Adverse effects: 2. Specific</outcomeName>
            <subgroupName>hypotensive episode</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: f. PERPHENAZINE</comparisonName>
            <group1Events>6</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>23</group1Total>
            <group2Events>2</group2Events>
            <group2Name>perphenazine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>21</group2Total>
            <outcomeName>Adverse effects: 2. Specific</outcomeName>
            <subgroupName>require antiparkinson medication</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: f. PERPHENAZINE</comparisonName>
            <group1Events>2</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>23</group1Total>
            <group2Events>1</group2Events>
            <group2Name>perphenazine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>21</group2Total>
            <outcomeName>Adverse effects: 2. Specific</outcomeName>
            <subgroupName>discontinued due to EPS</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: f. PERPHENAZINE</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>23</group1Total>
            <group2Events>0</group2Events>
            <group2Name>perphenazine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>21</group2Total>
            <outcomeName>Adverse effects: 2. Specific</outcomeName>
            <subgroupName>discontinued due to drowsiness/tension and no therapeutic effect</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: f. PERPHENAZINE</comparisonName>
            <group1Events>2</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>23</group1Total>
            <group2Events>1</group2Events>
            <group2Name>perphenazine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>21</group2Total>
            <outcomeName>Leaving the study early: 1. Specific reasons</outcomeName>
            <subgroupName>discontinued due to EPS</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: f. PERPHENAZINE</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>23</group1Total>
            <group2Events>0</group2Events>
            <group2Name>perphenazine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>21</group2Total>
            <outcomeName>Leaving the study early: 1. Specific reasons</outcomeName>
            <subgroupName>discontinued due to drowsiness/tension and no therapeutic effect</subgroupName>
        </outcomeList>
        <paralellTrial>false</paralellTrial>
        <performanceBiasJudgement>"haloperidol and perphenazine were supplied in identically appearing 1-mL ampoules each containing 5 mg of drug." (p.515).</performanceBiasJudgement>
        <performanceBiasRisk>Low risk</performanceBiasRisk>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Fitzgerald CH</references>
        <references>A double-blind comparison of haloperidol with perphenazine in acute psychiatric episodes</references>
        <references>Current Therapeutic Research</references>
        <references>1969</references>
        <references>11</references>
        <references>8</references>
        <references>515-9</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>"Most adverse reactions disappeared with the use of control measures" - author suspects that only the adverse effects severe enough for discontinuation are reported.</reportingBiasJudgement>
        <reportingBiasRisk>Unclear Risk</reportingBiasRisk>
        <revManID>STD-Fitzgerald-1969</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement>Not stated.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Unclear Risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>Described as randomised - method of randomisation is not reported.</selectionBiasRandomSequenceJudgement>
        <year>1969</year>
    </trialList>
    <trialList>
        <attritionBiasJudgement>No evidence of incomplete outcome data.</attritionBiasJudgement>
        <attritionBiasRisk>Low risk</attritionBiasRisk>
        <authorYearLetter>Foster1997</authorYearLetter>
        <countries>USA</countries>
        <crgID>0</crgID>
        <crossoverTrial>false</crossoverTrial>
        <detectionBiasJudgement>"All raters were unaware of the specific medication received by the patient". (p.176).</detectionBiasJudgement>
        <detectionBiasRisk>Low risk</detectionBiasRisk>
        <factorialTrial>false</factorialTrial>
        <mainAuthor>Foster</mainAuthor>
        <meerKatCountry>USA</meerKatCountry>
        <nrControl>0</nrControl>
        <nrIntervention>0</nrIntervention>
        <nrOfParticipants>0</nrOfParticipants>
        <otherBiasJudgement>Small short study.</otherBiasJudgement>
        <otherBiasRisk>High risk</otherBiasRisk>
        <otherDesign>false</otherDesign>
        <paralellTrial>false</paralellTrial>
        <performanceBiasJudgement>Described as double-blind, however it is not clear whether the study drugs appeared identical.</performanceBiasJudgement>
        <performanceBiasRisk>Unclear Risk</performanceBiasRisk>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Foster S, Kessel J, Berman ME, Simpson GM</references>
        <references>Efficacy of lorazepam and haloperidol for rapid tranquilization in a psychiatric emergency room setting</references>
        <references>International Clinical Psychopharmacology</references>
        <references>1997</references>
        <references>12</references>
        <references>3</references>
        <references>175-9</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>"patients continued to receive treatment with a benzodiazepine, if necessary, for the duration of their stay in the emergency department." (p.176). The amount was not reported.</reportingBiasJudgement>
        <reportingBiasRisk>High risk</reportingBiasRisk>
        <revManID>STD-Foster-1997</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement>Not stated.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Unclear Risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>Described as randomised - method of randomisation is not reported.</selectionBiasRandomSequenceJudgement>
        <year>1997</year>
    </trialList>
    <trialList>
        <attritionBiasJudgement>No evidence of incomplete data.</attritionBiasJudgement>
        <attritionBiasRisk>Low risk</attritionBiasRisk>
        <authorYearLetter>Fruensgaard1977</authorYearLetter>
        <countries>Denmark</countries>
        <crgID>0</crgID>
        <crossoverTrial>false</crossoverTrial>
        <detectionBiasJudgement>Described as double-blind, however no further details reported regarding rater-blinding.</detectionBiasJudgement>
        <detectionBiasRisk>Low risk</detectionBiasRisk>
        <dobj>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: d. LOXAPINE</comparisonName>
            <group1Events>2</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>15</group1Total>
            <group2Events>3</group2Events>
            <group2Name>loxapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>15</group2Total>
            <outcomeName>Adverse effects: 2e. Specific - miscellaneous</outcomeName>
            <subgroupName>pain - during 24 hours</subgroupName>
        </dobj>
        <factorialTrial>false</factorialTrial>
        <mainAuthor>Fruensgaard</mainAuthor>
        <meerKatCountry>Denmark</meerKatCountry>
        <nrControl>0</nrControl>
        <nrIntervention>0</nrIntervention>
        <nrOfParticipants>0</nrOfParticipants>
        <otherBiasJudgement>Small study.</otherBiasJudgement>
        <otherBiasRisk>High risk</otherBiasRisk>
        <otherDesign>false</otherDesign>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: d. LOXAPINE</comparisonName>
            <group1Events>11</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>15</group1Total>
            <group2Events>10</group2Events>
            <group2Name>loxapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>15</group2Total>
            <outcomeName>Specific behaviour: 2. Aggression - various measures</outcomeName>
            <subgroupName>no overall improvement</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: d. LOXAPINE</comparisonName>
            <group1Events>9</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>15</group1Total>
            <group2Events>7</group2Events>
            <group2Name>loxapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>15</group2Total>
            <outcomeName>Global outcome: 2a. Specific - not sedated - i. by 30 minutes</outcomeName>
            <subgroupName>at 30 minutes</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: d. LOXAPINE</comparisonName>
            <group1Events>7</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>15</group1Total>
            <group2Events>2</group2Events>
            <group2Name>loxapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>15</group2Total>
            <outcomeName>Global outcome: 2b. Specific - not sedated - ii. up to 2 hours</outcomeName>
            <subgroupName>at 1 hour</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: d. LOXAPINE</comparisonName>
            <group1Events>7</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>15</group1Total>
            <group2Events>1</group2Events>
            <group2Name>loxapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>15</group2Total>
            <outcomeName>Global outcome: 2b. Specific - not sedated - ii. up to 2 hours</outcomeName>
            <subgroupName>at 2 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: d. LOXAPINE</comparisonName>
            <group1Events>8</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>15</group1Total>
            <group2Events>10</group2Events>
            <group2Name>loxapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>15</group2Total>
            <outcomeName>Adverse effects: 1. General</outcomeName>
            <subgroupName>one or more drug related adverse effect</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: d. LOXAPINE</comparisonName>
            <group1Events>3</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>15</group1Total>
            <group2Events>4</group2Events>
            <group2Name>loxapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>15</group2Total>
            <outcomeName>Adverse effects: 2b. Specific - arousal level</outcomeName>
            <subgroupName>drowsiness during 72 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: d. LOXAPINE</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>15</group1Total>
            <group2Events>6</group2Events>
            <group2Name>loxapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>15</group2Total>
            <outcomeName>Adverse effects: 2c. Specific - cardiovascular</outcomeName>
            <subgroupName>dizziness - between 3-28 days</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: d. LOXAPINE</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>15</group1Total>
            <group2Events>1</group2Events>
            <group2Name>loxapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>15</group2Total>
            <outcomeName>Adverse effects: 2c. Specific - cardiovascular</outcomeName>
            <subgroupName>palpitations during 72 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: d. LOXAPINE</comparisonName>
            <group1Events>2</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>15</group1Total>
            <group2Events>0</group2Events>
            <group2Name>loxapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>15</group2Total>
            <outcomeName>Adverse effects: 2d. Specific - movement disorders</outcomeName>
            <subgroupName>dystonia during 72 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: d. LOXAPINE</comparisonName>
            <group1Events>3</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>15</group1Total>
            <group2Events>5</group2Events>
            <group2Name>loxapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>15</group2Total>
            <outcomeName>Adverse effects: 2d. Specific - movement disorders</outcomeName>
            <subgroupName>extrapyramidal effects - use of antiparkinson drugs during 72 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: d. LOXAPINE</comparisonName>
            <group1Events>7</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>15</group1Total>
            <group2Events>1</group2Events>
            <group2Name>loxapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>15</group2Total>
            <outcomeName>Adverse effects: 2d. Specific - movement disorders</outcomeName>
            <subgroupName>EPS during 72 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: d. LOXAPINE</comparisonName>
            <group1Events>2</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>15</group1Total>
            <group2Events>3</group2Events>
            <group2Name>loxapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>15</group2Total>
            <outcomeName>Adverse effects: 2e. Specific - miscellaneous</outcomeName>
            <subgroupName>pain - during 24 hours</subgroupName>
        </outcomeList>
        <paralellTrial>false</paralellTrial>
        <performanceBiasJudgement>"Both drugs were supplied in ampules of identical appearance." (p.257).</performanceBiasJudgement>
        <performanceBiasRisk>Low risk</performanceBiasRisk>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Fruensgaard K, Korsgaard S, Jorgensen H, Jensen K</references>
        <references>Loxapine versus haloperidol parenterally in acute psychosis with agitation. A double-blind study</references>
        <references>Acta Psychiatrica Scandinavica</references>
        <references>1977</references>
        <references>56</references>
        <references>4</references>
        <references>256-64</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>No evidence of selective reporting.</reportingBiasJudgement>
        <reportingBiasRisk>Low risk</reportingBiasRisk>
        <revManID>STD-Fruensgaard-1977</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement>Not stated.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Unclear Risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>Described as randomised - method of randomisation is not reported.</selectionBiasRandomSequenceJudgement>
        <year>1977</year>
    </trialList>
    <trialList>
        <attritionBiasJudgement>No evidence of incomplete data.</attritionBiasJudgement>
        <attritionBiasRisk>Low risk</attritionBiasRisk>
        <authorYearLetter>Garza-Trevino1989</authorYearLetter>
        <countries>USA</countries>
        <crgID>0</crgID>
        <crossoverTrial>false</crossoverTrial>
        <detectionBiasJudgement>Open trial.</detectionBiasJudgement>
        <detectionBiasRisk>High risk</detectionBiasRisk>
        <dobj>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: b. HALOPERIDOL + LORAZEPAM</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>21</group1Total>
            <group2Events>0</group2Events>
            <group2Name>haloperidol//lorazepam</group2Name>
            <group2NameProse> combinations: b. haloperidol + lorazepam</group2NameProse>
            <group2Total>24</group2Total>
            <outcomeName>Global outcome: 1. No overall improvement</outcomeName>
            <subgroupName>at &gt; 1 hour</subgroupName>
        </dobj>
        <factorialTrial>false</factorialTrial>
        <mainAuthor>Garza-Trevino</mainAuthor>
        <meerKatCountry>USA</meerKatCountry>
        <nrControl>0</nrControl>
        <nrIntervention>0</nrIntervention>
        <nrOfParticipants>0</nrOfParticipants>
        <otherBiasJudgement>The duration of the study is not reported.</otherBiasJudgement>
        <otherBiasRisk>Unclear Risk</otherBiasRisk>
        <otherDesign>false</otherDesign>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs BENZODIAZEPINE: b. LORAZEPAM</comparisonName>
            <group1Events>14</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>21</group1Total>
            <group2Events>14</group2Events>
            <group2Name>lorazepam</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>23</group2Total>
            <outcomeName>Global outcome: 1. No overall improvement</outcomeName>
            <subgroupName>by 30 minutes</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs BENZODIAZEPINE: b. LORAZEPAM</comparisonName>
            <group1Events>6</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>21</group1Total>
            <group2Events>4</group2Events>
            <group2Name>lorazepam</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>23</group2Total>
            <outcomeName>Global outcome: 1. No overall improvement</outcomeName>
            <subgroupName>at 1 hour</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs BENZODIAZEPINE: b. LORAZEPAM</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>21</group1Total>
            <group2Events>0</group2Events>
            <group2Name>lorazepam</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>23</group2Total>
            <outcomeName>Global outcome: 1. No overall improvement</outcomeName>
            <subgroupName>at &gt; 1 hour</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: b. HALOPERIDOL + LORAZEPAM</comparisonName>
            <group1Events>14</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>21</group1Total>
            <group2Events>6</group2Events>
            <group2Name>haloperidol//lorazepam</group2Name>
            <group2NameProse> combinations: b. haloperidol + lorazepam</group2NameProse>
            <group2Total>24</group2Total>
            <outcomeName>Global outcome: 1. No overall improvement</outcomeName>
            <subgroupName>by 30 minutes</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: b. HALOPERIDOL + LORAZEPAM</comparisonName>
            <group1Events>6</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>21</group1Total>
            <group2Events>0</group2Events>
            <group2Name>haloperidol//lorazepam</group2Name>
            <group2NameProse> combinations: b. haloperidol + lorazepam</group2NameProse>
            <group2Total>24</group2Total>
            <outcomeName>Global outcome: 1. No overall improvement</outcomeName>
            <subgroupName>at 1 hour</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: b. HALOPERIDOL + LORAZEPAM</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>21</group1Total>
            <group2Events>0</group2Events>
            <group2Name>haloperidol//lorazepam</group2Name>
            <group2NameProse> combinations: b. haloperidol + lorazepam</group2NameProse>
            <group2Total>24</group2Total>
            <outcomeName>Global outcome: 1. No overall improvement</outcomeName>
            <subgroupName>at &gt; 1 hour</subgroupName>
        </outcomeList>
        <paralellTrial>false</paralellTrial>
        <performanceBiasJudgement>Open trial.</performanceBiasJudgement>
        <performanceBiasRisk>High risk</performanceBiasRisk>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Garza-Trevino ES, Hollister LE, Overall JE, Alexander WF</references>
        <references>Efficacy of combinations of intramuscular antipsychotics and sedative-hypnotics for control of psychotic agitation</references>
        <references>American Journal of Psychiatry</references>
        <references>1989</references>
        <references>146</references>
        <references>12</references>
        <references>1598-601</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>There is no reporting regarding the incidence of adverse effects.</reportingBiasJudgement>
        <reportingBiasRisk>High risk</reportingBiasRisk>
        <revManID>STD-Garza_x002d_Trevino-1989</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement>Not stated.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Unclear Risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>Described as randomised - method of randomisation is not reported.</selectionBiasRandomSequenceJudgement>
        <year>1989</year>
    </trialList>
    <trialList>
        <attritionBiasJudgement>No incomplete outcome data.</attritionBiasJudgement>
        <attritionBiasRisk>Low risk</attritionBiasRisk>
        <authorYearLetter>Guo2007</authorYearLetter>
        <countries>China</countries>
        <crgID>0</crgID>
        <crossoverTrial>false</crossoverTrial>
        <detectionBiasJudgement>Open-label.</detectionBiasJudgement>
        <detectionBiasRisk>High risk</detectionBiasRisk>
        <dobj>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: g. QUETIAPINE + MAGNESIUM VALPROATE</comparisonName>
            <group1Events>7</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>30</group1Total>
            <group2Events>6</group2Events>
            <group2Name>quetiapine//mg v</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>30</group2Total>
            <outcomeName>Specific behaviour: 1a. Agitation - binary measures</outcomeName>
            <subgroupName>&lt;25% reduction, no effect (PANSS-EC)</subgroupName>
        </dobj>
        <factorialTrial>false</factorialTrial>
        <mainAuthor>Guo</mainAuthor>
        <meerKatCountry>China</meerKatCountry>
        <nrControl>0</nrControl>
        <nrIntervention>0</nrIntervention>
        <nrOfParticipants>0</nrOfParticipants>
        <otherBiasJudgement>None obvious.</otherBiasJudgement>
        <otherBiasRisk>Unclear Risk</otherBiasRisk>
        <otherDesign>false</otherDesign>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: g. QUETIAPINE + MAGNESIUM VALPROATE</comparisonName>
            <group1Events>7</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>30</group1Total>
            <group2Events>6</group2Events>
            <group2Name>quetiapine//mg v</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>30</group2Total>
            <outcomeName>Specific behaviour: 1a. Agitation - binary measures</outcomeName>
            <subgroupName>&lt;25% reduction, no effect (PANSS-EC)</subgroupName>
        </outcomeList>
        <paralellTrial>false</paralellTrial>
        <performanceBiasJudgement>Open-label.</performanceBiasJudgement>
        <performanceBiasRisk>High risk</performanceBiasRisk>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Guo C-R</references>
        <references>Study of quetiapine combined with magnesium valproate release tablets in treatment of schizophrenia with symptoms of elation and agitation</references>
        <references>Linchuang Jingshen Yixue Zazhi [临床精神医学杂志]</references>
        <references>2007</references>
        <references>17</references>
        <references>3</references>
        <references>183-4</references>
        <references>奎硫平合并丙戊酸镁缓释片治疗精神分裂症兴奋激越研究</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>CGI and TESS were measured, but not reported.</reportingBiasJudgement>
        <reportingBiasRisk>High risk</reportingBiasRisk>
        <revManID>STD-Guo-2007</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement>Not stated.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Unclear Risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>Described as randomised - method of randomisation is not reported.</selectionBiasRandomSequenceJudgement>
        <year>2007</year>
    </trialList>
    <trialList>
        <attritionBiasJudgement>No evidence of incomplete data.</attritionBiasJudgement>
        <attritionBiasRisk>Low risk</attritionBiasRisk>
        <authorYearLetter>Higashima2004</authorYearLetter>
        <countries>Japan</countries>
        <crgID>0</crgID>
        <crossoverTrial>false</crossoverTrial>
        <detectionBiasJudgement>Open trial.</detectionBiasJudgement>
        <detectionBiasRisk>High risk</detectionBiasRisk>
        <factorialTrial>false</factorialTrial>
        <mainAuthor>Higashima</mainAuthor>
        <meerKatCountry>Japan</meerKatCountry>
        <nrControl>0</nrControl>
        <nrIntervention>0</nrIntervention>
        <nrOfParticipants>0</nrOfParticipants>
        <otherBiasJudgement>Small N study.</otherBiasJudgement>
        <otherBiasRisk>High risk</otherBiasRisk>
        <otherDesign>false</otherDesign>
        <paralellTrial>false</paralellTrial>
        <performanceBiasJudgement>Open trial.</performanceBiasJudgement>
        <performanceBiasRisk>High risk</performanceBiasRisk>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Higashima M, Takeda T, Nagasawa T, Hirao N, Oka T, Nakamura M, et al</references>
        <references>Combined therapy with low-potency neuroleptic levomepromazine as an adjunct to haloperidol for agitated patients with acute exacerbation of schizophrenia</references>
        <references>European Psychiatry</references>
        <references>2004</references>
        <references>19</references>
        <references>6</references>
        <references>380-1</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>The discussion describes how the combination drug "produced moderate sedation without any cardiovascular adverse effect". However, there is no other reporting regarding the incidence adverse effects.</reportingBiasJudgement>
        <reportingBiasRisk>High risk</reportingBiasRisk>
        <revManID>STD-Higashima-2004</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement>Not stated.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Unclear Risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>Described as randomised - method of randomisation is not reported.</selectionBiasRandomSequenceJudgement>
        <year>2004</year>
    </trialList>
    <trialList>
        <attritionBiasJudgement>No evidence of incomplete outcome data.</attritionBiasJudgement>
        <attritionBiasRisk>Low risk</attritionBiasRisk>
        <authorYearLetter>Huf2007</authorYearLetter>
        <countries>Brazil</countries>
        <crgID>0</crgID>
        <crossoverTrial>false</crossoverTrial>
        <detectionBiasJudgement>Open trial.</detectionBiasJudgement>
        <detectionBiasRisk>High risk</detectionBiasRisk>
        <dobj>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: d. HALOPERIDOL + PROMETHAZINE</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>156</group1Total>
            <group2Events>1</group2Events>
            <group2Name>haloperidol//promethazine</group2Name>
            <group2NameProse> combinations: d. haloperidol + promethazine</group2NameProse>
            <group2Total>160</group2Total>
            <outcomeName>Leaving the study early</outcomeName>
            <subgroupName>withdrew consent</subgroupName>
        </dobj>
        <factorialTrial>false</factorialTrial>
        <mainAuthor>Huf</mainAuthor>
        <meerKatCountry>Brazil</meerKatCountry>
        <nrControl>0</nrControl>
        <nrIntervention>0</nrIntervention>
        <nrOfParticipants>0</nrOfParticipants>
        <otherBiasJudgement>The study was stopped early due to adverse effects, therefore it is possible that the available data may be biased.</otherBiasJudgement>
        <otherBiasRisk>Unclear Risk</otherBiasRisk>
        <otherDesign>false</otherDesign>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: d. HALOPERIDOL + PROMETHAZINE</comparisonName>
            <group1Events>70</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>156</group1Total>
            <group2Events>45</group2Events>
            <group2Name>haloperidol//promethazine</group2Name>
            <group2NameProse> combinations: d. haloperidol + promethazine</group2NameProse>
            <group2Total>160</group2Total>
            <outcomeName>Tranquillisation or asleep - not tranquil or asleep - i. by 30 minutes</outcomeName>
            <subgroupName>at 20 minutes</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: d. HALOPERIDOL + PROMETHAZINE</comparisonName>
            <group1Events>38</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>156</group1Total>
            <group2Events>31</group2Events>
            <group2Name>haloperidol//promethazine</group2Name>
            <group2NameProse> combinations: d. haloperidol + promethazine</group2NameProse>
            <group2Total>160</group2Total>
            <outcomeName>Tranquillisation or asleep - not tranquil or asleep - ii. up to 2 hours</outcomeName>
            <subgroupName>at 40 minutes</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: d. HALOPERIDOL + PROMETHAZINE</comparisonName>
            <group1Events>29</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>156</group1Total>
            <group2Events>21</group2Events>
            <group2Name>haloperidol//promethazine</group2Name>
            <group2NameProse> combinations: d. haloperidol + promethazine</group2NameProse>
            <group2Total>160</group2Total>
            <outcomeName>Tranquillisation or asleep - not tranquil or asleep - ii. up to 2 hours</outcomeName>
            <subgroupName>at 1 hour</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: d. HALOPERIDOL + PROMETHAZINE</comparisonName>
            <group1Events>18</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>156</group1Total>
            <group2Events>14</group2Events>
            <group2Name>haloperidol//promethazine</group2Name>
            <group2NameProse> combinations: d. haloperidol + promethazine</group2NameProse>
            <group2Total>160</group2Total>
            <outcomeName>Tranquillisation or asleep - not tranquil or asleep - ii. up to 2 hours</outcomeName>
            <subgroupName>at 2 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: d. HALOPERIDOL + PROMETHAZINE</comparisonName>
            <group1Events>13</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>156</group1Total>
            <group2Events>8</group2Events>
            <group2Name>haloperidol//promethazine</group2Name>
            <group2NameProse> combinations: d. haloperidol + promethazine</group2NameProse>
            <group2Total>160</group2Total>
            <outcomeName>Repeated need for tranquillisation - need for additional drugs for tranquillisation</outcomeName>
            <subgroupName>by 2 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: d. HALOPERIDOL + PROMETHAZINE</comparisonName>
            <group1Events>45</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>156</group1Total>
            <group2Events>38</group2Events>
            <group2Name>haloperidol//promethazine</group2Name>
            <group2NameProse> combinations: d. haloperidol + promethazine</group2NameProse>
            <group2Total>160</group2Total>
            <outcomeName>Global outcomes: 1. General - need for additional measures</outcomeName>
            <subgroupName>restraints needed by 2 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: d. HALOPERIDOL + PROMETHAZINE</comparisonName>
            <group1Events>54</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>156</group1Total>
            <group2Events>37</group2Events>
            <group2Name>haloperidol//promethazine</group2Name>
            <group2NameProse> combinations: d. haloperidol + promethazine</group2NameProse>
            <group2Total>160</group2Total>
            <outcomeName>Global outcomes: 2. Specific</outcomeName>
            <subgroupName>doctor called to see patient</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: d. HALOPERIDOL + PROMETHAZINE</comparisonName>
            <group1Events>27</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>156</group1Total>
            <group2Events>28</group2Events>
            <group2Name>haloperidol//promethazine</group2Name>
            <group2NameProse> combinations: d. haloperidol + promethazine</group2NameProse>
            <group2Total>160</group2Total>
            <outcomeName>Global outcomes: 2. Specific</outcomeName>
            <subgroupName>refuse oral drugs</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: d. HALOPERIDOL + PROMETHAZINE</comparisonName>
            <group1Events>11</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>156</group1Total>
            <group2Events>1</group2Events>
            <group2Name>haloperidol//promethazine</group2Name>
            <group2NameProse> combinations: d. haloperidol + promethazine</group2NameProse>
            <group2Total>160</group2Total>
            <outcomeName>Adverse effects: 1a. General</outcomeName>
            <subgroupName>one or more adverse effects up to 24 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: d. HALOPERIDOL + PROMETHAZINE</comparisonName>
            <group1Events>2</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>156</group1Total>
            <group2Events>1</group2Events>
            <group2Name>haloperidol//promethazine</group2Name>
            <group2NameProse> combinations: d. haloperidol + promethazine</group2NameProse>
            <group2Total>160</group2Total>
            <outcomeName>Adverse effects: 1b. General - serious</outcomeName>
            <subgroupName>seizure</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: d. HALOPERIDOL + PROMETHAZINE</comparisonName>
            <group1Events>9</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>156</group1Total>
            <group2Events>0</group2Events>
            <group2Name>haloperidol//promethazine</group2Name>
            <group2NameProse> combinations: d. haloperidol + promethazine</group2NameProse>
            <group2Total>160</group2Total>
            <outcomeName>Adverse effects: 2f. Specific - movement disorders</outcomeName>
            <subgroupName>acute dystonia</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: d. HALOPERIDOL + PROMETHAZINE</comparisonName>
            <group1Events>17</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>156</group1Total>
            <group2Events>17</group2Events>
            <group2Name>haloperidol//promethazine</group2Name>
            <group2NameProse> combinations: d. haloperidol + promethazine</group2NameProse>
            <group2Total>160</group2Total>
            <outcomeName>Leaving the study early</outcomeName>
            <subgroupName>any reason</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: d. HALOPERIDOL + PROMETHAZINE</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>156</group1Total>
            <group2Events>2</group2Events>
            <group2Name>haloperidol//promethazine</group2Name>
            <group2NameProse> combinations: d. haloperidol + promethazine</group2NameProse>
            <group2Total>160</group2Total>
            <outcomeName>Leaving the study early</outcomeName>
            <subgroupName>absconded before receiving drug</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: d. HALOPERIDOL + PROMETHAZINE</comparisonName>
            <group1Events>12</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>156</group1Total>
            <group2Events>11</group2Events>
            <group2Name>haloperidol//promethazine</group2Name>
            <group2NameProse> combinations: d. haloperidol + promethazine</group2NameProse>
            <group2Total>160</group2Total>
            <outcomeName>Leaving the study early</outcomeName>
            <subgroupName>incomplete information in notes</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: d. HALOPERIDOL + PROMETHAZINE</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>156</group1Total>
            <group2Events>0</group2Events>
            <group2Name>haloperidol//promethazine</group2Name>
            <group2NameProse> combinations: d. haloperidol + promethazine</group2NameProse>
            <group2Total>160</group2Total>
            <outcomeName>Leaving the study early</outcomeName>
            <subgroupName>seizure before drug was given</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: d. HALOPERIDOL + PROMETHAZINE</comparisonName>
            <group1Events>3</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>156</group1Total>
            <group2Events>3</group2Events>
            <group2Name>haloperidol//promethazine</group2Name>
            <group2NameProse> combinations: d. haloperidol + promethazine</group2NameProse>
            <group2Total>160</group2Total>
            <outcomeName>Leaving the study early</outcomeName>
            <subgroupName>transfer to another hospital/notes lost</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: d. HALOPERIDOL + PROMETHAZINE</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>156</group1Total>
            <group2Events>1</group2Events>
            <group2Name>haloperidol//promethazine</group2Name>
            <group2NameProse> combinations: d. haloperidol + promethazine</group2NameProse>
            <group2Total>160</group2Total>
            <outcomeName>Leaving the study early</outcomeName>
            <subgroupName>withdrew consent</subgroupName>
        </outcomeList>
        <paralellTrial>false</paralellTrial>
        <performanceBiasJudgement>Open trial.</performanceBiasJudgement>
        <performanceBiasRisk>High risk</performanceBiasRisk>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Barbui C</references>
        <references>Intramuscular haloperidol plus promethazine is more effective and safer than haloperidol alone for rapid tranquillisation of agitated mentally ill patients</references>
        <references>Evidence-Based Mental Health</references>
        <references>2008</references>
        <references>11</references>
        <references>3</references>
        <references>86-7</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>JOURNAL_ARTICLE</references>
        <references>YES</references>
        <references>Huf G, Coutinho ESF, Adams CE</references>
        <references>Rapid tranquillisation in psychiatric emergency settings in Brazil: pragmatic randomised controlled trial of intramuscular haloperidol versus intramuscular haloperidol plus promethazine</references>
        <references>BMJ</references>
        <references>2007</references>
        <references>335</references>
        <references>7625</references>
        <references>869-72</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>CONFERENCE_PROC</references>
        <references>NO</references>
        <references>Huf G, Coutinho ESF, Adams CE</references>
        <references>The pharmacological management of agitated patients in emergency psychiatric hospitals in Rio de Janeiro, Brazil: the results of two pragmatic randomized clinical trials</references>
        <references>Proceedings of the 5th European Congress on Violence in Clinical Psychiatry; 2007 Oct 25-27; Amsterdam, The Netherlands</references>
        <references>2007</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>UNPUBLISHED</references>
        <references>NO</references>
        <references>Huf G</references>
        <references>Haloperidol plus promethazine versus haloperidol for psychosis induced aggression</references>
        <references>Data on file</references>
        <references>2004</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>OTHER</references>
        <references>NO</references>
        <references>ISRCTN83261243</references>
        <references>TREC2 - Rapid tranquillisation for agitated patients in emergency psychiatric rooms in Rio de Janeiro. A randomised trial of intramuscular haloperidol versus intramuscular haloperidol + promethazine</references>
        <references>http://www.controlled-trials.com</references>
        <references>2005</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Migon MN, Coutinho ES, Huf G, Adams CE, Cunha GM, Allen MH</references>
        <references>Factors associated with the use of physical restraints for agitated patients in psychiatric emergency rooms</references>
        <references>General Hospital Psychiatry</references>
        <references>2008</references>
        <references>30</references>
        <references>3</references>
        <references>263-8</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>No evidence of selective reporting.</reportingBiasJudgement>
        <reportingBiasRisk>Low risk</reportingBiasRisk>
        <revManID>STD-Huf-2007</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Low risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement>"Boxes were consecutively numbered, sealed, opaque, and identical appearance and weight; on the outside was a form with questions to be completed by the attending doctor while "blind" to the contents of the box." (p.2).</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Low risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>A computer-generated randomised sequence was applied to a table of numbers.</selectionBiasRandomSequenceJudgement>
        <year>2007</year>
    </trialList>
    <trialList>
        <attritionBiasJudgement>No evidence of incomplete outcome data.</attritionBiasJudgement>
        <attritionBiasRisk>Low risk</attritionBiasRisk>
        <authorYearLetter>Kewala1984</authorYearLetter>
        <countries>USA</countries>
        <crgID>0</crgID>
        <crossoverTrial>false</crossoverTrial>
        <detectionBiasJudgement>Described as double-blind, however no further details reported regarding rater-blinding.</detectionBiasJudgement>
        <detectionBiasRisk>Unclear Risk</detectionBiasRisk>
        <dobj>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: i. THIOTHIXENE</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>24</group1Total>
            <group2Events>0</group2Events>
            <group2Name>thiothixene</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>20</group2Total>
            <outcomeName>Adverse effects: 2b. Specific - others</outcomeName>
            <subgroupName>other - weakness</subgroupName>
        </dobj>
        <factorialTrial>false</factorialTrial>
        <mainAuthor>Kewala</mainAuthor>
        <meerKatCountry>USA</meerKatCountry>
        <nrControl>0</nrControl>
        <nrIntervention>0</nrIntervention>
        <nrOfParticipants>0</nrOfParticipants>
        <otherBiasJudgement>Recieved grant from Roerig, a division of Phizer Pharmaceuticals (thiothixene manufacturers), small short study.</otherBiasJudgement>
        <otherBiasRisk>High risk</otherBiasRisk>
        <otherDesign>false</otherDesign>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: i. THIOTHIXENE</comparisonName>
            <group1Events>6</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>24</group1Total>
            <group2Events>2</group2Events>
            <group2Name>thiothixene</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>20</group2Total>
            <outcomeName>Global outcome</outcomeName>
            <subgroupName>no response to 1st injection</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: i. THIOTHIXENE</comparisonName>
            <group1Events>3</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>24</group1Total>
            <group2Events>5</group2Events>
            <group2Name>thiothixene</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>20</group2Total>
            <outcomeName>Global outcome</outcomeName>
            <subgroupName>no improvement at 1 hour</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: i. THIOTHIXENE</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>24</group1Total>
            <group2Events>2</group2Events>
            <group2Name>thiothixene</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>20</group2Total>
            <outcomeName>Global outcome</outcomeName>
            <subgroupName>no improvement at 2 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: i. THIOTHIXENE</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>24</group1Total>
            <group2Events>1</group2Events>
            <group2Name>thiothixene</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>20</group2Total>
            <outcomeName>Global outcome</outcomeName>
            <subgroupName>no improvement at 3 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: i. THIOTHIXENE</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>24</group1Total>
            <group2Events>1</group2Events>
            <group2Name>thiothixene</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>20</group2Total>
            <outcomeName>Global outcome</outcomeName>
            <subgroupName>no improvement at 4 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: i. THIOTHIXENE</comparisonName>
            <group1Events>2</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>24</group1Total>
            <group2Events>0</group2Events>
            <group2Name>thiothixene</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>20</group2Total>
            <outcomeName>Global outcome</outcomeName>
            <subgroupName>no improvement at 5 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: i. THIOTHIXENE</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>24</group1Total>
            <group2Events>1</group2Events>
            <group2Name>thiothixene</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>20</group2Total>
            <outcomeName>Adverse effects: 2a. Specific - movement disorders</outcomeName>
            <subgroupName>ataxia</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: i. THIOTHIXENE</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>24</group1Total>
            <group2Events>0</group2Events>
            <group2Name>thiothixene</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>20</group2Total>
            <outcomeName>Adverse effects: 2a. Specific - movement disorders</outcomeName>
            <subgroupName>thick tongue</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: i. THIOTHIXENE</comparisonName>
            <group1Events>2</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>24</group1Total>
            <group2Events>0</group2Events>
            <group2Name>thiothixene</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>20</group2Total>
            <outcomeName>Adverse effects: 2b. Specific - others</outcomeName>
            <subgroupName>anticholinergic - blurred vision</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: i. THIOTHIXENE</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>24</group1Total>
            <group2Events>2</group2Events>
            <group2Name>thiothixene</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>20</group2Total>
            <outcomeName>Adverse effects: 2b. Specific - others</outcomeName>
            <subgroupName>anticholinergic - dry mouth</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: i. THIOTHIXENE</comparisonName>
            <group1Events>18</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>24</group1Total>
            <group2Events>9</group2Events>
            <group2Name>thiothixene</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>20</group2Total>
            <outcomeName>Adverse effects: 2b. Specific - others</outcomeName>
            <subgroupName>arousal - drowsiness</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: i. THIOTHIXENE</comparisonName>
            <group1Events>2</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>24</group1Total>
            <group2Events>0</group2Events>
            <group2Name>thiothixene</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>20</group2Total>
            <outcomeName>Adverse effects: 2b. Specific - others</outcomeName>
            <subgroupName>arousal - lightheadedness</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: i. THIOTHIXENE</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>24</group1Total>
            <group2Events>1</group2Events>
            <group2Name>thiothixene</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>20</group2Total>
            <outcomeName>Adverse effects: 2b. Specific - others</outcomeName>
            <subgroupName>cardiac - chest pain</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: i. THIOTHIXENE</comparisonName>
            <group1Events>3</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>24</group1Total>
            <group2Events>1</group2Events>
            <group2Name>thiothixene</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>20</group2Total>
            <outcomeName>Adverse effects: 2b. Specific - others</outcomeName>
            <subgroupName>cardiac - dizziness</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: i. THIOTHIXENE</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>24</group1Total>
            <group2Events>1</group2Events>
            <group2Name>thiothixene</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>20</group2Total>
            <outcomeName>Adverse effects: 2b. Specific - others</outcomeName>
            <subgroupName>cardiac - orthostatic hypotension</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: i. THIOTHIXENE</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>24</group1Total>
            <group2Events>1</group2Events>
            <group2Name>thiothixene</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>20</group2Total>
            <outcomeName>Adverse effects: 2b. Specific - others</outcomeName>
            <subgroupName>cardiac - tachycardia</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: i. THIOTHIXENE</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>24</group1Total>
            <group2Events>0</group2Events>
            <group2Name>thiothixene</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>20</group2Total>
            <outcomeName>Adverse effects: 2b. Specific - others</outcomeName>
            <subgroupName>other - depressed mood</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: i. THIOTHIXENE</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>24</group1Total>
            <group2Events>1</group2Events>
            <group2Name>thiothixene</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>20</group2Total>
            <outcomeName>Adverse effects: 2b. Specific - others</outcomeName>
            <subgroupName>other - diaphoresis</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: i. THIOTHIXENE</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>24</group1Total>
            <group2Events>0</group2Events>
            <group2Name>thiothixene</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>20</group2Total>
            <outcomeName>Adverse effects: 2b. Specific - others</outcomeName>
            <subgroupName>other - weakness</subgroupName>
        </outcomeList>
        <paralellTrial>false</paralellTrial>
        <performanceBiasJudgement>Described as double-blind, however no further details reported regarding the blinding of participants and personnel.</performanceBiasJudgement>
        <performanceBiasRisk>Unclear Risk</performanceBiasRisk>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Kewala S, Ban TA, Berney SA, Wilson WH</references>
        <references>Rapid tranquilization: A comparative study of thiothixene and haloperidol</references>
        <references>Progress in Neuro-Psychopharmacology and Biological Psychiatry</references>
        <references>1984</references>
        <references>8</references>
        <references></references>
        <references>77-83</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>No evidence of selective reporting.</reportingBiasJudgement>
        <reportingBiasRisk>Unclear Risk</reportingBiasRisk>
        <revManID>STD-Kewala-1984</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement>Not stated.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Unclear Risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>Described as randomised - method of randomisation is not reported.</selectionBiasRandomSequenceJudgement>
        <year>1984</year>
    </trialList>
    <trialList>
        <attritionBiasJudgement>No evidence of incomplete outcome data.</attritionBiasJudgement>
        <attritionBiasRisk>Low risk</attritionBiasRisk>
        <authorYearLetter>Kinon2001d</authorYearLetter>
        <countries></countries>
        <crgID>0</crgID>
        <crossoverTrial>false</crossoverTrial>
        <detectionBiasJudgement>Described as double-blind, however no further details reported regarding rater-blinding.</detectionBiasJudgement>
        <detectionBiasRisk>Unclear Risk</detectionBiasRisk>
        <dobj>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>48</group1Total>
            <group2Events>1</group2Events>
            <group2Name>olanzapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>52</group2Total>
            <outcomeName>Leaving the study early</outcomeName>
            <subgroupName>sponsor decision</subgroupName>
        </dobj>
        <factorialTrial>false</factorialTrial>
        <mainAuthor>Kinon</mainAuthor>
        <meerKatCountry></meerKatCountry>
        <nrControl>0</nrControl>
        <nrIntervention>0</nrIntervention>
        <nrOfParticipants>0</nrOfParticipants>
        <otherBiasJudgement>Sponsored by the manufacturers of olanzapine.</otherBiasJudgement>
        <otherBiasRisk>High risk</otherBiasRisk>
        <otherDesign>false</otherDesign>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE</comparisonName>
            <group1Events>5</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>48</group1Total>
            <group2Events>5</group2Events>
            <group2Name>olanzapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>52</group2Total>
            <outcomeName>Specific behaviour: 1a. Agitation - various measures</outcomeName>
            <subgroupName>agitation during 21 days (if occurred in ≧10% at P &lt; 0.05) - reported as 'adverse effect'</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE</comparisonName>
            <group1Events>35</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>48</group1Total>
            <group2Events>38</group2Events>
            <group2Name>olanzapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>52</group2Total>
            <outcomeName>Global outcome: 1a. General - need for additional measures</outcomeName>
            <subgroupName>need for benzodiazepine during 7 days</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE</comparisonName>
            <group1Events>8</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>48</group1Total>
            <group2Events>9</group2Events>
            <group2Name>olanzapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>52</group2Total>
            <outcomeName>Global outcome: 1a. General - need for additional measures</outcomeName>
            <subgroupName>additional restraint, seclusion or special observation</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE</comparisonName>
            <group1Events>40</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>48</group1Total>
            <group2Events>35</group2Events>
            <group2Name>olanzapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>52</group2Total>
            <outcomeName>Global outcome: 2a. Specific - alert - i. up to 2 hours</outcomeName>
            <subgroupName>alert at 1 hour</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE</comparisonName>
            <group1Events>24</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>48</group1Total>
            <group2Events>27</group2Events>
            <group2Name>olanzapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>52</group2Total>
            <outcomeName>Global outcome: 2b. Specific - alert - ii. up to 4 hours</outcomeName>
            <subgroupName>alert at 4 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE</comparisonName>
            <group1Events>22</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>48</group1Total>
            <group2Events>23</group2Events>
            <group2Name>olanzapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>52</group2Total>
            <outcomeName>Global outcome: 2c. Specific - alert - iii. up to 24 hours</outcomeName>
            <subgroupName>alert at 8 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE</comparisonName>
            <group1Events>16</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>48</group1Total>
            <group2Events>17</group2Events>
            <group2Name>olanzapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>52</group2Total>
            <outcomeName>Global outcome: 2c. Specific - alert - iii. up to 24 hours</outcomeName>
            <subgroupName>alert at 16 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE</comparisonName>
            <group1Events>25</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>48</group1Total>
            <group2Events>32</group2Events>
            <group2Name>olanzapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>52</group2Total>
            <outcomeName>Global outcome: 2c. Specific - alert - iii. up to 24 hours</outcomeName>
            <subgroupName>alert at 24 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE</comparisonName>
            <group1Events>8</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>48</group1Total>
            <group2Events>14</group2Events>
            <group2Name>olanzapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>52</group2Total>
            <outcomeName>Global outcome: 2d. Specific - tranquil - i. up to 2 hours</outcomeName>
            <subgroupName>tranquil at 1 hour</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE</comparisonName>
            <group1Events>17</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>48</group1Total>
            <group2Events>10</group2Events>
            <group2Name>olanzapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>52</group2Total>
            <outcomeName>Global outcome: 2e. Specific - tranquil - ii. up to 4 hours</outcomeName>
            <subgroupName>tranquil at 4 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE</comparisonName>
            <group1Events>14</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>48</group1Total>
            <group2Events>15</group2Events>
            <group2Name>olanzapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>52</group2Total>
            <outcomeName>Global outcome: 2f. Specific - tranquil - iii. up to 24 hours</outcomeName>
            <subgroupName>tranquil at 8 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE</comparisonName>
            <group1Events>10</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>48</group1Total>
            <group2Events>15</group2Events>
            <group2Name>olanzapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>52</group2Total>
            <outcomeName>Global outcome: 2f. Specific - tranquil - iii. up to 24 hours</outcomeName>
            <subgroupName>tranquil at 16 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE</comparisonName>
            <group1Events>18</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>48</group1Total>
            <group2Events>13</group2Events>
            <group2Name>olanzapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>52</group2Total>
            <outcomeName>Global outcome: 2f. Specific - tranquil - iii. up to 24 hours</outcomeName>
            <subgroupName>tranquil at 24 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>48</group1Total>
            <group2Events>2</group2Events>
            <group2Name>olanzapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>52</group2Total>
            <outcomeName>Global outcome: 2g. Specific - sedated - i. up to 2 hours</outcomeName>
            <subgroupName>sedated at 1 hour</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE</comparisonName>
            <group1Events>6</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>48</group1Total>
            <group2Events>15</group2Events>
            <group2Name>olanzapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>52</group2Total>
            <outcomeName>Global outcome: 2h. Specific - sedated - ii. up to 4 hours</outcomeName>
            <subgroupName>sedated at 4 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE</comparisonName>
            <group1Events>10</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>48</group1Total>
            <group2Events>10</group2Events>
            <group2Name>olanzapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>52</group2Total>
            <outcomeName>Global outcome: 2i. Specific - sedated - iii. up to 24 hours</outcomeName>
            <subgroupName>sedated at 8 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE</comparisonName>
            <group1Events>14</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>48</group1Total>
            <group2Events>18</group2Events>
            <group2Name>olanzapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>52</group2Total>
            <outcomeName>Global outcome: 2i. Specific - sedated - iii. up to 24 hours</outcomeName>
            <subgroupName>sedated at 16 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE</comparisonName>
            <group1Events>4</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>48</group1Total>
            <group2Events>7</group2Events>
            <group2Name>olanzapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>52</group2Total>
            <outcomeName>Global outcome: 2i. Specific - sedated - iii. up to 24 hours</outcomeName>
            <subgroupName>sedated at 24 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>48</group1Total>
            <group2Events>1</group2Events>
            <group2Name>olanzapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>52</group2Total>
            <outcomeName>Global outcome: 2j. Specific - asleep - i. up to 2 hours</outcomeName>
            <subgroupName>asleep at 1 hour</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>48</group1Total>
            <group2Events>1</group2Events>
            <group2Name>olanzapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>52</group2Total>
            <outcomeName>Global outcome: 2k. Specific - asleep - ii. up to 4 hours</outcomeName>
            <subgroupName>asleep at 4 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>48</group1Total>
            <group2Events>4</group2Events>
            <group2Name>olanzapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>52</group2Total>
            <outcomeName>Global outcome: 2l. Specific - asleep - iii. up to 24 hours</outcomeName>
            <subgroupName>asleep at 8 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE</comparisonName>
            <group1Events>8</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>48</group1Total>
            <group2Events>2</group2Events>
            <group2Name>olanzapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>52</group2Total>
            <outcomeName>Global outcome: 2l. Specific - asleep - iii. up to 24 hours</outcomeName>
            <subgroupName>asleep at 16 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>48</group1Total>
            <group2Events>0</group2Events>
            <group2Name>olanzapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>52</group2Total>
            <outcomeName>Global outcome: 2l. Specific - asleep - iii. up to 24 hours</outcomeName>
            <subgroupName>asleep at 24 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE</comparisonName>
            <group1Events>2</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>48</group1Total>
            <group2Events>6</group2Events>
            <group2Name>olanzapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>52</group2Total>
            <outcomeName>Mental state: 1. Various outcomes reported as 'adverse events'</outcomeName>
            <subgroupName>anxiety during 21 days (if occurred in ≧10% at P &lt; 0.05)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE</comparisonName>
            <group1Events>8</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>48</group1Total>
            <group2Events>4</group2Events>
            <group2Name>olanzapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>52</group2Total>
            <outcomeName>Mental state: 1. Various outcomes reported as 'adverse events'</outcomeName>
            <subgroupName>nervousness during 21 days (if occurred in ≧10% at P &lt; 0.05)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE</comparisonName>
            <group1Events>41</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>48</group1Total>
            <group2Events>35</group2Events>
            <group2Name>olanzapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>52</group2Total>
            <outcomeName>Adverse effects: 1a. General</outcomeName>
            <subgroupName>one or more drug related adverse events</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE</comparisonName>
            <group1Events>4</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>48</group1Total>
            <group2Events>0</group2Events>
            <group2Name>olanzapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>52</group2Total>
            <outcomeName>Adverse effects: 2a. Specific - anticholinergic</outcomeName>
            <subgroupName>increased salivation during 21 days (if occurred in ≧10% at P &lt; 0.05)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE</comparisonName>
            <group1Events>6</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>48</group1Total>
            <group2Events>3</group2Events>
            <group2Name>olanzapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>52</group2Total>
            <outcomeName>Adverse effects: 2b. Specific - arousal level - i. various</outcomeName>
            <subgroupName>insomnia during 21 days (if occurred in ≧10% at P &lt; 0.05)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE</comparisonName>
            <group1Events>12</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>48</group1Total>
            <group2Events>9</group2Events>
            <group2Name>olanzapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>52</group2Total>
            <outcomeName>Adverse effects: 2b. Specific - arousal level - i. various</outcomeName>
            <subgroupName>somnolence during 21 days (if occurred in ≧10% at P &lt; 0.05)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE</comparisonName>
            <group1Events>4</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>48</group1Total>
            <group2Events>0</group2Events>
            <group2Name>olanzapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>52</group2Total>
            <outcomeName>Adverse effects: 2i. Specific - movement disorder - i. various</outcomeName>
            <subgroupName>dystonia during 21 days (if occurred in ≧10% at P &lt; 0.05)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE</comparisonName>
            <group1Events>4</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>48</group1Total>
            <group2Events>0</group2Events>
            <group2Name>olanzapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>52</group2Total>
            <outcomeName>Adverse effects: 2i. Specific - movement disorder - i. various</outcomeName>
            <subgroupName>hypertonia during 21 days (if occurred in ≧10% at P &lt; 0.05)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE</comparisonName>
            <group1Events>4</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>48</group1Total>
            <group2Events>0</group2Events>
            <group2Name>olanzapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>52</group2Total>
            <outcomeName>Adverse effects: 2i. Specific - movement disorder - i. various</outcomeName>
            <subgroupName>extrapyramidal effects - use of antiparkinson drugs during 21 days</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE</comparisonName>
            <group1Events>5</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>48</group1Total>
            <group2Events>5</group2Events>
            <group2Name>olanzapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>52</group2Total>
            <outcomeName>Adverse effects: 2m. Specific - miscellaneous</outcomeName>
            <subgroupName>pain during 21 days (if occurred in ≧10% at P &lt; 0.05)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE</comparisonName>
            <group1Events>12</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>48</group1Total>
            <group2Events>6</group2Events>
            <group2Name>olanzapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>52</group2Total>
            <outcomeName>Adverse effects: 2m. Specific - miscellaneous</outcomeName>
            <subgroupName>pain - headache during 21 days (if occurred in ≧10% at P &lt; 0.05)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>48</group1Total>
            <group2Events>0</group2Events>
            <group2Name>olanzapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>52</group2Total>
            <outcomeName>Adverse effects: 2m. Specific - miscellaneous</outcomeName>
            <subgroupName>other - clinically relevant laboratory changes</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE</comparisonName>
            <group1Events>26</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>48</group1Total>
            <group2Events>17</group2Events>
            <group2Name>olanzapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>52</group2Total>
            <outcomeName>Leaving the study early</outcomeName>
            <subgroupName>any reason</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE</comparisonName>
            <group1Events>8</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>48</group1Total>
            <group2Events>1</group2Events>
            <group2Name>olanzapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>52</group2Total>
            <outcomeName>Leaving the study early</outcomeName>
            <subgroupName>adverse effects</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE</comparisonName>
            <group1Events>2</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>48</group1Total>
            <group2Events>5</group2Events>
            <group2Name>olanzapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>52</group2Total>
            <outcomeName>Leaving the study early</outcomeName>
            <subgroupName>lack of efficacy</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE</comparisonName>
            <group1Events>2</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>48</group1Total>
            <group2Events>4</group2Events>
            <group2Name>olanzapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>52</group2Total>
            <outcomeName>Leaving the study early</outcomeName>
            <subgroupName>lost at follow-up</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE</comparisonName>
            <group1Events>6</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>48</group1Total>
            <group2Events>3</group2Events>
            <group2Name>olanzapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>52</group2Total>
            <outcomeName>Leaving the study early</outcomeName>
            <subgroupName>participants decision</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE</comparisonName>
            <group1Events>4</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>48</group1Total>
            <group2Events>2</group2Events>
            <group2Name>olanzapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>52</group2Total>
            <outcomeName>Leaving the study early</outcomeName>
            <subgroupName>non compliance</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE</comparisonName>
            <group1Events>4</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>48</group1Total>
            <group2Events>1</group2Events>
            <group2Name>olanzapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>52</group2Total>
            <outcomeName>Leaving the study early</outcomeName>
            <subgroupName>physician decision</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>48</group1Total>
            <group2Events>1</group2Events>
            <group2Name>olanzapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>52</group2Total>
            <outcomeName>Leaving the study early</outcomeName>
            <subgroupName>sponsor decision</subgroupName>
        </outcomeList>
        <paralellTrial>false</paralellTrial>
        <performanceBiasJudgement>Described as double-blind, however no further details reported regarding the blinding of participants and personnel.</performanceBiasJudgement>
        <performanceBiasRisk>Unclear Risk</performanceBiasRisk>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Kinon B, Rotelli MD, Gilmore JA</references>
        <references>Efficacy of olanzapine and adjunctive lorazepam to control agitation in schizophrenia</references>
        <references>International Journal of Neuropsychopharmacology</references>
        <references>2002</references>
        <references>5</references>
        <references>Suppl 1</references>
        <references>S128</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Kinon BJ, Ahl J, Rotelli MD, McMullen E</references>
        <references>Efficacy of accelerated dose titration of olanzapine with adjunctive lorazepam to treat acute agitation in schizophrenia</references>
        <references>American Journal of Emergency Medicine</references>
        <references>2004</references>
        <references>22</references>
        <references>3</references>
        <references>181-6</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>JOURNAL_ARTICLE</references>
        <references>YES</references>
        <references>Kinon BJ, Wang L, Rotelli MD, Gilmore JA</references>
        <references>The efficacy of olanzapine plus adjunctive lorazepam to control acute agitation in schizophrenia</references>
        <references>European Neuropsychopharmacology</references>
        <references>2001</references>
        <references>11</references>
        <references>3</references>
        <references>278</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>Significant findings from the within-group data are presented on a number of occasions, whilst acknowledging but omitting the non-significant between-group findings., The OASS is a 16 item rating scale, yet only the results for two items where the olanzapine group had significantly greater improvement than the haloperidol group were reported., Treatment-emergent adverse effects were only reported if they occurred with a frequency ≥10% or P&lt; .05 through the end of the study.</reportingBiasJudgement>
        <reportingBiasRisk>High risk</reportingBiasRisk>
        <revManID>STD-Kinon-2001d</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement>Not stated.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Unclear Risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>Described as randomised - method of randomisation is not reported.</selectionBiasRandomSequenceJudgement>
        <year>2001</year>
    </trialList>
    <trialList>
        <attritionBiasJudgement>No incomplete data.</attritionBiasJudgement>
        <attritionBiasRisk>Low risk</attritionBiasRisk>
        <authorYearLetter>Li2006</authorYearLetter>
        <countries></countries>
        <crgID>0</crgID>
        <crossoverTrial>false</crossoverTrial>
        <detectionBiasJudgement>Single-blind – however the author did not state who had been blinded.</detectionBiasJudgement>
        <detectionBiasRisk>Unclear Risk</detectionBiasRisk>
        <dobj>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZIPRASIDONE</comparisonName>
            <group1Events>27</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>116</group1Total>
            <group2Events>10</group2Events>
            <group2Name>ziprasidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>115</group2Total>
            <outcomeName>Adverse effects: 2i. Specific - movement disorders - i. binary measures</outcomeName>
            <subgroupName>tremor - by 72 hours</subgroupName>
        </dobj>
        <factorialTrial>false</factorialTrial>
        <mainAuthor>Li</mainAuthor>
        <meerKatCountry></meerKatCountry>
        <nrControl>0</nrControl>
        <nrIntervention>0</nrIntervention>
        <nrOfParticipants>0</nrOfParticipants>
        <otherBiasJudgement>None obvious.</otherBiasJudgement>
        <otherBiasRisk>Unclear Risk</otherBiasRisk>
        <otherDesign>false</otherDesign>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZIPRASIDONE</comparisonName>
            <group1Events>58</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>116</group1Total>
            <group2Events>43</group2Events>
            <group2Name>ziprasidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>115</group2Total>
            <outcomeName>Adverse effects: 1b. General - ii. over 24 hours</outcomeName>
            <subgroupName>one or more drug related adverse effects - by 72 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZIPRASIDONE</comparisonName>
            <group1Events>12</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>116</group1Total>
            <group2Events>3</group2Events>
            <group2Name>ziprasidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>115</group2Total>
            <outcomeName>Adverse effects: 2a. Specific - anticholinergic</outcomeName>
            <subgroupName>blurred vision by 72 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZIPRASIDONE</comparisonName>
            <group1Events>18</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>116</group1Total>
            <group2Events>6</group2Events>
            <group2Name>ziprasidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>115</group2Total>
            <outcomeName>Adverse effects: 2a. Specific - anticholinergic</outcomeName>
            <subgroupName>dry mouth by 72 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZIPRASIDONE</comparisonName>
            <group1Events>18</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>116</group1Total>
            <group2Events>7</group2Events>
            <group2Name>ziprasidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>115</group2Total>
            <outcomeName>Adverse effects: 2a. Specific - anticholinergic</outcomeName>
            <subgroupName>hypersalivation by 72 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZIPRASIDONE</comparisonName>
            <group1Events>19</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>116</group1Total>
            <group2Events>15</group2Events>
            <group2Name>ziprasidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>115</group2Total>
            <outcomeName>Adverse effects: 2b. Specific - arousal level - i. various</outcomeName>
            <subgroupName>lethargy - by 72 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZIPRASIDONE</comparisonName>
            <group1Events>5</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>116</group1Total>
            <group2Events>12</group2Events>
            <group2Name>ziprasidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>115</group2Total>
            <outcomeName>Adverse effects: 2f. Specific - cardiovascular</outcomeName>
            <subgroupName>dizziness - by 72 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZIPRASIDONE</comparisonName>
            <group1Events>5</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>116</group1Total>
            <group2Events>11</group2Events>
            <group2Name>ziprasidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>115</group2Total>
            <outcomeName>Adverse effects: 2f. Specific - cardiovascular</outcomeName>
            <subgroupName>ECG - abnormal - by 72 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZIPRASIDONE</comparisonName>
            <group1Events>7</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>116</group1Total>
            <group2Events>14</group2Events>
            <group2Name>ziprasidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>115</group2Total>
            <outcomeName>Adverse effects: 2f. Specific - cardiovascular</outcomeName>
            <subgroupName>tachycardia - by 72 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZIPRASIDONE</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>116</group1Total>
            <group2Events>6</group2Events>
            <group2Name>ziprasidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>115</group2Total>
            <outcomeName>Adverse effects: 2h. Specific - hematological tests</outcomeName>
            <subgroupName>haemogram abnormal - by 72 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZIPRASIDONE</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>116</group1Total>
            <group2Events>2</group2Events>
            <group2Name>ziprasidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>115</group2Total>
            <outcomeName>Adverse effects: 2h. Specific - hematological tests</outcomeName>
            <subgroupName>lactate dehydrogenase increase - by 72 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZIPRASIDONE</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>116</group1Total>
            <group2Events>2</group2Events>
            <group2Name>ziprasidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>115</group2Total>
            <outcomeName>Adverse effects: 2h. Specific - hematological tests</outcomeName>
            <subgroupName>liver function abnormal - by 72 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZIPRASIDONE</comparisonName>
            <group1Events>2</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>116</group1Total>
            <group2Events>0</group2Events>
            <group2Name>ziprasidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>115</group2Total>
            <outcomeName>Adverse effects: 2h. Specific - hematological tests</outcomeName>
            <subgroupName>triglyceride increase - by 72 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZIPRASIDONE</comparisonName>
            <group1Events>31</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>116</group1Total>
            <group2Events>10</group2Events>
            <group2Name>ziprasidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>115</group2Total>
            <outcomeName>Adverse effects: 2i. Specific - movement disorders - i. binary measures</outcomeName>
            <subgroupName>akathisia - by 72 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZIPRASIDONE</comparisonName>
            <group1Events>31</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>116</group1Total>
            <group2Events>8</group2Events>
            <group2Name>ziprasidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>115</group2Total>
            <outcomeName>Adverse effects: 2i. Specific - movement disorders - i. binary measures</outcomeName>
            <subgroupName>myotonia - by 72 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZIPRASIDONE</comparisonName>
            <group1Events>28</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>116</group1Total>
            <group2Events>13</group2Events>
            <group2Name>ziprasidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>115</group2Total>
            <outcomeName>Adverse effects: 2i. Specific - movement disorders - i. binary measures</outcomeName>
            <subgroupName>reduced movement - by 72 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZIPRASIDONE</comparisonName>
            <group1Events>10</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>116</group1Total>
            <group2Events>3</group2Events>
            <group2Name>ziprasidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>115</group2Total>
            <outcomeName>Adverse effects: 2i. Specific - movement disorders - i. binary measures</outcomeName>
            <subgroupName>torsional spasm - by 72 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZIPRASIDONE</comparisonName>
            <group1Events>27</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>116</group1Total>
            <group2Events>10</group2Events>
            <group2Name>ziprasidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>115</group2Total>
            <outcomeName>Adverse effects: 2i. Specific - movement disorders - i. binary measures</outcomeName>
            <subgroupName>tremor - by 72 hours</subgroupName>
        </outcomeList>
        <paralellTrial>false</paralellTrial>
        <performanceBiasJudgement>Single-blind – however the author did not state who had been blinded.</performanceBiasJudgement>
        <performanceBiasRisk>Unclear Risk</performanceBiasRisk>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Li L-H, Zhao J-P, Xu X-F</references>
        <references>A comparative study of intramuscular ziprasidone and haloperidol in treating acute agitation in schizophrenia</references>
        <references>Chinese Journal of Psychiatry</references>
        <references>2006</references>
        <references>39</references>
        <references>4</references>
        <references>216-9</references>
        <references>国产齐拉西酮与氟哌啶醇注射液治疗精神分裂症急性激越症状的对照研究</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>TESS and SAS were used for assessment of adverse events.  No continuous data were reported from either scales, but binary outcomes for adverse events were reported.</reportingBiasJudgement>
        <reportingBiasRisk>Unclear Risk</reportingBiasRisk>
        <revManID>STD-Li-2006</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement>Not stated.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Unclear Risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>Described as randomised - method of randomisation is not reported.</selectionBiasRandomSequenceJudgement>
        <year>2006</year>
    </trialList>
    <trialList>
        <attritionBiasJudgement>A total of 5 dropped out in haloperidol group (adverse events = 4, lost to contact = 1) and 4 dropped out in quetiapine group (adverse events = 1, lost to contact = 3); missing data have not been imputed using appropriate methods such as LOCF.</attritionBiasJudgement>
        <attritionBiasRisk>High risk</attritionBiasRisk>
        <authorYearLetter>Liang2013</authorYearLetter>
        <countries>China</countries>
        <crgID>0</crgID>
        <crossoverTrial>false</crossoverTrial>
        <detectionBiasJudgement>Not stated.</detectionBiasJudgement>
        <detectionBiasRisk>Unclear Risk</detectionBiasRisk>
        <dobj>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: g. QUETIAPINE</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>40</group1Total>
            <group2Events>3</group2Events>
            <group2Name>quetiapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>40</group2Total>
            <outcomeName>Leaving the study early</outcomeName>
            <subgroupName>lost at follow-up</subgroupName>
        </dobj>
        <factorialTrial>false</factorialTrial>
        <mainAuthor>Liang</mainAuthor>
        <meerKatCountry>China</meerKatCountry>
        <nrControl>0</nrControl>
        <nrIntervention>0</nrIntervention>
        <nrOfParticipants>0</nrOfParticipants>
        <otherBiasJudgement>None obvious.</otherBiasJudgement>
        <otherBiasRisk>Unclear Risk</otherBiasRisk>
        <otherDesign>false</otherDesign>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: g. QUETIAPINE</comparisonName>
            <group1Events>29</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>40</group1Total>
            <group2Events>16</group2Events>
            <group2Name>quetiapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>40</group2Total>
            <outcomeName>Adverse effects: 1. General</outcomeName>
            <subgroupName>one or more drug related adverse events by 28 days</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: g. QUETIAPINE</comparisonName>
            <group1Events>5</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>40</group1Total>
            <group2Events>4</group2Events>
            <group2Name>quetiapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>40</group2Total>
            <outcomeName>Leaving the study early</outcomeName>
            <subgroupName>any reason</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: g. QUETIAPINE</comparisonName>
            <group1Events>4</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>40</group1Total>
            <group2Events>1</group2Events>
            <group2Name>quetiapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>40</group2Total>
            <outcomeName>Leaving the study early</outcomeName>
            <subgroupName>adverse event</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: g. QUETIAPINE</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>40</group1Total>
            <group2Events>3</group2Events>
            <group2Name>quetiapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>40</group2Total>
            <outcomeName>Leaving the study early</outcomeName>
            <subgroupName>lost at follow-up</subgroupName>
        </outcomeList>
        <paralellTrial>false</paralellTrial>
        <performanceBiasJudgement>Not stated.</performanceBiasJudgement>
        <performanceBiasRisk>Unclear Risk</performanceBiasRisk>
        <references>OTHER</references>
        <references>NO</references>
        <references>Liang Y, Su Y, Huang J, Tang M, Li K, Yang F, et al</references>
        <references>Effect of quetiapine and haloperidol on QTc interval in treating schizophrenic patients with excitement and agitation</references>
        <references>Chinese New Drugs Journal [Zhongguo Xin Yao Za Zhi; 中国新药杂志]</references>
        <references>2013</references>
        <references>22</references>
        <references>16</references>
        <references>1886-9+1894</references>
        <references>喹硫平和氟哌啶醇治疗精神分裂症急性期兴奋激越对QTc间期的影响</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>OTHER</references>
        <references>YES</references>
        <references>Liang Y, Su Y, Huang J, Tang M, Li K, Yang P, et al</references>
        <references>A randomized controlled study of effect and safety of quetiapine and haloperidol in treatment of schizophrenic patients with excitement and agitation</references>
        <references>Chinese Mental Health Journal [Zhongguo Xin Li Wei Sheng Za Zhi; 中国心理卫生杂志]</references>
        <references>2013</references>
        <references>27</references>
        <references>4</references>
        <references>262-7</references>
        <references>喹硫平和氟哌啶醇治疗精神分裂症急性期兴奋激越的多中心随机对照研究</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>No evidence of selective reporting.</reportingBiasJudgement>
        <reportingBiasRisk>Low risk</reportingBiasRisk>
        <revManID>STD-Liang-2013</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement>Not stated.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Low risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>"randomised by using random number table".</selectionBiasRandomSequenceJudgement>
        <year>2013</year>
    </trialList>
    <trialList>
        <attritionBiasJudgement>There is no evidence of incomplete outcome data. The authors give reasons for the participants who discontinued the study.</attritionBiasJudgement>
        <attritionBiasRisk>Low risk</attritionBiasRisk>
        <authorYearLetter>Lim2010</authorYearLetter>
        <countries>Korea</countries>
        <crgID>0</crgID>
        <crossoverTrial>false</crossoverTrial>
        <detectionBiasJudgement>The study was rater-blinded.</detectionBiasJudgement>
        <detectionBiasRisk>Low risk</detectionBiasRisk>
        <dobj>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: h. RISPERIDONE</comparisonName>
            <group1Events>2</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>62</group1Total>
            <group2Events>0</group2Events>
            <group2Name>risperidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>62</group2Total>
            <outcomeName>Leaving the study early - i. up to 24 hours</outcomeName>
            <subgroupName>due to acute dystonia</subgroupName>
        </dobj>
        <factorialTrial>false</factorialTrial>
        <mainAuthor>Lim</mainAuthor>
        <meerKatCountry>Korea</meerKatCountry>
        <nrControl>0</nrControl>
        <nrIntervention>0</nrIntervention>
        <nrOfParticipants>0</nrOfParticipants>
        <otherBiasJudgement>Sponsored by drug company (Janssen Phamaceutica Korea).</otherBiasJudgement>
        <otherBiasRisk>High risk</otherBiasRisk>
        <otherDesign>false</otherDesign>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: h. RISPERIDONE</comparisonName>
            <group1Events>47</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>62</group1Total>
            <group2Events>49</group2Events>
            <group2Name>risperidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>62</group2Total>
            <outcomeName>Specific behaviour: 1a. Agitation - various measures</outcomeName>
            <subgroupName>≥50% reduction in PANSS-EC score up to 24 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: h. RISPERIDONE</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>62</group1Total>
            <group2Events>1</group2Events>
            <group2Name>risperidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>62</group2Total>
            <outcomeName>Specific behaviour: 1a. Agitation - various measures</outcomeName>
            <subgroupName>discontinued due to severe agitation up to 24 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: h. RISPERIDONE</comparisonName>
            <group1Events>8</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>62</group1Total>
            <group2Events>7</group2Events>
            <group2Name>risperidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>62</group2Total>
            <outcomeName>Global outcome: 1. Binary measures</outcomeName>
            <subgroupName>needing additional benzodiazepine</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: h. RISPERIDONE</comparisonName>
            <group1Events>18</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>62</group1Total>
            <group2Events>17</group2Events>
            <group2Name>risperidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>62</group2Total>
            <outcomeName>Adverse effects: 1a. General - one or more adverse effects</outcomeName>
            <subgroupName>up to 24 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: h. RISPERIDONE</comparisonName>
            <group1Events>7</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>62</group1Total>
            <group2Events>9</group2Events>
            <group2Name>risperidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>62</group2Total>
            <outcomeName>Adverse effects: 2a. Specific - arousal</outcomeName>
            <subgroupName>somnolence during 24 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: h. RISPERIDONE</comparisonName>
            <group1Events>4</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>62</group1Total>
            <group2Events>4</group2Events>
            <group2Name>risperidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>62</group2Total>
            <outcomeName>Adverse effects: 2b. Specific - cardiovascular - i. binary outcomes</outcomeName>
            <subgroupName>dizziness during 24 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: h. RISPERIDONE</comparisonName>
            <group1Events>2</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>62</group1Total>
            <group2Events>0</group2Events>
            <group2Name>risperidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>62</group2Total>
            <outcomeName>Adverse effects: 2e. Specific - movement disorder - i. binary outcomes</outcomeName>
            <subgroupName>dystonia during 24 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: h. RISPERIDONE</comparisonName>
            <group1Events>8</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>62</group1Total>
            <group2Events>5</group2Events>
            <group2Name>risperidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>62</group2Total>
            <outcomeName>Adverse effects: 2e. Specific - movement disorder - i. binary outcomes</outcomeName>
            <subgroupName>movement disorder</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: h. RISPERIDONE</comparisonName>
            <group1Events>4</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>62</group1Total>
            <group2Events>3</group2Events>
            <group2Name>risperidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>62</group2Total>
            <outcomeName>Adverse effects: 2h. Specific - miscellaneous</outcomeName>
            <subgroupName>headache during 24 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: h. RISPERIDONE</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>62</group1Total>
            <group2Events>1</group2Events>
            <group2Name>risperidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>62</group2Total>
            <outcomeName>Leaving the study early - i. up to 24 hours</outcomeName>
            <subgroupName>due to severe agitation</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: h. RISPERIDONE</comparisonName>
            <group1Events>2</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>62</group1Total>
            <group2Events>0</group2Events>
            <group2Name>risperidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>62</group2Total>
            <outcomeName>Leaving the study early - i. up to 24 hours</outcomeName>
            <subgroupName>due to acute dystonia</subgroupName>
        </outcomeList>
        <paralellTrial>false</paralellTrial>
        <performanceBiasJudgement>This was an open-label study where one group received IM and the other group received an orodispersible tablet.</performanceBiasJudgement>
        <performanceBiasRisk>High risk</performanceBiasRisk>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Kim JJ, Lim HK, Lee CU, Lee C, Pae CU, Paik IH</references>
        <references>Risperidone orodispersible tablet and intramuscular haloperidol in treatment of acute psychotic agitation</references>
        <references>European Neuropsychopharmacology</references>
        <references>2007</references>
        <references>17</references>
        <references>Suppl 4</references>
        <references>S467</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>JOURNAL_ARTICLE</references>
        <references>YES</references>
        <references>Lim HK, Kim JJ, Pae CU, Lee CU, Lee C, Paik IH</references>
        <references>Comparison of risperidone orodispersible tablet and intramuscular haloperidol in the treatment of acute psychotic agitation: A randomized open, prospective study</references>
        <references>Neuropsychobiology</references>
        <references>2010</references>
        <references>62</references>
        <references>2</references>
        <references>81-6</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>The authors report that antiparkinsonian drugs could be given at the lowest effective dose, however the amount administered is not described in the results.</reportingBiasJudgement>
        <reportingBiasRisk>High risk</reportingBiasRisk>
        <revManID>STD-Lim-2010</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement>Not stated.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Low risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>Participants were assigned "according to a predefined randomization code that was balanced to ensure even distribution of patients in each treatment group." (p.82).</selectionBiasRandomSequenceJudgement>
        <year>2010</year>
    </trialList>
    <trialList>
        <attritionBiasJudgement>No incomplete data.</attritionBiasJudgement>
        <attritionBiasRisk>Low risk</attritionBiasRisk>
        <authorYearLetter>Liu2012</authorYearLetter>
        <countries>China</countries>
        <crgID>0</crgID>
        <crossoverTrial>false</crossoverTrial>
        <detectionBiasJudgement>Not stated.</detectionBiasJudgement>
        <detectionBiasRisk>Unclear Risk</detectionBiasRisk>
        <dobj>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: h. RISPERIDONE + CLONAZEPAM</comparisonName>
            <group1Events>2</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>50</group1Total>
            <group2Events>5</group2Events>
            <group2Name>risperidone//clonazepam</group2Name>
            <group2NameProse> combinations: h. risperidone + clonazepam</group2NameProse>
            <group2Total>50</group2Total>
            <outcomeName>Adverse effects: 2d. Specific - miscellaneous</outcomeName>
            <subgroupName>Increased salivation during 14 days</subgroupName>
        </dobj>
        <factorialTrial>false</factorialTrial>
        <mainAuthor>Liu</mainAuthor>
        <meerKatCountry>China</meerKatCountry>
        <nrControl>0</nrControl>
        <nrIntervention>0</nrIntervention>
        <nrOfParticipants>0</nrOfParticipants>
        <otherBiasJudgement>None obvious.</otherBiasJudgement>
        <otherBiasRisk>Low risk</otherBiasRisk>
        <otherDesign>false</otherDesign>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: e. HALOPERIDOL + RISPERIDONE</comparisonName>
            <group1Events>3</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>50</group1Total>
            <group2Events>8</group2Events>
            <group2Name>haloperidol//risperidone</group2Name>
            <group2NameProse> combinations: e. haloperidol + risperidone</group2NameProse>
            <group2Total>50</group2Total>
            <outcomeName>Global outcome: No improvement</outcomeName>
            <subgroupName>at 72 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: e. HALOPERIDOL + RISPERIDONE</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>50</group1Total>
            <group2Events>4</group2Events>
            <group2Name>haloperidol//risperidone</group2Name>
            <group2NameProse> combinations: e. haloperidol + risperidone</group2NameProse>
            <group2Total>50</group2Total>
            <outcomeName>Global outcome: No improvement</outcomeName>
            <subgroupName>at 5 days</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: e. HALOPERIDOL + RISPERIDONE</comparisonName>
            <group1Events>2</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>50</group1Total>
            <group2Events>3</group2Events>
            <group2Name>haloperidol//risperidone</group2Name>
            <group2NameProse> combinations: e. haloperidol + risperidone</group2NameProse>
            <group2Total>50</group2Total>
            <outcomeName>Global outcome: No improvement</outcomeName>
            <subgroupName>at 1 week</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: e. HALOPERIDOL + RISPERIDONE</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>50</group1Total>
            <group2Events>1</group2Events>
            <group2Name>haloperidol//risperidone</group2Name>
            <group2NameProse> combinations: e. haloperidol + risperidone</group2NameProse>
            <group2Total>50</group2Total>
            <outcomeName>Global outcome: No improvement</outcomeName>
            <subgroupName>at 2 weeks</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: e. HALOPERIDOL + RISPERIDONE</comparisonName>
            <group1Events>6</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>50</group1Total>
            <group2Events>5</group2Events>
            <group2Name>haloperidol//risperidone</group2Name>
            <group2NameProse> combinations: e. haloperidol + risperidone</group2NameProse>
            <group2Total>50</group2Total>
            <outcomeName>Adverse effects: 1a. Specific - arousal level - i. various</outcomeName>
            <subgroupName>insomnia during 14 days</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: e. HALOPERIDOL + RISPERIDONE</comparisonName>
            <group1Events>11</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>50</group1Total>
            <group2Events>12</group2Events>
            <group2Name>haloperidol//risperidone</group2Name>
            <group2NameProse> combinations: e. haloperidol + risperidone</group2NameProse>
            <group2Total>50</group2Total>
            <outcomeName>Adverse effects: 1a. Specific - arousal level - i. various</outcomeName>
            <subgroupName>somnolence during 14 days</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: e. HALOPERIDOL + RISPERIDONE</comparisonName>
            <group1Events>16</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>50</group1Total>
            <group2Events>17</group2Events>
            <group2Name>haloperidol//risperidone</group2Name>
            <group2NameProse> combinations: e. haloperidol + risperidone</group2NameProse>
            <group2Total>50</group2Total>
            <outcomeName>Adverse effects: 1b. Specific - movement disorders - i. various</outcomeName>
            <subgroupName>tremor during 14 days</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: e. HALOPERIDOL + RISPERIDONE</comparisonName>
            <group1Events>14</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>50</group1Total>
            <group2Events>16</group2Events>
            <group2Name>haloperidol//risperidone</group2Name>
            <group2NameProse> combinations: e. haloperidol + risperidone</group2NameProse>
            <group2Total>50</group2Total>
            <outcomeName>Adverse effects: 1b. Specific - movement disorders - i. various</outcomeName>
            <subgroupName>akathisia during 14 days</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: e. HALOPERIDOL + RISPERIDONE</comparisonName>
            <group1Events>8</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>50</group1Total>
            <group2Events>9</group2Events>
            <group2Name>haloperidol//risperidone</group2Name>
            <group2NameProse> combinations: e. haloperidol + risperidone</group2NameProse>
            <group2Total>50</group2Total>
            <outcomeName>Adverse effects: 1c. Specific - miscellaneous</outcomeName>
            <subgroupName>Dry mouth during 14 days</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: e. HALOPERIDOL + RISPERIDONE</comparisonName>
            <group1Events>6</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>50</group1Total>
            <group2Events>4</group2Events>
            <group2Name>haloperidol//risperidone</group2Name>
            <group2NameProse> combinations: e. haloperidol + risperidone</group2NameProse>
            <group2Total>50</group2Total>
            <outcomeName>Adverse effects: 1c. Specific - miscellaneous</outcomeName>
            <subgroupName>Constipation during 14 days</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: e. HALOPERIDOL + RISPERIDONE</comparisonName>
            <group1Events>2</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>50</group1Total>
            <group2Events>1</group2Events>
            <group2Name>haloperidol//risperidone</group2Name>
            <group2NameProse> combinations: e. haloperidol + risperidone</group2NameProse>
            <group2Total>50</group2Total>
            <outcomeName>Adverse effects: 1c. Specific - miscellaneous</outcomeName>
            <subgroupName>Increased salivation during 14 days</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: h. RISPERIDONE + CLONAZEPAM</comparisonName>
            <group1Events>3</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>50</group1Total>
            <group2Events>5</group2Events>
            <group2Name>risperidone//clonazepam</group2Name>
            <group2NameProse> combinations: h. risperidone + clonazepam</group2NameProse>
            <group2Total>50</group2Total>
            <outcomeName>Global outcome: No improvement</outcomeName>
            <subgroupName>at 72 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: h. RISPERIDONE + CLONAZEPAM</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>50</group1Total>
            <group2Events>4</group2Events>
            <group2Name>risperidone//clonazepam</group2Name>
            <group2NameProse> combinations: h. risperidone + clonazepam</group2NameProse>
            <group2Total>50</group2Total>
            <outcomeName>Global outcome: No improvement</outcomeName>
            <subgroupName>at 5 days</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: h. RISPERIDONE + CLONAZEPAM</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>50</group1Total>
            <group2Events>2</group2Events>
            <group2Name>risperidone//clonazepam</group2Name>
            <group2NameProse> combinations: h. risperidone + clonazepam</group2NameProse>
            <group2Total>50</group2Total>
            <outcomeName>Global outcome: No improvement</outcomeName>
            <subgroupName>at 1 week</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: h. RISPERIDONE + CLONAZEPAM</comparisonName>
            <group1Events>2</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>50</group1Total>
            <group2Events>4</group2Events>
            <group2Name>risperidone//clonazepam</group2Name>
            <group2NameProse> combinations: h. risperidone + clonazepam</group2NameProse>
            <group2Total>50</group2Total>
            <outcomeName>Global outcome: No improvement</outcomeName>
            <subgroupName>at 2 weeks</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: h. RISPERIDONE + CLONAZEPAM</comparisonName>
            <group1Events>6</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>50</group1Total>
            <group2Events>12</group2Events>
            <group2Name>risperidone//clonazepam</group2Name>
            <group2NameProse> combinations: h. risperidone + clonazepam</group2NameProse>
            <group2Total>50</group2Total>
            <outcomeName>Adverse effects: 2a. Specific - arousal - i. various</outcomeName>
            <subgroupName>insomnia during 14 days</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: h. RISPERIDONE + CLONAZEPAM</comparisonName>
            <group1Events>11</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>50</group1Total>
            <group2Events>4</group2Events>
            <group2Name>risperidone//clonazepam</group2Name>
            <group2NameProse> combinations: h. risperidone + clonazepam</group2NameProse>
            <group2Total>50</group2Total>
            <outcomeName>Adverse effects: 2a. Specific - arousal - i. various</outcomeName>
            <subgroupName>somnolence during 14 days</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: h. RISPERIDONE + CLONAZEPAM</comparisonName>
            <group1Events>14</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>50</group1Total>
            <group2Events>6</group2Events>
            <group2Name>risperidone//clonazepam</group2Name>
            <group2NameProse> combinations: h. risperidone + clonazepam</group2NameProse>
            <group2Total>50</group2Total>
            <outcomeName>Adverse effects: 2c. Specific - movement disorders - i. various</outcomeName>
            <subgroupName>akathisia during 14 days</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: h. RISPERIDONE + CLONAZEPAM</comparisonName>
            <group1Events>16</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>50</group1Total>
            <group2Events>5</group2Events>
            <group2Name>risperidone//clonazepam</group2Name>
            <group2NameProse> combinations: h. risperidone + clonazepam</group2NameProse>
            <group2Total>50</group2Total>
            <outcomeName>Adverse effects: 2c. Specific - movement disorders - i. various</outcomeName>
            <subgroupName>tremor during 14 days</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: h. RISPERIDONE + CLONAZEPAM</comparisonName>
            <group1Events>8</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>50</group1Total>
            <group2Events>2</group2Events>
            <group2Name>risperidone//clonazepam</group2Name>
            <group2NameProse> combinations: h. risperidone + clonazepam</group2NameProse>
            <group2Total>50</group2Total>
            <outcomeName>Adverse effects: 2d. Specific - miscellaneous</outcomeName>
            <subgroupName>Dry mouth during 14 days</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: h. RISPERIDONE + CLONAZEPAM</comparisonName>
            <group1Events>6</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>50</group1Total>
            <group2Events>9</group2Events>
            <group2Name>risperidone//clonazepam</group2Name>
            <group2NameProse> combinations: h. risperidone + clonazepam</group2NameProse>
            <group2Total>50</group2Total>
            <outcomeName>Adverse effects: 2d. Specific - miscellaneous</outcomeName>
            <subgroupName>Constipation during 14 days</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: h. RISPERIDONE + CLONAZEPAM</comparisonName>
            <group1Events>2</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>50</group1Total>
            <group2Events>5</group2Events>
            <group2Name>risperidone//clonazepam</group2Name>
            <group2NameProse> combinations: h. risperidone + clonazepam</group2NameProse>
            <group2Total>50</group2Total>
            <outcomeName>Adverse effects: 2d. Specific - miscellaneous</outcomeName>
            <subgroupName>Increased salivation during 14 days</subgroupName>
        </outcomeList>
        <paralellTrial>false</paralellTrial>
        <performanceBiasJudgement>Not stated.</performanceBiasJudgement>
        <performanceBiasRisk>Unclear Risk</performanceBiasRisk>
        <references>OTHER</references>
        <references>NO</references>
        <references>刘锟, 刘云, 宁南义, 孙建中, 孙亚军, 孙同勋, et al</references>
        <references>Consolidation of short-term risperidone intramuscular haloperidol in the treatment of acute agitation in schizophrenia randomized controlled study of the efficacy of behavior [Google Translate]</references>
        <references>中国医药导报</references>
        <references>2012</references>
        <references></references>
        <references>35</references>
        <references>104-6</references>
        <references>利培酮合并短期肌注氟哌啶醇治疗精神分裂症急性期激越行为疗效的随机对照研究</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>No evidence of selective reporting.</reportingBiasJudgement>
        <reportingBiasRisk>Low risk</reportingBiasRisk>
        <revManID>STD-Liu-2012</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement>Not stated.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Low risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>"randomised by using random number table".</selectionBiasRandomSequenceJudgement>
        <year>2012</year>
    </trialList>
    <trialList>
        <attritionBiasJudgement>The authors give reasons for the participants who discontinued the study. However, the results are only presented for the 27 participants who completed the study. Missing data have not been imputed using appropriate methods such as LOCF.</attritionBiasJudgement>
        <attritionBiasRisk>High risk</attritionBiasRisk>
        <authorYearLetter>Man1973</authorYearLetter>
        <countries>China</countries>
        <crgID>0</crgID>
        <crossoverTrial>false</crossoverTrial>
        <detectionBiasJudgement>Described as double-blind, however no further details reported regarding rater blinding.</detectionBiasJudgement>
        <detectionBiasRisk>Unclear Risk</detectionBiasRisk>
        <dobj>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: b. CHLORPROMAZINE</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>15</group1Total>
            <group2Events>0</group2Events>
            <group2Name>chlorpromazine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>15</group2Total>
            <outcomeName>Leaving the study early</outcomeName>
            <subgroupName>deviation from protocol</subgroupName>
        </dobj>
        <factorialTrial>false</factorialTrial>
        <mainAuthor>Man</mainAuthor>
        <meerKatCountry>China</meerKatCountry>
        <nrControl>0</nrControl>
        <nrIntervention>0</nrIntervention>
        <nrOfParticipants>0</nrOfParticipants>
        <otherBiasJudgement>Small study.</otherBiasJudgement>
        <otherBiasRisk>High risk</otherBiasRisk>
        <otherDesign>false</otherDesign>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: b. CHLORPROMAZINE</comparisonName>
            <group1Events>15</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>15</group1Total>
            <group2Events>14</group2Events>
            <group2Name>chlorpromazine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>15</group2Total>
            <outcomeName>Repeated need for rapid tranquillisation</outcomeName>
            <subgroupName>more that 1 injection</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: b. CHLORPROMAZINE</comparisonName>
            <group1Events>6</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>15</group1Total>
            <group2Events>4</group2Events>
            <group2Name>chlorpromazine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>15</group2Total>
            <outcomeName>Repeated need for rapid tranquillisation</outcomeName>
            <subgroupName>more than 3 injections</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: b. CHLORPROMAZINE</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>15</group1Total>
            <group2Events>0</group2Events>
            <group2Name>chlorpromazine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>15</group2Total>
            <outcomeName>Adverse effects: any serious or specific adverse effects</outcomeName>
            <subgroupName>allergy - skin irritation - local</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: b. CHLORPROMAZINE</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>15</group1Total>
            <group2Events>2</group2Events>
            <group2Name>chlorpromazine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>15</group2Total>
            <outcomeName>Adverse effects: any serious or specific adverse effects</outcomeName>
            <subgroupName>cardiovascular - hypotension</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: b. CHLORPROMAZINE</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>15</group1Total>
            <group2Events>1</group2Events>
            <group2Name>chlorpromazine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>15</group2Total>
            <outcomeName>Adverse effects: any serious or specific adverse effects</outcomeName>
            <subgroupName>central nervous system - seizures</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: b. CHLORPROMAZINE</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>15</group1Total>
            <group2Events>0</group2Events>
            <group2Name>chlorpromazine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>15</group2Total>
            <outcomeName>Adverse effects: any serious or specific adverse effects</outcomeName>
            <subgroupName>movement disorders - extrapyramidal adverse effects</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: b. CHLORPROMAZINE</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>15</group1Total>
            <group2Events>2</group2Events>
            <group2Name>chlorpromazine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>15</group2Total>
            <outcomeName>Leaving the study early</outcomeName>
            <subgroupName>any reason/general reasons</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: b. CHLORPROMAZINE</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>15</group1Total>
            <group2Events>2</group2Events>
            <group2Name>chlorpromazine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>15</group2Total>
            <outcomeName>Leaving the study early</outcomeName>
            <subgroupName>severe hypotensive reaction</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: b. CHLORPROMAZINE</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>15</group1Total>
            <group2Events>0</group2Events>
            <group2Name>chlorpromazine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>15</group2Total>
            <outcomeName>Leaving the study early</outcomeName>
            <subgroupName>deviation from protocol</subgroupName>
        </outcomeList>
        <paralellTrial>false</paralellTrial>
        <performanceBiasJudgement>Described as double-blind, however it is unclear whether the syringes appeared identical given the varied doses.</performanceBiasJudgement>
        <performanceBiasRisk>Unclear Risk</performanceBiasRisk>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Man-Pang L, Chen CH</references>
        <references>Rapid tranquilization of acutely psychotic patients with intramuscular haloperidol and chlorpromazine</references>
        <references>Psychosomatics</references>
        <references>1973</references>
        <references>14</references>
        <references>1</references>
        <references>59-63</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>No evidence of selective reporting.</reportingBiasJudgement>
        <reportingBiasRisk>Low risk</reportingBiasRisk>
        <revManID>STD-Man-1973</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement>Not stated.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>High risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>Not explicitly described as randomised.</selectionBiasRandomSequenceJudgement>
        <year>1973</year>
    </trialList>
    <trialList>
        <attritionBiasJudgement>No evidence of incomplete outcome data.</attritionBiasJudgement>
        <attritionBiasRisk>Low risk</attritionBiasRisk>
        <authorYearLetter>Nobay2004</authorYearLetter>
        <countries>USA</countries>
        <crgID>0</crgID>
        <crossoverTrial>false</crossoverTrial>
        <detectionBiasJudgement>"The research assistant [rater], the administering physician, and the patient were all blinded to the drug delivered." (p.745).</detectionBiasJudgement>
        <detectionBiasRisk>Low risk</detectionBiasRisk>
        <dobj>
            <comparisonName>HALOPERIDOL vs BENZODIAZEPINE: c. MIDAZOLAM</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>42</group1Total>
            <group2Events>0</group2Events>
            <group2Name>midazolam</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>42</group2Total>
            <outcomeName>Adverse effects: 2. Specific</outcomeName>
            <subgroupName>apnoea</subgroupName>
        </dobj>
        <factorialTrial>false</factorialTrial>
        <mainAuthor>Nobay</mainAuthor>
        <meerKatCountry>USA</meerKatCountry>
        <nrControl>0</nrControl>
        <nrIntervention>0</nrIntervention>
        <nrOfParticipants>0</nrOfParticipants>
        <otherBiasJudgement>The duration of the study was not reported, therefore it is difficult to establish how long participants were monitored for adverse effects.</otherBiasJudgement>
        <otherBiasRisk>High risk</otherBiasRisk>
        <otherDesign>false</otherDesign>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs BENZODIAZEPINE: c. MIDAZOLAM</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>42</group1Total>
            <group2Events>0</group2Events>
            <group2Name>midazolam</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>42</group2Total>
            <outcomeName>Adverse effects: 2. Specific</outcomeName>
            <subgroupName>hypotensive</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs BENZODIAZEPINE: c. MIDAZOLAM</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>42</group1Total>
            <group2Events>0</group2Events>
            <group2Name>midazolam</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>42</group2Total>
            <outcomeName>Adverse effects: 2. Specific</outcomeName>
            <subgroupName>apnoea</subgroupName>
        </outcomeList>
        <paralellTrial>false</paralellTrial>
        <performanceBiasJudgement>"The research assistant [rater], the administering physician, and the patient were all blinded to the drug delivered." (p.745).</performanceBiasJudgement>
        <performanceBiasRisk>Low risk</performanceBiasRisk>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Nobay F, Simon BC, Levitt MA, Dresden GM</references>
        <references>A prospective, double-blind, randomized trial of midazolam versus haloperidol versus lorazepam in the chemical restraint of violent and severely agitated patients</references>
        <references>Academic Emergency Medicine</references>
        <references>2004</references>
        <references>11</references>
        <references>7</references>
        <references>744-9</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>No evidence of selective reporting.</reportingBiasJudgement>
        <reportingBiasRisk>Low risk</reportingBiasRisk>
        <revManID>STD-Nobay-2004</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Low risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement>"The administered drugs were prepared in the pharmacy using a computer generated randomisation code." (p.745).</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Low risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>"The administered drugs were prepared in the pharmacy using a computer generated randomisation code." (p.745).</selectionBiasRandomSequenceJudgement>
        <year>2004</year>
    </trialList>
    <trialList>
        <attritionBiasJudgement>The number of participants reported is inconsistent (reported at 36 in one instance and 35 at other times) and it is not clear if this is a typing error.</attritionBiasJudgement>
        <attritionBiasRisk>Unclear Risk</attritionBiasRisk>
        <authorYearLetter>Paprocki1977</authorYearLetter>
        <countries>USA</countries>
        <crgID>0</crgID>
        <crossoverTrial>false</crossoverTrial>
        <detectionBiasJudgement>Described as double-blind - no further details given regarding rater blinding.</detectionBiasJudgement>
        <detectionBiasRisk>Unclear Risk</detectionBiasRisk>
        <dobj>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: d. LOXAPINE</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>18</group1Total>
            <group2Events>0</group2Events>
            <group2Name>loxapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>17</group2Total>
            <outcomeName>Leaving the study early: 2. Specific reasons</outcomeName>
            <subgroupName>adverse effects by 72 hours</subgroupName>
        </dobj>
        <factorialTrial>false</factorialTrial>
        <mainAuthor>Paprocki</mainAuthor>
        <meerKatCountry>USA</meerKatCountry>
        <nrControl>0</nrControl>
        <nrIntervention>0</nrIntervention>
        <nrOfParticipants>0</nrOfParticipants>
        <otherBiasJudgement>Small study.</otherBiasJudgement>
        <otherBiasRisk>High risk</otherBiasRisk>
        <otherDesign>false</otherDesign>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: d. LOXAPINE</comparisonName>
            <group1Events>3</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>18</group1Total>
            <group2Events>7</group2Events>
            <group2Name>loxapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>17</group2Total>
            <outcomeName>Global outcome: 1. General - no change - i. over 24 hours</outcomeName>
            <subgroupName>at endpoint (CGI-I, high=worse)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: d. LOXAPINE</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>18</group1Total>
            <group2Events>1</group2Events>
            <group2Name>loxapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>17</group2Total>
            <outcomeName>Adverse effects: 2a. Specific - anticholinergic</outcomeName>
            <subgroupName>constipation - between 3-28 days (Oral phase)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: d. LOXAPINE</comparisonName>
            <group1Events>3</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>18</group1Total>
            <group2Events>1</group2Events>
            <group2Name>loxapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>17</group2Total>
            <outcomeName>Adverse effects: 2a. Specific - anticholinergic</outcomeName>
            <subgroupName>salivation - too little - between 0-3 days (IM phase)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: d. LOXAPINE</comparisonName>
            <group1Events>3</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>18</group1Total>
            <group2Events>3</group2Events>
            <group2Name>loxapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>17</group2Total>
            <outcomeName>Adverse effects: 2a. Specific - anticholinergic</outcomeName>
            <subgroupName>salivation - too little - between 3-28 days (Oral phase)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: d. LOXAPINE</comparisonName>
            <group1Events>5</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>18</group1Total>
            <group2Events>5</group2Events>
            <group2Name>loxapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>17</group2Total>
            <outcomeName>Adverse effects: 2a. Specific - anticholinergic</outcomeName>
            <subgroupName>salivation - too much - between 0-3 days (IM phase)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: d. LOXAPINE</comparisonName>
            <group1Events>10</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>18</group1Total>
            <group2Events>9</group2Events>
            <group2Name>loxapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>17</group2Total>
            <outcomeName>Adverse effects: 2a. Specific - anticholinergic</outcomeName>
            <subgroupName>salivation - too much - between 3-28 days (Oral phase)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: d. LOXAPINE</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>18</group1Total>
            <group2Events>0</group2Events>
            <group2Name>loxapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>17</group2Total>
            <outcomeName>Adverse effects: 2a. Specific - anticholinergic</outcomeName>
            <subgroupName>polyuria - between 3-28 days (Oral phase)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: d. LOXAPINE</comparisonName>
            <group1Events>2</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>18</group1Total>
            <group2Events>2</group2Events>
            <group2Name>loxapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>17</group2Total>
            <outcomeName>Adverse effects: 2a. Specific - anticholinergic</outcomeName>
            <subgroupName>sweating - between 0-3 days (IM phase)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: d. LOXAPINE</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>18</group1Total>
            <group2Events>0</group2Events>
            <group2Name>loxapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>17</group2Total>
            <outcomeName>Adverse effects: 2a. Specific - anticholinergic</outcomeName>
            <subgroupName>sweating - between 3-28 days (Oral phase)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: d. LOXAPINE</comparisonName>
            <group1Events>15</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>18</group1Total>
            <group2Events>16</group2Events>
            <group2Name>loxapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>17</group2Total>
            <outcomeName>Adverse effects: 2b. Specific - arousal level</outcomeName>
            <subgroupName>drowsiness - between 0-3 days (IM phase)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: d. LOXAPINE</comparisonName>
            <group1Events>17</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>18</group1Total>
            <group2Events>0</group2Events>
            <group2Name>loxapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>17</group2Total>
            <outcomeName>Adverse effects: 2b. Specific - arousal level</outcomeName>
            <subgroupName>drowsiness - between 3-28 days (Oral phase)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: d. LOXAPINE</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>18</group1Total>
            <group2Events>1</group2Events>
            <group2Name>loxapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>17</group2Total>
            <outcomeName>Adverse effects: 2b. Specific - arousal level</outcomeName>
            <subgroupName>insomnia - between 0-3 days (IM phase)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: d. LOXAPINE</comparisonName>
            <group1Events>3</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>18</group1Total>
            <group2Events>0</group2Events>
            <group2Name>loxapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>17</group2Total>
            <outcomeName>Adverse effects: 2b. Specific - arousal level</outcomeName>
            <subgroupName>insomnia - between 3-28 days (Oral phase)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: d. LOXAPINE</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>18</group1Total>
            <group2Events>0</group2Events>
            <group2Name>loxapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>17</group2Total>
            <outcomeName>Adverse effects: 2c. Specific - cardiovascular</outcomeName>
            <subgroupName>dizziness - between 3-28 days</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: d. LOXAPINE</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>18</group1Total>
            <group2Events>0</group2Events>
            <group2Name>loxapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>17</group2Total>
            <outcomeName>Adverse effects: 2c. Specific - cardiovascular</outcomeName>
            <subgroupName>dyspnoea - between 3-28 days (Oral phase)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: d. LOXAPINE</comparisonName>
            <group1Events>3</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>18</group1Total>
            <group2Events>5</group2Events>
            <group2Name>loxapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>17</group2Total>
            <outcomeName>Adverse effects: 2d. Specific - movement disorders</outcomeName>
            <subgroupName>akathisia between 0-3 days (IM phase)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: d. LOXAPINE</comparisonName>
            <group1Events>10</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>18</group1Total>
            <group2Events>8</group2Events>
            <group2Name>loxapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>17</group2Total>
            <outcomeName>Adverse effects: 2d. Specific - movement disorders</outcomeName>
            <subgroupName>akathisia between 3-28 days (Oral phase)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: d. LOXAPINE</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>18</group1Total>
            <group2Events>3</group2Events>
            <group2Name>loxapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>17</group2Total>
            <outcomeName>Adverse effects: 2d. Specific - movement disorders</outcomeName>
            <subgroupName>dysarthria between 3-28 days (Oral phase)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: d. LOXAPINE</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>18</group1Total>
            <group2Events>1</group2Events>
            <group2Name>loxapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>17</group2Total>
            <outcomeName>Adverse effects: 2d. Specific - movement disorders</outcomeName>
            <subgroupName>dystonia between 0-3 days (IM phase)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: d. LOXAPINE</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>18</group1Total>
            <group2Events>1</group2Events>
            <group2Name>loxapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>17</group2Total>
            <outcomeName>Adverse effects: 2d. Specific - movement disorders</outcomeName>
            <subgroupName>involuntary movement between 3-28 days (Oral phase)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: d. LOXAPINE</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>18</group1Total>
            <group2Events>1</group2Events>
            <group2Name>loxapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>17</group2Total>
            <outcomeName>Adverse effects: 2d. Specific - movement disorders</outcomeName>
            <subgroupName>motor retardation between 3-28 days (Oral phase)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: d. LOXAPINE</comparisonName>
            <group1Events>4</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>18</group1Total>
            <group2Events>3</group2Events>
            <group2Name>loxapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>17</group2Total>
            <outcomeName>Adverse effects: 2d. Specific - movement disorders</outcomeName>
            <subgroupName>muscle spasms between 0-3 days (IM phase)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: d. LOXAPINE</comparisonName>
            <group1Events>14</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>18</group1Total>
            <group2Events>15</group2Events>
            <group2Name>loxapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>17</group2Total>
            <outcomeName>Adverse effects: 2d. Specific - movement disorders</outcomeName>
            <subgroupName>rigidity between 0-3 days (IM phase)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: d. LOXAPINE</comparisonName>
            <group1Events>18</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>18</group1Total>
            <group2Events>15</group2Events>
            <group2Name>loxapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>17</group2Total>
            <outcomeName>Adverse effects: 2d. Specific - movement disorders</outcomeName>
            <subgroupName>rigidity during between 3-28 days (Oral phase)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: d. LOXAPINE</comparisonName>
            <group1Events>7</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>18</group1Total>
            <group2Events>7</group2Events>
            <group2Name>loxapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>17</group2Total>
            <outcomeName>Adverse effects: 2d. Specific - movement disorders</outcomeName>
            <subgroupName>tremor between 0-3 days (IM phase)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: d. LOXAPINE</comparisonName>
            <group1Events>13</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>18</group1Total>
            <group2Events>11</group2Events>
            <group2Name>loxapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>17</group2Total>
            <outcomeName>Adverse effects: 2d. Specific - movement disorders</outcomeName>
            <subgroupName>tremor during between 3-28 days (Oral phase)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: d. LOXAPINE</comparisonName>
            <group1Events>6</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>18</group1Total>
            <group2Events>2</group2Events>
            <group2Name>loxapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>17</group2Total>
            <outcomeName>Adverse effects: 2d. Specific - movement disorders</outcomeName>
            <subgroupName>use of antiparkinson medication</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: d. LOXAPINE</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>18</group1Total>
            <group2Events>0</group2Events>
            <group2Name>loxapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>17</group2Total>
            <outcomeName>Adverse effects: 2e. Specific - miscellaneous</outcomeName>
            <subgroupName>allergy - itch - between 3-28 days (Oral phase)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: d. LOXAPINE</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>18</group1Total>
            <group2Events>1</group2Events>
            <group2Name>loxapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>17</group2Total>
            <outcomeName>Adverse effects: 2e. Specific - miscellaneous</outcomeName>
            <subgroupName>pain - headache - between 0-3 days (IM phase)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: d. LOXAPINE</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>18</group1Total>
            <group2Events>0</group2Events>
            <group2Name>loxapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>17</group2Total>
            <outcomeName>Adverse effects: 2e. Specific - miscellaneous</outcomeName>
            <subgroupName>pain - myalgia - between 3-28 days (Oral phase)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: d. LOXAPINE</comparisonName>
            <group1Events>4</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>18</group1Total>
            <group2Events>6</group2Events>
            <group2Name>loxapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>17</group2Total>
            <outcomeName>Leaving the study early: 1. For general reasons</outcomeName>
            <subgroupName>by 72 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: d. LOXAPINE</comparisonName>
            <group1Events>7</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>18</group1Total>
            <group2Events>7</group2Events>
            <group2Name>loxapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>17</group2Total>
            <outcomeName>Leaving the study early: 1. For general reasons</outcomeName>
            <subgroupName>by endpoint</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: d. LOXAPINE</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>18</group1Total>
            <group2Events>0</group2Events>
            <group2Name>loxapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>17</group2Total>
            <outcomeName>Leaving the study early: 2. Specific reasons</outcomeName>
            <subgroupName>adverse effects by 72 hours</subgroupName>
        </outcomeList>
        <paralellTrial>false</paralellTrial>
        <performanceBiasJudgement>Described as double-blind - "supplied in 1ml ampules...of identical appearance, individually packaged and labelled with the code number assigned to each patient". Capsules used in the oral phase were also of identical appearance.</performanceBiasJudgement>
        <performanceBiasRisk>Low risk</performanceBiasRisk>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Paprocki J, Versiani M</references>
        <references>A double-blind comparison between loxapine and haloperidol by parenteral route in acute schizophrenia</references>
        <references>Current Therapeutic Research</references>
        <references>1977</references>
        <references>21</references>
        <references>1</references>
        <references>80-100</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>No evidence of selective reporting.</reportingBiasJudgement>
        <reportingBiasRisk>Low risk</reportingBiasRisk>
        <revManID>STD-Paprocki-1977</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement>Not stated.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Unclear Risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>Described as randomised - method of randomisation is not reported.</selectionBiasRandomSequenceJudgement>
        <year>1977</year>
    </trialList>
    <trialList>
        <attritionBiasJudgement>No evidence of incomplete outcome data.</attritionBiasJudgement>
        <attritionBiasRisk>Low risk</attritionBiasRisk>
        <authorYearLetter>Reschke1974</authorYearLetter>
        <countries></countries>
        <crgID>0</crgID>
        <crossoverTrial>false</crossoverTrial>
        <detectionBiasJudgement>Described as double-blind, however no further details reported regarding rater blinding.</detectionBiasJudgement>
        <detectionBiasRisk>Unclear Risk</detectionBiasRisk>
        <dobj>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: b. CHLORPROMAZINE</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>29</group1Total>
            <group2Events>5</group2Events>
            <group2Name>chlorpromazine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>10</group2Total>
            <outcomeName>Leaving the study early</outcomeName>
            <subgroupName>could not be evaluated due to being asleep</subgroupName>
        </dobj>
        <factorialTrial>false</factorialTrial>
        <mainAuthor>Reschke</mainAuthor>
        <meerKatCountry></meerKatCountry>
        <nrControl>0</nrControl>
        <nrIntervention>0</nrIntervention>
        <nrOfParticipants>0</nrOfParticipants>
        <otherBiasJudgement>Small study.</otherBiasJudgement>
        <otherBiasRisk>Unclear Risk</otherBiasRisk>
        <otherDesign>false</otherDesign>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs PLACEBO/NIL</comparisonName>
            <group1Events>29</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>29</group1Total>
            <group2Events>11</group2Events>
            <group2Name>placebo</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>11</group2Total>
            <outcomeName>Tranquillisation or asleep - asleep</outcomeName>
            <subgroupName>not asleep up to 2 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs PLACEBO/NIL</comparisonName>
            <group1Events>17</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>29</group1Total>
            <group2Events>11</group2Events>
            <group2Name>placebo</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>11</group2Total>
            <outcomeName>Global outcome: 1. Not improved</outcomeName>
            <subgroupName>not marked improvement</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs PLACEBO/NIL</comparisonName>
            <group1Events>3</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>29</group1Total>
            <group2Events>4</group2Events>
            <group2Name>placebo</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>11</group2Total>
            <outcomeName>Global outcome: 1. Not improved</outcomeName>
            <subgroupName>not any improvement</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs PLACEBO/NIL</comparisonName>
            <group1Events>12</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>29</group1Total>
            <group2Events>0</group2Events>
            <group2Name>placebo</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>11</group2Total>
            <outcomeName>Adverse effects: 2a. Specific - arousal level</outcomeName>
            <subgroupName>"over" sedated</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs PLACEBO/NIL</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>29</group1Total>
            <group2Events>0</group2Events>
            <group2Name>placebo</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>11</group2Total>
            <outcomeName>Adverse effects: 2a. Specific - arousal level</outcomeName>
            <subgroupName>somnolence during 24 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs PLACEBO/NIL</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>29</group1Total>
            <group2Events>0</group2Events>
            <group2Name>placebo</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>11</group2Total>
            <outcomeName>Adverse effects: 2b. Specific - cardiovascular - miscellaneous outcomes</outcomeName>
            <subgroupName>hypotension during 24 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs PLACEBO/NIL</comparisonName>
            <group1Events>6</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>29</group1Total>
            <group2Events>0</group2Events>
            <group2Name>placebo</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>11</group2Total>
            <outcomeName>Adverse effects: 2d. Specific - movement disorders</outcomeName>
            <subgroupName>EPS during 24 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs PLACEBO/NIL</comparisonName>
            <group1Events>4</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>29</group1Total>
            <group2Events>0</group2Events>
            <group2Name>placebo</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>11</group2Total>
            <outcomeName>Adverse effects: 2f. Specific - miscellaneous</outcomeName>
            <subgroupName>dry mouth</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs PLACEBO/NIL</comparisonName>
            <group1Events>2</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>29</group1Total>
            <group2Events>6</group2Events>
            <group2Name>placebo</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>11</group2Total>
            <outcomeName>Leaving the study early</outcomeName>
            <subgroupName>any reason</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs PLACEBO/NIL</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>29</group1Total>
            <group2Events>6</group2Events>
            <group2Name>placebo</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>11</group2Total>
            <outcomeName>Leaving the study early</outcomeName>
            <subgroupName>lack of efficacy</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs PLACEBO/NIL</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>29</group1Total>
            <group2Events>0</group2Events>
            <group2Name>placebo</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>11</group2Total>
            <outcomeName>Leaving the study early</outcomeName>
            <subgroupName>adverse effects</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs PLACEBO/NIL</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>29</group1Total>
            <group2Events>0</group2Events>
            <group2Name>placebo</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>11</group2Total>
            <outcomeName>Leaving the study early</outcomeName>
            <subgroupName>could not be evaluated due to being asleep</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: b. CHLORPROMAZINE</comparisonName>
            <group1Events>28</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>29</group1Total>
            <group2Events>5</group2Events>
            <group2Name>chlolrpromazine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>10</group2Total>
            <outcomeName>Tranquillisation or asleep - asleep</outcomeName>
            <subgroupName>not asleep up to 2 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: b. CHLORPROMAZINE</comparisonName>
            <group1Events>17</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>29</group1Total>
            <group2Events>10</group2Events>
            <group2Name>chlorpromazine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>10</group2Total>
            <outcomeName>Global outcome: 1. Not improved</outcomeName>
            <subgroupName>not marked improvement</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: b. CHLORPROMAZINE</comparisonName>
            <group1Events>3</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>29</group1Total>
            <group2Events>6</group2Events>
            <group2Name>chlorpromazine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>10</group2Total>
            <outcomeName>Global outcome: 1. Not improved</outcomeName>
            <subgroupName>not any improvement</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: b. CHLORPROMAZINE</comparisonName>
            <group1Events>4</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>29</group1Total>
            <group2Events>1</group2Events>
            <group2Name>chlorpromazine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>10</group2Total>
            <outcomeName>Adverse effects: any serious or specific adverse effects</outcomeName>
            <subgroupName>anticholinergic - dry mouth</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: b. CHLORPROMAZINE</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>29</group1Total>
            <group2Events>6</group2Events>
            <group2Name>chlorpromazine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>10</group2Total>
            <outcomeName>Adverse effects: any serious or specific adverse effects</outcomeName>
            <subgroupName>arousal - drowsy but asleep</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: b. CHLORPROMAZINE</comparisonName>
            <group1Events>12</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>29</group1Total>
            <group2Events>0</group2Events>
            <group2Name>chlorpromazine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>10</group2Total>
            <outcomeName>Adverse effects: any serious or specific adverse effects</outcomeName>
            <subgroupName>arousal - drowsy but awake</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: b. CHLORPROMAZINE</comparisonName>
            <group1Events>3</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>29</group1Total>
            <group2Events>1</group2Events>
            <group2Name>chlorpromazine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>10</group2Total>
            <outcomeName>Adverse effects: any serious or specific adverse effects</outcomeName>
            <subgroupName>cardiovascular - hypotension</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: b. CHLORPROMAZINE</comparisonName>
            <group1Events>6</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>29</group1Total>
            <group2Events>1</group2Events>
            <group2Name>chlorpromazine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>10</group2Total>
            <outcomeName>Adverse effects: any serious or specific adverse effects</outcomeName>
            <subgroupName>movement disorders - extrapyramidal adverse effects</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: b. CHLORPROMAZINE</comparisonName>
            <group1Events>2</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>29</group1Total>
            <group2Events>5</group2Events>
            <group2Name>chlorpromazine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>10</group2Total>
            <outcomeName>Leaving the study early</outcomeName>
            <subgroupName>any reason/general reasons</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: b. CHLORPROMAZINE</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>29</group1Total>
            <group2Events>5</group2Events>
            <group2Name>chlorpromazine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>10</group2Total>
            <outcomeName>Leaving the study early</outcomeName>
            <subgroupName>could not be evaluated due to being asleep</subgroupName>
        </outcomeList>
        <paralellTrial>false</paralellTrial>
        <performanceBiasJudgement>Described as double-blind, however no further details are given. It is not clear whether the study drugs appeared identical.</performanceBiasJudgement>
        <performanceBiasRisk>Unclear Risk</performanceBiasRisk>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Reshke RW</references>
        <references>Parenteral haloperidol for rapid control of severe, disruptive symptoms of acute schizophrenia</references>
        <references>Diseases of the Nervous System</references>
        <references>1974</references>
        <references>35</references>
        <references></references>
        <references>112-5</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>No evidence of selective reporting.</reportingBiasJudgement>
        <reportingBiasRisk>Low risk</reportingBiasRisk>
        <revManID>STD-Reschke-1974</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement>Not stated.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Unclear Risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>Described as randomised - method of randomisation is not reported.</selectionBiasRandomSequenceJudgement>
        <year>1974</year>
    </trialList>
    <trialList>
        <attritionBiasJudgement>No evidence of incomplete data.</attritionBiasJudgement>
        <attritionBiasRisk>Low risk</attritionBiasRisk>
        <authorYearLetter>Resnick1984</authorYearLetter>
        <countries>USA</countries>
        <crgID>0</crgID>
        <crossoverTrial>false</crossoverTrial>
        <detectionBiasJudgement>Described as double-blind, however no further details reported regarding rater blinding.</detectionBiasJudgement>
        <detectionBiasRisk>Unclear Risk</detectionBiasRisk>
        <dobj>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: c. DROPERIDOL</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>16</group1Total>
            <group2Events>0</group2Events>
            <group2Name>droperidol</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>11</group2Total>
            <outcomeName>Adverse effects: 2c. Specific - movement disorders</outcomeName>
            <subgroupName>dystonia</subgroupName>
        </dobj>
        <factorialTrial>false</factorialTrial>
        <mainAuthor>Resnick</mainAuthor>
        <meerKatCountry>USA</meerKatCountry>
        <nrControl>0</nrControl>
        <nrIntervention>0</nrIntervention>
        <nrOfParticipants>0</nrOfParticipants>
        <otherBiasJudgement>Small short study.</otherBiasJudgement>
        <otherBiasRisk>High risk</otherBiasRisk>
        <otherDesign>false</otherDesign>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: c. DROPERIDOL</comparisonName>
            <group1Events>13</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>16</group1Total>
            <group2Events>4</group2Events>
            <group2Name>droperidol</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>11</group2Total>
            <outcomeName>Repeated need for rapid tranquillisation</outcomeName>
            <subgroupName>more than 1 injection</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: c. DROPERIDOL</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>16</group1Total>
            <group2Events>0</group2Events>
            <group2Name>droperidol</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>11</group2Total>
            <outcomeName>Repeated need for rapid tranquillisation</outcomeName>
            <subgroupName>more than 3 injections</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: c. DROPERIDOL</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>16</group1Total>
            <group2Events>0</group2Events>
            <group2Name>droperidol</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>11</group2Total>
            <outcomeName>Adverse effects: 2c. Specific - movement disorders</outcomeName>
            <subgroupName>dystonia</subgroupName>
        </outcomeList>
        <paralellTrial>false</paralellTrial>
        <performanceBiasJudgement>"packages of medication were identified only by a code which was kept in the pharmacy until the conclusion of the study" (p.298).</performanceBiasJudgement>
        <performanceBiasRisk>Low risk</performanceBiasRisk>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Resnick M, Burton BT</references>
        <references>Droperidol vs. haloperidol in the initial management of acutely agitated patients</references>
        <references>Journal of Clinical Psychological Medicine [临床精神医学杂志]</references>
        <references>1984</references>
        <references>45</references>
        <references>7</references>
        <references>298-9</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>No evidence of selective reporting.</reportingBiasJudgement>
        <reportingBiasRisk>Low risk</reportingBiasRisk>
        <revManID>STD-Resnick-1984</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Low risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement>"packages of medication were identified only by a code which was kept in the pharmacy until the conclusion of the study" (p.298).</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Unclear Risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>Described as randomised - method of randomisation is not reported.</selectionBiasRandomSequenceJudgement>
        <year>1984</year>
    </trialList>
    <trialList>
        <attritionBiasJudgement>No evidence of incomplete outcome data.</attritionBiasJudgement>
        <attritionBiasRisk>Low risk</attritionBiasRisk>
        <authorYearLetter>Ritter1972</authorYearLetter>
        <countries></countries>
        <crgID>0</crgID>
        <crossoverTrial>false</crossoverTrial>
        <detectionBiasJudgement>Described as double-blind, however no further details reported regarding rater blinding.</detectionBiasJudgement>
        <detectionBiasRisk>Unclear Risk</detectionBiasRisk>
        <dobj>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: b. CHLORPROMAZINE</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>25</group1Total>
            <group2Events>0</group2Events>
            <group2Name>chlorpromazine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>25</group2Total>
            <outcomeName>Leaving the study early</outcomeName>
            <subgroupName>any reason/general reasons</subgroupName>
        </dobj>
        <factorialTrial>false</factorialTrial>
        <mainAuthor>Ritter</mainAuthor>
        <meerKatCountry></meerKatCountry>
        <nrControl>0</nrControl>
        <nrIntervention>0</nrIntervention>
        <nrOfParticipants>0</nrOfParticipants>
        <otherBiasJudgement>None obvious.</otherBiasJudgement>
        <otherBiasRisk>Unclear Risk</otherBiasRisk>
        <otherDesign>false</otherDesign>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: b. CHLORPROMAZINE</comparisonName>
            <group1Events>17</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>25</group1Total>
            <group2Events>18</group2Events>
            <group2Name>chlorpromazine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>25</group2Total>
            <outcomeName>Global outcome: 1. Not improved</outcomeName>
            <subgroupName>not marked improvement</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: b. CHLORPROMAZINE</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>25</group1Total>
            <group2Events>4</group2Events>
            <group2Name>chlorpromazine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>25</group2Total>
            <outcomeName>Global outcome: 1. Not improved</outcomeName>
            <subgroupName>not any improvement</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: b. CHLORPROMAZINE</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>25</group1Total>
            <group2Events>0</group2Events>
            <group2Name>chlorpromazine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>25</group2Total>
            <outcomeName>Adverse effects: any serious or specific adverse effects</outcomeName>
            <subgroupName>allergy - haematological - leucopenia - mild</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: b. CHLORPROMAZINE</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>25</group1Total>
            <group2Events>1</group2Events>
            <group2Name>chlorpromazine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>25</group2Total>
            <outcomeName>Adverse effects: any serious or specific adverse effects</outcomeName>
            <subgroupName>allergy - hepatic - glutamic pyruvic transaminase elevated</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: b. CHLORPROMAZINE</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>25</group1Total>
            <group2Events>0</group2Events>
            <group2Name>chlorpromazine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>25</group2Total>
            <outcomeName>Leaving the study early</outcomeName>
            <subgroupName>any reason/general reasons</subgroupName>
        </outcomeList>
        <paralellTrial>false</paralellTrial>
        <performanceBiasJudgement>Described as double-blind - the test drugs were supplied in identically appearing ampoules.</performanceBiasJudgement>
        <performanceBiasRisk>Low risk</performanceBiasRisk>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Ritter RM, Davidson DE, Robinson TA</references>
        <references>Comparison of injectable haloperidol and chlorpromazine</references>
        <references>American Journal of Psychiatry</references>
        <references>1972</references>
        <references>129</references>
        <references>1</references>
        <references>78-81</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>Do not report all adverse effects. The authors do not report the mean dosages/number of injections needed.</reportingBiasJudgement>
        <reportingBiasRisk>High risk</reportingBiasRisk>
        <revManID>STD-Ritter-1972</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement>Not stated.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Unclear Risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>Described as randomised - method of randomisation is not reported.</selectionBiasRandomSequenceJudgement>
        <year>1972</year>
    </trialList>
    <trialList>
        <attritionBiasJudgement>It is reported that the number of participants declined after the baseline assessment because they were discharged or transferred. However, exact numbers are not given and it is not clear if the participants were transferred because they had a positive or negative outcome. Attrition approaching 50% for some outcomes at 24 hours.</attritionBiasJudgement>
        <attritionBiasRisk>High risk</attritionBiasRisk>
        <authorYearLetter>Salzman1991</authorYearLetter>
        <countries>USA</countries>
        <crgID>0</crgID>
        <crossoverTrial>false</crossoverTrial>
        <detectionBiasJudgement>"Raters were blind to the treatment condition received by the patient." (p.178).</detectionBiasJudgement>
        <detectionBiasRisk>Low risk</detectionBiasRisk>
        <dobj>
            <comparisonName>HALOPERIDOL vs BENZODIAZEPINE: b. LORAZEPAM</comparisonName>
            <group1Events>15</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>30</group1Total>
            <group2Events>1</group2Events>
            <group2Name>lorazepam</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>30</group2Total>
            <outcomeName>Adverse effects: 2d. Specific - movement disorder</outcomeName>
            <subgroupName>EPS</subgroupName>
        </dobj>
        <factorialTrial>false</factorialTrial>
        <mainAuthor>Salzman</mainAuthor>
        <meerKatCountry>USA</meerKatCountry>
        <nrControl>0</nrControl>
        <nrIntervention>0</nrIntervention>
        <nrOfParticipants>0</nrOfParticipants>
        <otherBiasJudgement>Sponsored by drug company.</otherBiasJudgement>
        <otherBiasRisk>High risk</otherBiasRisk>
        <otherDesign>false</otherDesign>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs BENZODIAZEPINE: b. LORAZEPAM</comparisonName>
            <group1Events>22</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>30</group1Total>
            <group2Events>21</group2Events>
            <group2Name>lorazepam</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>30</group2Total>
            <outcomeName>Tranquillisation or asleep - not asleep</outcomeName>
            <subgroupName>at 1 hour</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs BENZODIAZEPINE: b. LORAZEPAM</comparisonName>
            <group1Events>8</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>30</group1Total>
            <group2Events>9</group2Events>
            <group2Name>lorazepam</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>30</group2Total>
            <outcomeName>Adverse effects: 2b. Specific - arousal</outcomeName>
            <subgroupName>asleep - at 1 hour</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs BENZODIAZEPINE: b. LORAZEPAM</comparisonName>
            <group1Events>15</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>30</group1Total>
            <group2Events>1</group2Events>
            <group2Name>lorazepam</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>30</group2Total>
            <outcomeName>Adverse effects: 2d. Specific - movement disorder</outcomeName>
            <subgroupName>EPS</subgroupName>
        </outcomeList>
        <paralellTrial>false</paralellTrial>
        <performanceBiasJudgement>"Parenteral medication was prepared in advance by a member of staff who had no direct clinical responsibility for the patient." (p.177).</performanceBiasJudgement>
        <performanceBiasRisk>Low risk</performanceBiasRisk>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Salzman C, Solomon D, Miyawaki E, Glassman R, Rood L</references>
        <references>Parenteral lorazepam versus parenteral haloperidol for the control of psychotic disruptive behavior</references>
        <references>Journal of Clinical Psychiatry</references>
        <references>1991</references>
        <references>52</references>
        <references>4</references>
        <references>177-80</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>No evidence of selective reporting.</reportingBiasJudgement>
        <reportingBiasRisk>Low risk</reportingBiasRisk>
        <revManID>STD-Salzman-1991</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement>Not stated.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>High risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>Not explicitly described as randomised.</selectionBiasRandomSequenceJudgement>
        <year>1991</year>
    </trialList>
    <trialList>
        <attritionBiasJudgement>No evidence of incomplete outcome data.</attritionBiasJudgement>
        <attritionBiasRisk>Low risk</attritionBiasRisk>
        <authorYearLetter>Shi2010</authorYearLetter>
        <countries>China</countries>
        <crgID>0</crgID>
        <crossoverTrial>false</crossoverTrial>
        <detectionBiasJudgement>Not stated.</detectionBiasJudgement>
        <detectionBiasRisk>Unclear Risk</detectionBiasRisk>
        <dobj>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: f. OLANZAPINE + MAGNESIUM VALPROATE</comparisonName>
            <group1Events>23</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>31</group1Total>
            <group2Events>8</group2Events>
            <group2Name>olanzapine//magnesium valproate</group2Name>
            <group2NameProse> combinations: f. olanzapine + magnesium valproate</group2NameProse>
            <group2Total>33</group2Total>
            <outcomeName>Adverse effects: General - over 24 hours</outcomeName>
            <subgroupName>one or more drug related adverse effects - by 14 days</subgroupName>
        </dobj>
        <factorialTrial>false</factorialTrial>
        <mainAuthor>Shi</mainAuthor>
        <meerKatCountry>China</meerKatCountry>
        <nrControl>0</nrControl>
        <nrIntervention>0</nrIntervention>
        <nrOfParticipants>0</nrOfParticipants>
        <otherBiasJudgement>None obvious.</otherBiasJudgement>
        <otherBiasRisk>Low risk</otherBiasRisk>
        <otherDesign>false</otherDesign>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: f. OLANZAPINE + MAGNESIUM VALPROATE</comparisonName>
            <group1Events>23</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>31</group1Total>
            <group2Events>8</group2Events>
            <group2Name>olanzapine//magnesium valproate</group2Name>
            <group2NameProse> combinations: f. olanzapine + magnesium valproate</group2NameProse>
            <group2Total>33</group2Total>
            <outcomeName>Adverse effects: General - over 24 hours</outcomeName>
            <subgroupName>one or more drug related adverse effects - by 14 days</subgroupName>
        </outcomeList>
        <paralellTrial>false</paralellTrial>
        <performanceBiasJudgement>Not stated.</performanceBiasJudgement>
        <performanceBiasRisk>Unclear Risk</performanceBiasRisk>
        <references>OTHER</references>
        <references>NO</references>
        <references>Shi Y, Dai T, Yi P</references>
        <references>olanzapine combined magnesium valproate sustained-release tablets in the treatment of schizophrenia, acute agitation excited [Google Translate]</references>
        <references>Modern Practical Medicine</references>
        <references>2010</references>
        <references>22</references>
        <references>4</references>
        <references>398-9</references>
        <references>奥氮平合并丙戊酸镁缓释片治疗精神分裂症急性期兴奋激越研究</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>No evidence of selective reporting.</reportingBiasJudgement>
        <reportingBiasRisk>Low risk</reportingBiasRisk>
        <revManID>STD-Shi-2010</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement>Not stated.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Low risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>"randomised by using random number table".</selectionBiasRandomSequenceJudgement>
        <year>2010</year>
    </trialList>
    <trialList>
        <attritionBiasJudgement>The reasons for leaving the study early were reported for those participants who did not complete the study. However, the number of participants completing different assessments at the same time point vary and reasons are not given.</attritionBiasJudgement>
        <attritionBiasRisk>Unclear Risk</attritionBiasRisk>
        <authorYearLetter>Shu2010</authorYearLetter>
        <countries>China</countries>
        <crgID>0</crgID>
        <crossoverTrial>false</crossoverTrial>
        <detectionBiasJudgement>Rater-blinded.</detectionBiasJudgement>
        <detectionBiasRisk>Low risk</detectionBiasRisk>
        <dobj>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZIPRASIDONE</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>187</group1Total>
            <group2Events>2</group2Events>
            <group2Name>ziprasidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>189</group2Total>
            <outcomeName>Leaving the study early: 2. For specific reasons - i. over 24 hours</outcomeName>
            <subgroupName>other - by 72 hours</subgroupName>
        </dobj>
        <factorialTrial>false</factorialTrial>
        <mainAuthor>Shu</mainAuthor>
        <meerKatCountry>China</meerKatCountry>
        <nrControl>0</nrControl>
        <nrIntervention>0</nrIntervention>
        <nrOfParticipants>0</nrOfParticipants>
        <otherBiasJudgement>Sponsored by drug company.</otherBiasJudgement>
        <otherBiasRisk>High risk</otherBiasRisk>
        <otherDesign>false</otherDesign>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZIPRASIDONE</comparisonName>
            <group1Events>116</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>187</group1Total>
            <group2Events>54</group2Events>
            <group2Name>ziprasidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>189</group2Total>
            <outcomeName>Adverse effects: 1b. General - ii. over 24 hours</outcomeName>
            <subgroupName>one or more drug related adverse effects - by 72 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZIPRASIDONE</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>187</group1Total>
            <group2Events>0</group2Events>
            <group2Name>ziprasidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>189</group2Total>
            <outcomeName>Adverse effects: 1c. General - serious</outcomeName>
            <subgroupName>severe adverse effect - by 72 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZIPRASIDONE</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>187</group1Total>
            <group2Events>3</group2Events>
            <group2Name>ziprasidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>189</group2Total>
            <outcomeName>Adverse effects: 1c. General - serious</outcomeName>
            <subgroupName>death</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZIPRASIDONE</comparisonName>
            <group1Events>2</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>187</group1Total>
            <group2Events>5</group2Events>
            <group2Name>ziprasidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>189</group2Total>
            <outcomeName>Adverse effects: 2a. Specific - anticholinergic</outcomeName>
            <subgroupName>constipation by 72 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZIPRASIDONE</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>187</group1Total>
            <group2Events>2</group2Events>
            <group2Name>ziprasidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>189</group2Total>
            <outcomeName>Adverse effects: 2b. Specific - arousal level - i. various</outcomeName>
            <subgroupName>insomnia - by 72 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZIPRASIDONE</comparisonName>
            <group1Events>8</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>187</group1Total>
            <group2Events>7</group2Events>
            <group2Name>ziprasidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>189</group2Total>
            <outcomeName>Adverse effects: 2b. Specific - arousal level - i. various</outcomeName>
            <subgroupName>somnolence - by 72 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZIPRASIDONE</comparisonName>
            <group1Events>6</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>187</group1Total>
            <group2Events>7</group2Events>
            <group2Name>ziprasidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>189</group2Total>
            <outcomeName>Adverse effects: 2f. Specific - cardiovascular</outcomeName>
            <subgroupName>dizziness - by 72 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZIPRASIDONE</comparisonName>
            <group1Events>3</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>187</group1Total>
            <group2Events>10</group2Events>
            <group2Name>ziprasidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>189</group2Total>
            <outcomeName>Adverse effects: 2f. Specific - cardiovascular</outcomeName>
            <subgroupName>ECG - abnormal - by 72 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZIPRASIDONE</comparisonName>
            <group1Events>24</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>187</group1Total>
            <group2Events>24</group2Events>
            <group2Name>ziprasidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>189</group2Total>
            <outcomeName>Adverse effects: 2f. Specific - cardiovascular</outcomeName>
            <subgroupName>ECG change - clinically significant - by 72 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZIPRASIDONE</comparisonName>
            <group1Events>2</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>187</group1Total>
            <group2Events>4</group2Events>
            <group2Name>ziprasidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>189</group2Total>
            <outcomeName>Adverse effects: 2f. Specific - cardiovascular</outcomeName>
            <subgroupName>tachycardia - by 72 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZIPRASIDONE</comparisonName>
            <group1Events>2</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>187</group1Total>
            <group2Events>5</group2Events>
            <group2Name>ziprasidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>189</group2Total>
            <outcomeName>Adverse effects: 2g. Specific - gastrointestinal</outcomeName>
            <subgroupName>nausea by 72 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZIPRASIDONE</comparisonName>
            <group1Events>61</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>187</group1Total>
            <group2Events>70</group2Events>
            <group2Name>ziprasidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>189</group2Total>
            <outcomeName>Adverse effects: 2h. Specific - hematological tests</outcomeName>
            <subgroupName>abnormal lab results - by 72 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZIPRASIDONE</comparisonName>
            <group1Events>5</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>187</group1Total>
            <group2Events>0</group2Events>
            <group2Name>ziprasidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>189</group2Total>
            <outcomeName>Adverse effects: 2h. Specific - hematological tests</outcomeName>
            <subgroupName>aspartate aminotransference - by 72 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZIPRASIDONE</comparisonName>
            <group1Events>7</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>187</group1Total>
            <group2Events>5</group2Events>
            <group2Name>ziprasidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>189</group2Total>
            <outcomeName>Adverse effects: 2i. Specific - movement disorders - i. binary measures</outcomeName>
            <subgroupName>akathisia - by 72 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZIPRASIDONE</comparisonName>
            <group1Events>7</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>187</group1Total>
            <group2Events>0</group2Events>
            <group2Name>ziprasidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>189</group2Total>
            <outcomeName>Adverse effects: 2i. Specific - movement disorders - i. binary measures</outcomeName>
            <subgroupName>dystonia - by 72 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZIPRASIDONE</comparisonName>
            <group1Events>69</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>187</group1Total>
            <group2Events>4</group2Events>
            <group2Name>ziprasidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>189</group2Total>
            <outcomeName>Adverse effects: 2i. Specific - movement disorders - i. binary measures</outcomeName>
            <subgroupName>EPS - by 72 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZIPRASIDONE</comparisonName>
            <group1Events>8</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>187</group1Total>
            <group2Events>0</group2Events>
            <group2Name>ziprasidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>189</group2Total>
            <outcomeName>Adverse effects: 2i. Specific - movement disorders - i. binary measures</outcomeName>
            <subgroupName>pyramidal tract syndrome - by 72 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZIPRASIDONE</comparisonName>
            <group1Events>13</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>187</group1Total>
            <group2Events>0</group2Events>
            <group2Name>ziprasidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>189</group2Total>
            <outcomeName>Adverse effects: 2k. Specific - miscellaneous</outcomeName>
            <subgroupName>physical examination significant changes - by 72 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZIPRASIDONE</comparisonName>
            <group1Events>7</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>187</group1Total>
            <group2Events>4</group2Events>
            <group2Name>ziprasidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>189</group2Total>
            <outcomeName>Leaving the study early: 1. For any reason - i. over 24 hours</outcomeName>
            <subgroupName>by 72 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZIPRASIDONE</comparisonName>
            <group1Events>4</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>187</group1Total>
            <group2Events>1</group2Events>
            <group2Name>ziprasidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>189</group2Total>
            <outcomeName>Leaving the study early: 2. For specific reasons - i. over 24 hours</outcomeName>
            <subgroupName>adverse events - by 72 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZIPRASIDONE</comparisonName>
            <group1Events>2</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>187</group1Total>
            <group2Events>0</group2Events>
            <group2Name>ziprasidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>189</group2Total>
            <outcomeName>Leaving the study early: 2. For specific reasons - i. over 24 hours</outcomeName>
            <subgroupName>withdrew consent - by 72 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZIPRASIDONE</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>187</group1Total>
            <group2Events>2</group2Events>
            <group2Name>ziprasidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>189</group2Total>
            <outcomeName>Leaving the study early: 2. For specific reasons - i. over 24 hours</outcomeName>
            <subgroupName>other - by 72 hours</subgroupName>
        </outcomeList>
        <paralellTrial>false</paralellTrial>
        <performanceBiasJudgement>Open-label.</performanceBiasJudgement>
        <performanceBiasRisk>High risk</performanceBiasRisk>
        <references>OTHER</references>
        <references>NO</references>
        <references>NCT00723606</references>
        <references>A randomized, open-label, multi-center study to evaluate the efficacy and safety of intramuscular ziprasidone in patients with agitation</references>
        <references>http://www.clinicaltrials.gov</references>
        <references>2008</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>OTHER</references>
        <references>NO</references>
        <references>Pfizer</references>
        <references>A randomized, open label, rater blind, flexible dose multi-center study comparing the efficacy and safety of intramuscular ziprasidone with haloperidol for three days in patients with agitation of schizophrenia</references>
        <references>http://www.clinicalstudyresults.org/documents/company-study_10505_0.pdf</references>
        <references>(accessed 13 June 2011)</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>JOURNAL_ARTICLE</references>
        <references>YES</references>
        <references>Shu L, Zhang H, Wang G, Zhao J, Xie S, Xu X, et al</references>
        <references>Intramuscular ziprasidone has improved tolerability over haloperidol and comparable efficacy for control of agitation in schizophrenia in Chinese patients</references>
        <references>Schizophrenia Research</references>
        <references>2010</references>
        <references>117</references>
        <references>2-3</references>
        <references>260</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>OTHER</references>
        <references>NO</references>
        <references>Zhang H, Wang G, Zhao J, Xie S, Xu X, Shi J, et al</references>
        <references>Intramuscular ziprasidone versus haloperidol for managing agitation in Chinese patients with schizophrenia</references>
        <references>Journal of Clinical Psychopharmacology</references>
        <references>2013</references>
        <references>33</references>
        <references>2</references>
        <references>178-85</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>Only report side effects experienced by ≥2% of people.</reportingBiasJudgement>
        <reportingBiasRisk>Unclear Risk</reportingBiasRisk>
        <revManID>STD-Shu-2010</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement>Not stated.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Unclear Risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>"randomized in a 1:1 ratio (in blocks of 4)" (p.179); no further informations on the randomization procedure is stated.</selectionBiasRandomSequenceJudgement>
        <year>2010</year>
    </trialList>
    <trialList>
        <attritionBiasJudgement>No evidence of incomplete outcome data.</attritionBiasJudgement>
        <attritionBiasRisk>Low risk</attritionBiasRisk>
        <authorYearLetter>Stotsky1977</authorYearLetter>
        <countries>USA</countries>
        <crgID>0</crgID>
        <crossoverTrial>false</crossoverTrial>
        <detectionBiasJudgement>"Ratings were performed by the psychiatrist ordering the medication who was not aware which drug was administered to the patient. When asked to guess which drug was given, the psychiatrists administering the drug were unable to guess significantly better than chance." (p.968).</detectionBiasJudgement>
        <detectionBiasRisk>Low risk</detectionBiasRisk>
        <dobj>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: i. THIOTHIXENE</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>15</group1Total>
            <group2Events>0</group2Events>
            <group2Name>thiothixene</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>15</group2Total>
            <outcomeName>Adverse effects: 2b. Specific - others</outcomeName>
            <subgroupName>other - unsteadiness</subgroupName>
        </dobj>
        <factorialTrial>false</factorialTrial>
        <mainAuthor>Stotsky</mainAuthor>
        <meerKatCountry>USA</meerKatCountry>
        <nrControl>0</nrControl>
        <nrIntervention>0</nrIntervention>
        <nrOfParticipants>0</nrOfParticipants>
        <otherBiasJudgement>Small short study, sponsored by drug company.</otherBiasJudgement>
        <otherBiasRisk>High risk</otherBiasRisk>
        <otherDesign>false</otherDesign>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: i. THIOTHIXENE</comparisonName>
            <group1Events>15</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>15</group1Total>
            <group2Events>14</group2Events>
            <group2Name>thiothixene</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>15</group2Total>
            <outcomeName>Repeated need for rapid tranquillisation</outcomeName>
            <subgroupName>more than 1 injection</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: i. THIOTHIXENE</comparisonName>
            <group1Events>5</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>15</group1Total>
            <group2Events>2</group2Events>
            <group2Name>thiothixene</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>15</group2Total>
            <outcomeName>Repeated need for rapid tranquillisation</outcomeName>
            <subgroupName>more than 3 injections</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: i. THIOTHIXENE</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>15</group1Total>
            <group2Events>0</group2Events>
            <group2Name>thiothixene</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>15</group2Total>
            <outcomeName>Adverse effects: 2a. Specific - movement disorders</outcomeName>
            <subgroupName>use of antiparkinson drugs</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: i. THIOTHIXENE</comparisonName>
            <group1Events>4</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>15</group1Total>
            <group2Events>2</group2Events>
            <group2Name>thiothixene</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>15</group2Total>
            <outcomeName>Adverse effects: 2b. Specific - others</outcomeName>
            <subgroupName>arousal - drowsiness</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: i. THIOTHIXENE</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>15</group1Total>
            <group2Events>0</group2Events>
            <group2Name>thiothixene</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>15</group2Total>
            <outcomeName>Adverse effects: 2b. Specific - others</outcomeName>
            <subgroupName>cardiac - hypotensive crisis</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: i. THIOTHIXENE</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>15</group1Total>
            <group2Events>0</group2Events>
            <group2Name>thiothixene</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>15</group2Total>
            <outcomeName>Adverse effects: 2b. Specific - others</outcomeName>
            <subgroupName>other - weakness</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: i. THIOTHIXENE</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>15</group1Total>
            <group2Events>0</group2Events>
            <group2Name>thiothixene</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>15</group2Total>
            <outcomeName>Adverse effects: 2b. Specific - others</outcomeName>
            <subgroupName>other - unsteadiness</subgroupName>
        </outcomeList>
        <paralellTrial>false</paralellTrial>
        <performanceBiasJudgement>"Medication was provided in identically appearing 2cc. ampules each containing 4 mg's. Prior to the administration of the drug labels were removed by a person not involved either in the prescription or administration of the drug." (p.968).</performanceBiasJudgement>
        <performanceBiasRisk>Low risk</performanceBiasRisk>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Stotsky BA</references>
        <references>Relative efficacy of parenteral haloperidol and thiothixene for the emergency treatment of acutely excited and agitated patients</references>
        <references>Diseases of the Nervous System</references>
        <references>1977</references>
        <references>38</references>
        <references>12</references>
        <references>967-73</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>No evidence of selective reporting.</reportingBiasJudgement>
        <reportingBiasRisk>Low risk</reportingBiasRisk>
        <revManID>STD-Stotsky-1977</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement>Not stated.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Unclear Risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>Randomised in blocks of 10. Method of sequence generation not clear.</selectionBiasRandomSequenceJudgement>
        <year>1977</year>
    </trialList>
    <trialList>
        <attritionBiasJudgement>No evidence of incomplete outcome data.</attritionBiasJudgement>
        <attritionBiasRisk>Low risk</attritionBiasRisk>
        <authorYearLetter>Taymeeyapradit2002</authorYearLetter>
        <countries>Thailand</countries>
        <crgID>0</crgID>
        <crossoverTrial>false</crossoverTrial>
        <detectionBiasJudgement>The BPRS was completed by a psychiatric nurse who was blind to the intervention. However, it is not reported whether the rater for CGI and adverse effects was blinded.</detectionBiasJudgement>
        <detectionBiasRisk>Unclear Risk</detectionBiasRisk>
        <dobj>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: k. ZUCLOPENTHIXOL ACETATE</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>32</group1Total>
            <group2Events>0</group2Events>
            <group2Name>zuclopenthixol acetate</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>38</group2Total>
            <outcomeName>Adverse effects: 1b. Specific - miscellaneous</outcomeName>
            <subgroupName>pain/allergy - reaction at injection site</subgroupName>
        </dobj>
        <factorialTrial>false</factorialTrial>
        <mainAuthor>Taymeeyapradit</mainAuthor>
        <meerKatCountry>Thailand</meerKatCountry>
        <nrControl>0</nrControl>
        <nrIntervention>0</nrIntervention>
        <nrOfParticipants>0</nrOfParticipants>
        <otherBiasJudgement>None obvious.</otherBiasJudgement>
        <otherBiasRisk>Unclear Risk</otherBiasRisk>
        <otherDesign>false</otherDesign>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: k. ZUCLOPENTHIXOL ACETATE</comparisonName>
            <group1Events>7</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>32</group1Total>
            <group2Events>2</group2Events>
            <group2Name>zuclopenthixol acetate</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>38</group2Total>
            <outcomeName>Adverse effects: 1a. Specific - movement disorders</outcomeName>
            <subgroupName>movement disorder - tremor by 7 days</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: k. ZUCLOPENTHIXOL ACETATE</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>32</group1Total>
            <group2Events>0</group2Events>
            <group2Name>zuclopenthixol acetate</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>38</group2Total>
            <outcomeName>Adverse effects: 1b. Specific - miscellaneous</outcomeName>
            <subgroupName>pain/allergy - reaction at injection site</subgroupName>
        </outcomeList>
        <paralellTrial>false</paralellTrial>
        <performanceBiasJudgement>Open-label.</performanceBiasJudgement>
        <performanceBiasRisk>High risk</performanceBiasRisk>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Taymeeyapradit U, Kuasirikul S</references>
        <references>Comparative study of the effectiveness of zuclopenthixol acetate and haloperidol in acutely disturbed psychotic patients</references>
        <references>Journal of the Medical Association of Thailand</references>
        <references>2002</references>
        <references>85</references>
        <references>12</references>
        <references>1301-8</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>No evidence of selective reporting.</reportingBiasJudgement>
        <reportingBiasRisk>Low risk</reportingBiasRisk>
        <revManID>STD-Taymeeyapradit-2002</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement>Not stated.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Unclear Risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>Described as randomised - method of randomisation is not reported.</selectionBiasRandomSequenceJudgement>
        <year>2002</year>
    </trialList>
    <trialList>
        <attritionBiasJudgement>Participants who were discharged/transferred were not followed up. The number of participants reported as leaving the study is contradictory as follows; "On Day 3, 19% of the haloperidol patients were withdrawn from the study while all loxapine patients remained" "the others (6 loxapine and 11 haloperidol) were dropped on Day 2, when all were still rated severely or very severely ill." (p.127). By day 10, over 50% attrition in both groups.</attritionBiasJudgement>
        <attritionBiasRisk>High risk</attritionBiasRisk>
        <authorYearLetter>Tuason1986</authorYearLetter>
        <countries>USA</countries>
        <crgID>0</crgID>
        <crossoverTrial>false</crossoverTrial>
        <detectionBiasJudgement>Rater-blinded.</detectionBiasJudgement>
        <detectionBiasRisk>Low risk</detectionBiasRisk>
        <dobj>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: d. LOXAPINE</comparisonName>
            <group1Events>15</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>29</group1Total>
            <group2Events>11</group2Events>
            <group2Name>loxapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>25</group2Total>
            <outcomeName>Leaving the study early: 1. For general reasons</outcomeName>
            <subgroupName>by 10 days</subgroupName>
        </dobj>
        <factorialTrial>false</factorialTrial>
        <mainAuthor>Tuason</mainAuthor>
        <meerKatCountry>USA</meerKatCountry>
        <nrControl>0</nrControl>
        <nrIntervention>0</nrIntervention>
        <nrOfParticipants>0</nrOfParticipants>
        <otherBiasJudgement>None obvious.</otherBiasJudgement>
        <otherBiasRisk>Unclear Risk</otherBiasRisk>
        <otherDesign>false</otherDesign>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: d. LOXAPINE</comparisonName>
            <group1Events>2</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>29</group1Total>
            <group2Events>2</group2Events>
            <group2Name>loxapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>27</group2Total>
            <outcomeName>Global outcome: 1. General - no change - i. over 24 hours</outcomeName>
            <subgroupName>up to 48 hours (CGI-I, high=worse)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: d. LOXAPINE</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>25</group1Total>
            <group2Events>3</group2Events>
            <group2Name>loxapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>29</group2Total>
            <outcomeName>Global outcome: 1. General - no change - i. over 24 hours</outcomeName>
            <subgroupName>up to 72 hours (CGI-I, high=worse)</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: d. LOXAPINE</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>29</group1Total>
            <group2Events>2</group2Events>
            <group2Name>loxapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>25</group2Total>
            <outcomeName>Adverse effects: 2a. Specific - anticholinergic</outcomeName>
            <subgroupName>salivation - too much - between 0-10 days</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: d. LOXAPINE</comparisonName>
            <group1Events>24</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>29</group1Total>
            <group2Events>24</group2Events>
            <group2Name>loxapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>25</group2Total>
            <outcomeName>Adverse effects: 2b. Specific - arousal level</outcomeName>
            <subgroupName>asleep - by 12 hours</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: d. LOXAPINE</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>29</group1Total>
            <group2Events>2</group2Events>
            <group2Name>loxapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>25</group2Total>
            <outcomeName>Adverse effects: 2c. Specific - cardiovascular</outcomeName>
            <subgroupName>blood pressure - increased - between 0-10 days</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: d. LOXAPINE</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>29</group1Total>
            <group2Events>1</group2Events>
            <group2Name>loxapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>25</group2Total>
            <outcomeName>Adverse effects: 2c. Specific - cardiovascular</outcomeName>
            <subgroupName>pulse rate - increased - between 0-10 days</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: d. LOXAPINE</comparisonName>
            <group1Events>6</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>29</group1Total>
            <group2Events>8</group2Events>
            <group2Name>loxapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>25</group2Total>
            <outcomeName>Adverse effects: 2d. Specific - movement disorders</outcomeName>
            <subgroupName>akathisia between 0-10 days</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: d. LOXAPINE</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>29</group1Total>
            <group2Events>1</group2Events>
            <group2Name>loxapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>25</group2Total>
            <outcomeName>Adverse effects: 2d. Specific - movement disorders</outcomeName>
            <subgroupName>dyskinesia between 0-10 days</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: d. LOXAPINE</comparisonName>
            <group1Events>6</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>29</group1Total>
            <group2Events>8</group2Events>
            <group2Name>loxapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>25</group2Total>
            <outcomeName>Adverse effects: 2d. Specific - movement disorders</outcomeName>
            <subgroupName>dystonia between 0-10 days</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: d. LOXAPINE</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>29</group1Total>
            <group2Events>0</group2Events>
            <group2Name>loxapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>25</group2Total>
            <outcomeName>Adverse effects: 2d. Specific - movement disorders</outcomeName>
            <subgroupName>oculogyric crisis between 0-10 days</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: d. LOXAPINE</comparisonName>
            <group1Events>2</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>29</group1Total>
            <group2Events>2</group2Events>
            <group2Name>loxapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>25</group2Total>
            <outcomeName>Adverse effects: 2d. Specific - movement disorders</outcomeName>
            <subgroupName>rigidity between 0-10 days</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: d. LOXAPINE</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>29</group1Total>
            <group2Events>0</group2Events>
            <group2Name>loxapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>25</group2Total>
            <outcomeName>Adverse effects: 2d. Specific - movement disorders</outcomeName>
            <subgroupName>tremor between 0-10 days</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: d. LOXAPINE</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>29</group1Total>
            <group2Events>1</group2Events>
            <group2Name>loxapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>25</group2Total>
            <outcomeName>Adverse effects: 2d. Specific - movement disorders</outcomeName>
            <subgroupName>thick tongue - between 0-10 days</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: d. LOXAPINE</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>29</group1Total>
            <group2Events>0</group2Events>
            <group2Name>loxapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>25</group2Total>
            <outcomeName>Adverse effects: 2e. Specific - miscellaneous</outcomeName>
            <subgroupName>allergy - tissue reaction at injection site - between 0-10 days</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: d. LOXAPINE</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>29</group1Total>
            <group2Events>1</group2Events>
            <group2Name>loxapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>25</group2Total>
            <outcomeName>Adverse effects: 2e. Specific - miscellaneous</outcomeName>
            <subgroupName>nervousness - between 0-10 days</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: d. LOXAPINE</comparisonName>
            <group1Events>15</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>29</group1Total>
            <group2Events>11</group2Events>
            <group2Name>loxapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>25</group2Total>
            <outcomeName>Leaving the study early: 1. For general reasons</outcomeName>
            <subgroupName>by 10 days</subgroupName>
        </outcomeList>
        <paralellTrial>false</paralellTrial>
        <performanceBiasJudgement>Staff administering the medication were not blind to the intervention.</performanceBiasJudgement>
        <performanceBiasRisk>High risk</performanceBiasRisk>
        <references>JOURNAL_ARTICLE</references>
        <references>NO</references>
        <references>Tuason VB</references>
        <references>A comparison of parenteral loxapine and haloperidol in hostile and aggressive acutely schizophrenic patients</references>
        <references>Journal of Clinical Psychiatry</references>
        <references>1986</references>
        <references>47</references>
        <references>3</references>
        <references>126-9</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>The amount of anticholinergic and sleeping medication administered was not reported. Table 3 and 3 present data from 48 hours after the 1st injection, rather than from 24 hours, despite referring to two of the outcomes in the text; "Twenty-four hours after the first I.M. dose, 72% (18 of 25) of the loxapine patients and 59% (12 of 27) of the haloperidol patients showed moderate or marked improvement" (p.128).</reportingBiasJudgement>
        <reportingBiasRisk>High risk</reportingBiasRisk>
        <revManID>STD-Tuason-1986</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement>Not stated.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Unclear Risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>Described as randomised - method of randomisation is not reported.</selectionBiasRandomSequenceJudgement>
        <year>1986</year>
    </trialList>
    <trialList>
        <attritionBiasJudgement>9 participants were excluded post-randomisation due to refusal to provide post-hoc consent; their treatment assignment was not provided.</attritionBiasJudgement>
        <attritionBiasRisk>High risk</attritionBiasRisk>
        <authorYearLetter>Walther2014</authorYearLetter>
        <countries>Switzerland</countries>
        <crgID>0</crgID>
        <crossoverTrial>false</crossoverTrial>
        <detectionBiasJudgement>Not stated.</detectionBiasJudgement>
        <detectionBiasRisk>Unclear Risk</detectionBiasRisk>
        <dobj>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: h. RISPERIDONE</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>14</group1Total>
            <group2Events>4</group2Events>
            <group2Name>risperidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>14</group2Total>
            <outcomeName>Leaving the study early - ii. over 24 hours</outcomeName>
            <subgroupName>Lack of efficacy at 96 hours</subgroupName>
        </dobj>
        <factorialTrial>false</factorialTrial>
        <mainAuthor>Walther</mainAuthor>
        <meerKatCountry>Switzerland</meerKatCountry>
        <nrControl>0</nrControl>
        <nrIntervention>0</nrIntervention>
        <nrOfParticipants>0</nrOfParticipants>
        <otherBiasJudgement>Small study.</otherBiasJudgement>
        <otherBiasRisk>Unclear Risk</otherBiasRisk>
        <otherDesign>false</otherDesign>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>14</group1Total>
            <group2Events>0</group2Events>
            <group2Name>olanzapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>15</group2Total>
            <outcomeName>Adverse effects: 1b. General - serious</outcomeName>
            <subgroupName>death</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>14</group1Total>
            <group2Events>2</group2Events>
            <group2Name>olanzapine</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>15</group2Total>
            <outcomeName>Leaving the study early</outcomeName>
            <subgroupName>lack of efficacy</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: h. RISPERIDONE</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>14</group1Total>
            <group2Events>4</group2Events>
            <group2Name>risperidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>14</group2Total>
            <outcomeName>Leaving the study early - ii. over 24 hours</outcomeName>
            <subgroupName>Lack of efficacy at 96 hours</subgroupName>
        </outcomeList>
        <paralellTrial>false</paralellTrial>
        <performanceBiasJudgement>Not stated.</performanceBiasJudgement>
        <performanceBiasRisk>Unclear Risk</performanceBiasRisk>
        <references>OTHER</references>
        <references>YES</references>
        <references>Walther S, Moggi F, Horn H, Moskvitin K, Abderhalden C, Maier N, et al</references>
        <references>Rapid tranquilization of severely agitated patients with schizophrenia spectrum disorders: a naturalistic, rater-blinded, randomized, controlled study with oral haloperidol, risperidone, and olanzapine</references>
        <references>Journal of Clinical Psychopharmacology</references>
        <references>2014</references>
        <references>34</references>
        <references>1</references>
        <references>124-8</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references>OTHER</references>
        <references>NO</references>
        <references>Walther S, Moggi F, Horn H, Moskvitin K, Maier N, Abderhalden C, et al</references>
        <references>Rapid tranquilization of severely agitated patients with schizophrenia spectrum disorders: A naturalistic, rater-blinded, randomized controlled study with oral haloperidol, risperidone, and olanzapine</references>
        <references>PharmacoPsychiatry</references>
        <references>2013</references>
        <references>46</references>
        <references>6</references>
        <references>A77</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>PANSS-PAS scores at 24, 48, 72, and 96 hours not provided., PANSS scores at 96 hours not provided., Number of patients that needed additional BDZ not provided., Number of patients that needed additional biperiden not provided.</reportingBiasJudgement>
        <reportingBiasRisk>Unclear Risk</reportingBiasRisk>
        <revManID>STD-Walther-2014</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Low risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement>"The randomization list was locked in the office of the principal investigator (T.J.M.), who was engaged neither in treatment nor in study assessments" (p.125).</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Low risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>"Randomization was performed by creating 3 sets of random numbers between 1 and 60 using a computer-based research randomizer" (p.125).</selectionBiasRandomSequenceJudgement>
        <year>2014</year>
    </trialList>
    <trialList>
        <attritionBiasJudgement>No evidence of incomplete outcome data.</attritionBiasJudgement>
        <attritionBiasRisk>Low risk</attritionBiasRisk>
        <authorYearLetter>Yin2012</authorYearLetter>
        <countries>China</countries>
        <crgID>0</crgID>
        <crossoverTrial>false</crossoverTrial>
        <detectionBiasJudgement>Not stated.</detectionBiasJudgement>
        <detectionBiasRisk>Unclear Risk</detectionBiasRisk>
        <dobj>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZIPRASIDONE</comparisonName>
            <group1Events>16</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>30</group1Total>
            <group2Events>11</group2Events>
            <group2Name>ziprasidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>30</group2Total>
            <outcomeName>Adverse effects: 1b. General - ii. over 24 hours</outcomeName>
            <subgroupName>one or more drug related adverse effects - by 72 hours</subgroupName>
        </dobj>
        <factorialTrial>false</factorialTrial>
        <mainAuthor>Yin</mainAuthor>
        <meerKatCountry>China</meerKatCountry>
        <nrControl>0</nrControl>
        <nrIntervention>0</nrIntervention>
        <nrOfParticipants>0</nrOfParticipants>
        <otherBiasJudgement>None obvious.</otherBiasJudgement>
        <otherBiasRisk>Low risk</otherBiasRisk>
        <otherDesign>false</otherDesign>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZIPRASIDONE</comparisonName>
            <group1Events>16</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>30</group1Total>
            <group2Events>11</group2Events>
            <group2Name>ziprasidone</group2Name>
            <group2NameProse></group2NameProse>
            <group2Total>30</group2Total>
            <outcomeName>Adverse effects: 1b. General - ii. over 24 hours</outcomeName>
            <subgroupName>one or more drug related adverse effects - by 72 hours</subgroupName>
        </outcomeList>
        <paralellTrial>false</paralellTrial>
        <performanceBiasJudgement>Researcher blinded to assignment.</performanceBiasJudgement>
        <performanceBiasRisk>Unclear Risk</performanceBiasRisk>
        <references>OTHER</references>
        <references>NO</references>
        <references>尹析凡, 王刚</references>
        <references>齐拉西酮注射液治疗精神分裂症激越症状的研究</references>
        <references>中国当代医药</references>
        <references>2012</references>
        <references>30</references>
        <references></references>
        <references>9-11</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>No evidence of selective reporting.</reportingBiasJudgement>
        <reportingBiasRisk>Low risk</reportingBiasRisk>
        <revManID>STD-Yin-2012</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement>Not stated.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Unclear Risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>Described as randomised - method of randomisation is not reported.</selectionBiasRandomSequenceJudgement>
        <year>2012</year>
    </trialList>
    <trialList>
        <attritionBiasJudgement>A total of 3 dropped out in haloperidol group (serious adverse events = 2, not following protocol = 1) and 2 dropped out in ziprasidone + clonazepam (lost to contact = 1, not following protocol = 1); missing data have not been imputed using appropriate methods such as LOCF.</attritionBiasJudgement>
        <attritionBiasRisk>High risk</attritionBiasRisk>
        <authorYearLetter>Zhou2014</authorYearLetter>
        <countries>China</countries>
        <crgID>0</crgID>
        <crossoverTrial>false</crossoverTrial>
        <detectionBiasJudgement>Not stated.</detectionBiasJudgement>
        <detectionBiasRisk>Unclear Risk</detectionBiasRisk>
        <dobj>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: i. ZIPRASIDONE + CLONAZEPAM</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>38</group1Total>
            <group2Events>1</group2Events>
            <group2Name>ziprasidone//clonazepam</group2Name>
            <group2NameProse> combinations: i. ziprasidone + clonazepam</group2NameProse>
            <group2Total>38</group2Total>
            <outcomeName>Leaving the study early</outcomeName>
            <subgroupName>non compliance</subgroupName>
        </dobj>
        <factorialTrial>false</factorialTrial>
        <mainAuthor>Zhou</mainAuthor>
        <meerKatCountry>China</meerKatCountry>
        <nrControl>0</nrControl>
        <nrIntervention>0</nrIntervention>
        <nrOfParticipants>0</nrOfParticipants>
        <otherBiasJudgement>None obvious.</otherBiasJudgement>
        <otherBiasRisk>Low risk</otherBiasRisk>
        <otherDesign>false</otherDesign>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: i. ZIPRASIDONE + CLONAZEPAM</comparisonName>
            <group1Events>3</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>38</group1Total>
            <group2Events>2</group2Events>
            <group2Name>ziprasidone//clonazepam</group2Name>
            <group2NameProse> combinations: i. ziprasidone + clonazepam</group2NameProse>
            <group2Total>38</group2Total>
            <outcomeName>Leaving the study early</outcomeName>
            <subgroupName>any reason</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: i. ZIPRASIDONE + CLONAZEPAM</comparisonName>
            <group1Events>2</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>38</group1Total>
            <group2Events>0</group2Events>
            <group2Name>ziprasidone//clonazepam</group2Name>
            <group2NameProse> combinations: i. ziprasidone + clonazepam</group2NameProse>
            <group2Total>38</group2Total>
            <outcomeName>Leaving the study early</outcomeName>
            <subgroupName>adverse effects</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: i. ZIPRASIDONE + CLONAZEPAM</comparisonName>
            <group1Events>0</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>38</group1Total>
            <group2Events>1</group2Events>
            <group2Name>ziprasidone//clonazepam</group2Name>
            <group2NameProse> combinations: i. ziprasidone + clonazepam</group2NameProse>
            <group2Total>38</group2Total>
            <outcomeName>Leaving the study early</outcomeName>
            <subgroupName>lost at follow-up</subgroupName>
        </outcomeList>
        <outcomeList>
            <comparisonName>HALOPERIDOL vs COMBINATIONS: i. ZIPRASIDONE + CLONAZEPAM</comparisonName>
            <group1Events>1</group1Events>
            <group1Intervention>true</group1Intervention>
            <group1Name>haloperidol</group1Name>
            <group1NameProse></group1NameProse>
            <group1Total>38</group1Total>
            <group2Events>1</group2Events>
            <group2Name>ziprasidone//clonazepam</group2Name>
            <group2NameProse> combinations: i. ziprasidone + clonazepam</group2NameProse>
            <group2Total>38</group2Total>
            <outcomeName>Leaving the study early</outcomeName>
            <subgroupName>non compliance</subgroupName>
        </outcomeList>
        <paralellTrial>false</paralellTrial>
        <performanceBiasJudgement>Not stated.</performanceBiasJudgement>
        <performanceBiasRisk>Unclear Risk</performanceBiasRisk>
        <references>OTHER</references>
        <references>NO</references>
        <references>周升宝, 孙晓丹, 庞琦, 李志梅, 赵继舒, 张峰</references>
        <references>齐拉西酮联合氯硝西泮治疗精神分裂症急性期兴奋激越症状对照研究</references>
        <references>临床心身疾病杂志</references>
        <references>2014</references>
        <references>20</references>
        <references>2</references>
        <references>17-20</references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <references></references>
        <reportingBiasJudgement>No evidence of selective reporting.</reportingBiasJudgement>
        <reportingBiasRisk>Low risk</reportingBiasRisk>
        <revManID>STD-Zhou-2014</revManID>
        <selectionBiasAllocationConcealmentBiasRisk>Unclear Risk</selectionBiasAllocationConcealmentBiasRisk>
        <selectionBiasAllocationConcealmentJudgement>Not stated.</selectionBiasAllocationConcealmentJudgement>
        <selectionBiasRandomSequenceBiasRisk>Low risk</selectionBiasRandomSequenceBiasRisk>
        <selectionBiasRandomSequenceJudgement>"randomised by using random number table".</selectionBiasRandomSequenceJudgement>
        <year>2014</year>
    </trialList>
</database>
